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Self-renewing cell populations, such as stem and cancer cells, are highly metabolically active 
and proliferate by up regulating glycolytic metabolism. Nephron progenitors—which give rise to 
nephrons—are particularly metabolically active and similarly rely on the glycolysis pathway to 
drive proliferation. Conversely, as nephron progenitors mature they switch to mitochondrial 
oxidative phosphorylation coinciding with loss of stemness and rapid differentiation. The 
mechanism driving this metabolic switch and subsequent differentiation is currently unknown. 
Oxygenation is an important developmental process tightly regulated by several oxygen-
dependent molecules. Although the kidney develops in a relatively hypoxic environment, as the 
renal vasculature matures, oxygen tension increases. The major hypoxia-responsive pathway 
expressed in the developing kidney allows for the recruitment of the ubiquitin ligase von Hippel 
Lindau (VHL) to mark the transcription factor hypoxia-inducible factor 1α (HIF-1α) for 
proteasomal degradation, a process that we hypothesize leads to normal nephron progenitor 
differentiation. Prolonged hypoxic insult however, interrupts this pathway such that HIF-1α 
remains stabilized and activates transcription of genes involved in cellular processes including 
angiogenesis, cell cycle regulation, and metabolism. This investigation reveals a previously 
unknown mechanism controlling the balance between nephron progenitor 
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 self-renewal and differentiation. Collectively, this study found that hypoxia and the VHL/HIF 
pathway play a critical role in this process by mediating the metabolic switch that is required for 
nephron progenitor differentiation. 
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1.0  INTRODUCTION 
A portion of this section was adapted from the author’s version of a review paper. The definitive 
version of this work was published in Pediatric Nephrology. 
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1.1 KIDNEY DEVELOPMENT 
1.1.1 Transient kidney structures 
Mammalian organogenesis arises from three basic germ cell layers known as the ectoderm 
(spinal cord and nervous system), mesoderm (bones, kidney, and blood), and endoderm (gut and 
gastrointestinal tract) [1]. The developing metanephric kidney is derived from the intermediate 
mesoderm, which also gives rise to the reproductive system and urinary tract. The kidney 
initially progresses through two transient structures early in development, known as the 
pronephros and mesonephros (Figure 1) [2]. Both the pronephros and mesonephros form and, in 
mammals, subsequently deteriorate prior to the formation of the metanephric kidney [1].  
The pronephros is the first primitive kidney structure in mammals including mice and 
humans. It is largely non-functional and includes a few tubular structures that empty into primary 
ducts [2, 3]. In humans, the pronephros completely disappears by the 4th week of gestation. The 
mesonephros arises soon after pronephros degeneration and remains from the 4th to the 8th weeks 
of gestation in humans. The mesonephros is comprised of more complex tubular structures that 
serve as the primary excretory organ during these weeks and gradually deteriorates. Some parts 
of the mesonephros tubules and duct system remain and become incorporated into primitive 
gonads [3]. As the kidney passes through these intermediate structures, it migrates downwards 
from the heart region to fuse with the urogenital sinus. Soon after the development and migration 
of the mesonephros, the metanephros forms by the 5th week of human gestation (embryonic day 
10.5 [E10.5] in mice). This kidney structure is permanent and becomes a fully functional organ.  
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Pronephros 
Mesonephros 
Metanephros 
 
Figure 1: Early kidney organogenesis 
Stages of early kidney development: pronephros (light blue), mesonephros (dark blue), metanephros (pink).  
1.1.2 Ureteric epithelium and metanephric mesenchyme 
The metanephros is comprised of complex tubular networks, extensive collecting duct branching, 
and nephron abundance. Functional kidney development involves complex signaling processes 
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between two tissue types: the metanephric mesenchyme (MM) and the ureteric epithelium (UE) 
(Figures 2-3). Reciprocal signaling between these two structures prompts elongation and 
branching of the UE, which ultimately forms the collecting duct system [4]. Simultaneously, the 
MM undergoes division into the renal stroma and nephron progenitors [5]. The stroma gives rise 
to the interstitial and connective tissues, pericytes, mesangium of the glomerulus (cluster of 
capillaries around the end of the kidney tubule), and some endothelium in adult kidneys as well 
as some of the renal blood vessels to facilitate oxygen delivery in the developing kidney. The 
stroma is also thought to play a major role in the fibrotic response after kidney injury. The self-
renewing nephron progenitors condense around the UE branches to give rise to nephrons, the 
functional units of the kidney [2, 4]. Nephrogenesis (period of nephron formation) involves strict 
and sequential genetic expression dictating nephron progenitor differentiation into mature cells. 
This process begins with the formation of pre-tubular aggregates, which develop into renal 
vesicles and eventually form the mature nephron (Figure 2) [6, 7]. Once the nephron progenitors 
have matured into renal vesicles, they undergo a mesenchyme to epithelial transition (MET), 
which will lead to the formation of glomeruli and tubular epithelial cells including the proximal 
and distal tubules [2, 8]. Total nephron number is determined during development and no new 
nephrons form once nephrogenesis has concluded, which occurs around gestation week 36 in 
humans (post natal day 3 [P3] in mice) [9]. Any perturbation to nephron formation causing 
decreased nephron endowment increases an individual’s susceptibility to renal diseases [9-11]. 
Therefore, a greater understanding of these developmental processes will provide insight into the 
underlying mechanisms leading to serious renal disease [12-14].  
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1.1.3 Nephron progenitors and nephron-derived structures 
Nephron progenitors are a population of self-renewing cells that differentiate into the functional 
unit of the kidney called the nephrons. Structurally, nephrons are composed of glomeruli, 
proximal tubules, the loop of Henle, and distal tubules, which drain into UE-derived collecting 
ducts (Figure 2) [7]. The epithelialized glomerular and tubular segments are all derived from 
nephron progenitors. Filtrate first enters and passes through the glomerulus, a structure 
surrounded by highly specialized epithelial cells called podocytes. Together, the podocytes, 
glomerular basement membrane, and glomerular endothelial cells make up the glomerular filter 
and restrict large proteins and molecules from entering into the nephron [2]. Once small 
molecules such as water, salts, and sugars pass through the glomerular filter, the filtrate (urine) 
encounters the proximal tubule region. Proximal tubules are responsible for reabsorbing 
metabolic solutes from the urine filtrate [2]. The urine then flows into the loop of Henle where 
water and sodium chloride recovery occurs [15]. Next, the urine flows through the distal tubules, 
which are responsible for magnesium, calcium, and potassium reabsorption as well as water 
absorption [2]. From the distal tubules the urine flows into the collecting ducts—responsible for 
water reabsorption—before moving into the urinary tract system.  
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Figure 2: Basic kidney development 
During nephrogenesis, nephron progenitors condense around the ureteric bud tips (purple) to form the cap 
mesenchyme (orange). Once differentiation cues are received by the nephron progenitors, they will mature into 
sequential structures 1) pre-tubular aggregate 2) renal vesicle 3) comma-shaped body 4) S-shaped body 5) mature 
nephron. 
1.1.4 Kidney function and clinical significance 
The primary function of the kidney is to eliminate waste, filter blood, and maintain physiological 
processes including pH and electrolyte homeostasis, blood pressure, and nutrient reabsorption [6, 
7, 16]. These functions are predominantly accomplished by the nephron. As a whole, the nephron 
is responsible for filtration and reabsorption through specialized cells and ion transporters. Since 
the nephron is the major structure involved in kidney function, robust nephron number is critical 
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for kidney function. In fact, humans have approximately 200,000 – 2,500,000 nephrons per 
kidney endowed at birth (~10,000 – 15,000 per mouse kidney) [17, 18]. Although this is a large 
range of nephron number, falling below this threshold greatly decreases kidney function and 
increases an individual’s susceptibility to diseases such as hypertension and chronic kidney 
disease (CKD), which have a prevalence of 29% and 14%, respectively, in the United States [9, 
10, 19-22].  Moreover, congenital abnormalities of the kidney and urinary tract (CAKUT) 
constitute approximately 25% of abnormalities identified prenatally and affect 1 in 500 pediatric 
patients (4.2 cases per 10,000 births) [23]. It has also been revealed that approximately 50% of 
pediatric patients with end stage renal disease (ESRD) have disease due to a CAKUT [24]. 
Although CAKUT includes a broad range of renal abnormalities, failure of normal nephron 
development has been identified as one major cause of renal malformation [24, 25].   
1.2 GENETIC EXPRESSION DICTATING KIDNEY DEVELOPMENT 
This section will describe a limited number of molecules involved in kidney development 
essential for understanding the entirety of this work. In the metanephric kidney, the MM secretes 
the signaling molecule glial-derived growth factor (GDNF) and fibroblast growth factor 10 
(FGF10) to induce bifurcation and branching of the UE. Branching of the UE forms ureteric bud 
tips (UB), which the MM condenses around to form cap mesenchyme (CM). Cells derived from 
the UE lineage express markers such as paired box gene 2 (PAX2) marking the UBs [26]. The 
nephron progenitors reside in the CM region and are marked by expression of sine oculis 
homeobox homolog 2 (SIX2) and Cbp/P300-interacting transactivator 1 (CITED1; Figure 3) [6, 
7]. The transcription factors SIX2 and WT1 play major roles in the maintenance of the 
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proliferating progenitor population and in early pre-tubular aggregation, respectively [7]. SIX2 is 
expressed in both self-renewing nephron progenitors and those poised for differentiation [7, 27, 
28], while WT1 is expressed in late-stage progenitors and during early pre-tubular aggregates [6, 
7]. The transcriptional co-activator CITED1 does not have a specific role and is expressed only 
in self-renewing nephron progenitors. Further, maintenance of SIX2+ self-renewing nephron 
progenitors is balanced by canonical wingless-type MMTB integration site family member 9B 
(WNT9B) signaling from the UE, therefore as CITED1, SIX2, and WT1 becomes down 
regulated, WNT9B is expressed and plays a role in inducing differentiation [29].  
As the nephron progenitors exit the nephron progenitor pool, CITED1 and SIX2 become 
down regulated while markers such as lymphoid enhancer binding factor 1 (LEF1), wingless-
type MMTV integration site family member 4 (WNT4), and lim homeobox protein 1 (LHX1) are 
up regulated (Figure 3) [2, 30]. These latter markers are expressed in pre-tubular aggregates and 
renal vesicles. As nephron progenitors mature and the expression of differentiation markers 
increases, the cells are committed to undergo differentiation via a mesenchymal to epithelia 
transition (MET) [11, 31]. Together, these regulators play important roles in the self-renewal, 
and differentiation of nephron progenitors and aid in the formation of robust nephron numbers.
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Figure 3: Genetic expression of nephron formation 
During nephrogenesis, nephron progenitors condense around the ureteric bud tips (purple) to form the cap 
mesenchyme (orange). The distinct developmental stages are dictated by the expression of molecules such as Cited1 
(self-renewing), Six2 (self-renewing/poised for differentiation), Lef1 (early differentiation), Wnt4 (differentiation), 
and Lhx1 (differentiation) to name a few. 
1.3 METABOLIC PROCESSES 
1.3.1 Glycolysis  
Cellular metabolism relies mainly on two forms of energy production: glycolysis and 
mitochondrial respiration. Glycolysis is the preferred mechanism for ATP energy production in 
developing stem and progenitors cells [32], such as nephron progenitors [17] (Table 1). 
Glycolytic metabolism can occur under anaerobic (without oxygen) or aerobic (with oxygen) 
conditions. Glycolysis is the catabolism of glucose to generate ATP and the reducing equivalent 
NADH. Glucose enters cells through specialized glucose transporter proteins where it then 
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undergoes a series of enzymatic reactions in the cytosol (Figure 4). The end product of this 
pathway is pyruvate. Furthermore, two pyruvate molecules are generated from every one glucose 
molecule [33]. From here, the presence or absence of oxygen dictates the fate of pyruvate. 
During aerobic glycolysis, pyruvate is shunted into the mitochondria allowing for more 
energy production [33, 34]. Once pyruvate enters the mitochondria, it is oxidized into acetyl-
coenzyme A (acetyl-coA) and used in the tricarboxylic acid cycle (TCA cycle) [35] as described 
in section 1.3.2. Anaerobic glycolysis, however, is the primary mechanism for ATP production 
in cells lacking oxygen availability [36]. Anaerobic glycolysis is characterized by the reduction 
of pyruvate to lactate (Figure 4), which is then transported out of the cell to be utilized as a 
metabolic intermediate by adjacent cells [36]. Although this reduction of pyruvate to lactate 
primarily occurs in the absence of oxygen, it can occur under oxygenated conditions through the 
Warburg effect [37], a phenomenon that leads to increased production of lactate through 
glycolysis in rapidly proliferating cells, first observed by Dr. Otto Warburg in the 1950s [38].  
Table 1: Metabolic pathways utilized by the nephron 
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1.3.2 Pentose phosphate pathway 
It is essential to note that parallel to glycolysis, highly proliferative cells like nephron progenitors 
require synthesis of biomolecules such as nucleotides in addition to ATP and NADH (Table 1). 
Nucleotide precursors are generated by the pentose phosphate pathway (PPP; Figure 4), which 
provides ribose-5-phosphate, sugars (pentose), and NADPH [39]. Importantly, the first step of 
glycolysis generates glucose-6-phosphate. Glucose-6-phosphate can proceed through glycolysis 
or it can be shuttled into the PPP [39]. The PPP consists of an oxidative phase characterized by 
the oxidation of NADPH from NADP+, and a non-oxidative phase resulting in pentose sugars 
and ribose-5-phosphate [39]. A previous investigation involving nephron progenitors has shown 
that PPP dysregulation may have some affect on renal development [28]. Moreover in a brief 
study of diabetic kidney development, Steer et al determined that there is a correlation between 
renal growth and the PPP [40, 41], however mechanisms of PPP utilization in the nephron and 
nephron progenitors have not been further studied. It is apparent that the PPP has not been 
readily interrogated in nephrons and nephron progenitors and future work in this lesser studied 
pathway would provide valuable insight into metabolic intermediate requirements in these cells.    
1.3.3 Gluconeogenesis: “reverse glycolysis” 
Interestingly, the kidney is unique in that it is the only organ other than the liver to perform 
gluconeogenesis or reverse glycolysis [42, 43]. Gluconeogenesis is a metabolic pathway utilized 
to maintain glucose homeostasis [44, 45]. In fact, the kidney has recently been shown to 
contribute to up to 20% of all glucose production [44]. Gluconeogenesis is a pathway that 
generated glucose from non-carbohydrate molecules such as glutamine (Figure 4) [46]. The 
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pathway is considered “reverse glycolysis” because many of the intermediate conversions during 
glycolysis are done in the opposite direction by the same enzymes utilized during glycolysis 
[47]. The exceptions to this include enzymes that catalyze the rate-limiting steps of glycolysis 
(hexokinase, phosphofructokinase, and pyruvate kinase), which are not bi-directional [47]. 
Therefore gluconeogenesis differs from glycolysis at those conversion points. The resulting 
glucose can then be metabolized to help maintain blood glucose levels [48]. 
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Figure 4: Overview of metabolic processes 
Glucose molecules (blue) enter the cell and are ultimately converted into pyruvate (purple). An alternative fate for 
glucose-6-phosphate (G6P) is that it can be shuttled into the pentose phosphate pathway (PPP) where it is used for 
nucleotide, NADP, sugar, and amino acid synthesis. After glycolysis, pyruvate can either undergo conversion to 
lactate (red) or be transported into mitochondria and utilized in the first step of the TCA cycle through conversion 
into acetyl-coenzyme A (Ac-CoA; orange). Alternatively fatty acid oxidation occurs when an acyl-coenzyme A 
(acyl-coA; light purple) and a long chain fatty acid (LCFA; dark grey) molecule are transported into mitochondria 
with the transporter carnitine. Once inside the mitochondria, the fatty acid-acyl-coA molecule is cleaved into an ac-
coA and a shorter LCFA. The ac-coA is shuttled into the TCA cycle while the LCFA is exported from the 
mitochondria to undergo another round of oxidation. Reactive oxygen species (ROS) are generated from the electron 
transport chain (ETC; green). Gluconeogenesis (reverse glycolysis) can also occur and in the kidney typically 
involves the conversion of glutamine (green) to glucose (blue).  
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1.3.4 Fatty acid oxidation 
β-oxidation is a metabolic process that involves the catabolism of fatty acids and is named such 
due to the oxidation of the β -carbon to a carbonyl carbon in a fatty acid molecule. This type of 
metabolism is an oxygen-dependent process that occurs primarily in the mitochondria, however 
this can also occur to a lesser extent in peroxisomes [49]. Since the proximal tubules are the 
second most abundant sources of mitochondria (second to the heart), fatty acid oxidation and 
mitochondrial respiration play a large role in proximal tubule function (Table 1) [50]. During this 
metabolic process, fatty acids that are transported into the cell are conjugated to acyl-coenzyme 
A (acyl-coA) for activation (Figure 4) [51]. The conjugated fatty-acyl-coA molecule is then 
transported into the mitochondria via the co-transporter carnitine (Figure 4) [52]. In the 
mitochondria, the fatty acyl-coA is next cleaved into a shorter chain fatty acyl-coA and an 
acetyl-coA [52]. The acetyl-coA enters into the tricarboxylic acid (TCA) cycle while the fatty 
acyl-coA continues through β-oxidation until only acetyl-coA molecules remain, which are 
incorporated into the TCA cycle [51]. This process generates a large range of ATP (anywhere 
from 30-200 ATP) depending on the size of the fatty acid [51].  
1.3.5 Mitochondrial respiration 
Mitochondrial respiration includes various biochemical pathways including the TCA cycle, 
oxidative phosphorylation, and fatty acid oxidation [53]. The major function of mitochondria is 
to generate ATP for cellular metabolism, which is required for renal cell function and injury 
recovery. One way the mitochondria generates energy and metabolic intermediates is through the 
TCA cycle [54]. In this pathway, pyruvate or fatty acyl-coA molecules enter into the 
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mitochondrial matrix to undergo conversion into acetyl-coA and a series of chemical reactions 
that produce 3 NADH, 1 FADH2, 2 CO2, and 1 ATP (Figure 4) [55]. Although the TCA cycle 
itself does not directly produce large quantities of ATP, the products NADH and FADH2 are 
known as electron carriers and are utilized in the electron transport chain during the next step of 
mitochondrial respiration called oxidative phosphorylation [55, 56]. 
Oxidative phosphorylation is utilized by a majority of the nephron segments [42, 57, 58] 
including nephron progenitors exiting the progenitor niche [17] (Table 1). During the metabolic 
process of oxidative phosphorylation, electrons are passed through five protein complexes, 
collectively called the electron transport chain (ETC), to create a proton gradient (Figure 4) [56]. 
To begin this “chain,” the electron carriers NADH and FADH2 shuttle electrons acquired through 
the TCA cycle and donate the electrons to one of the first two complexes of the ETC. NADH and 
FADH2 are then reduced and can be recycled back through the TCA cycle [55]. NADH donates 
its electrons to NADH dehydrogenase (Complex I) while FADH2 donates to succinate 
dehydrogenase (Complex II) [59]. Both Complex I and Complex II donate their electrons onto 
ubiquinone [60]. All electrons are then shuttled to cytochrome c reductase (Complex III) [61] 
before flowing through to cytochrome c oxidase (Complex IV) and being donated to the final 
electron acceptor, oxygen, to form H2O. Throughout the flow of electrons, protons are passing 
through complexes I, III, and IV into the intermembrane space to build a proton gradient [55]. 
By a process called chemiosmosis, the protons flow back through a protein complex called ATP 
synthase (Complex V) [62]. As the name suggests, ATP synthase uses the energy stored in the 
proton gradient to drive the synthesis of ATP [54]. Oxidative phosphorylation and ATP synthase 
generates a majority of the energy used by cells [55]. Combining aerobic glycolysis (net gain 2 
ATP per glucose), the TCA cycle (net gain 4 ATP per glucose), and oxidative phosphorylation 
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together generate a net of approximately 32-38 ATP per glucose molecule [56]. This high output 
of energy allows nephrons, particularly proximal tubule structures, to perform complex functions 
such as ion transport and water reabsorption.   
1.3.6 Reactive oxygen species 
Although mitochondria are considered the “power house of the cell,” they also produce toxic 
metabolic byproducts known as reactive oxygen species (ROS) [63]. ROS are generated 
primarily by the electron transport chain as electrons leak back through the inner mitochondrial 
membrane (Figure 4) [64]. Leakage of electrons leads to the formation of superoxide and 
hydrogen peroxide ROS molecules (Figure 4) [65]. Higher ROS production can result in 
oxidative damage and tissue pathologies. Conversely, ROS can act as second messengers in 
critical signaling pathways and may even be a necessary molecule for basic biological processes 
[66]. Although there is new evidence that ROS can play a positive role in a cell (such as driving 
cellular proliferation, function, and viability) [66], too many ROS can be damaging and lead to 
cell death. Given that mitochondria generate the majority of cellular aerobic energy and ROS, 
they are common sources of dysregulation and disease, such as in hypertension, diabetes 
mellitus, and acute and chronic kidney diseases [65, 67, 68]. 
1.3.7 Nephron progenitor metabolism 
Nephron progenitors are highly metabolically active, and rely on high rates of glycolysis to 
support energy and nucleotide demands during periods of proliferation and self-renewal [69]. In 
mice, nephron progenitors show age-dependent metabolic switching. Nephron progenitors at 
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embryonic day 13.5 (E13.5) exhibit higher rates of glycolysis and overall ATP production 
compared to postnatal day 0 (P0) progenitors [17]. E13.5 nephron progenitors utilize mostly 
glycolysis and low levels of oxidative phosphorylation, while the opposite is true for P0 nephron 
progenitors (Table 1) [17]. The mechanisms controlling these different metabolic profiles of 
nephron progenitors are unknown.  
One possibility is in the inherent nature of nephron progenitor development, which 
occurs in a relatively hypoxic environment and promotes hypoxia-inducible factor (HIF) 
expression. HIFs regulate several genes including those implicated in glycolysis, mitochondrial 
metabolism, cell proliferation/apoptosis, and cell cycle [70]. HIFs are stabilized during hypoxia, 
however when oxygen is present, they are hydroxylated by prolyl-4-hydroxylase domain (PHD) 
dioxygenases [71] and subsequently degraded by the ubiquitin ligase von Hippel-Lindau (VHL). 
PHD oxygen sensors have also been shown to be essential during nephrogenesis and inactivation 
of both PHD2 and PHD3 in Foxd1+ stromal cells results in reduced glomerular number, nephron 
dysfunction, and kidney malformation [71]. Although HIFs heavily influence metabolism during 
periods of hypoxia, inhibition of glycolysis can induce premature nephron progenitor 
differentiation [17], which suggests that additional mechanisms, such as PHDs, may contribute 
to the interplay between metabolism and cell fate through mitochondrial regulation.  
In addition to HIF-mediated cellular hypoxia response, tumor protein 53 (p53) is 
expressed in nephron progenitors and has been implicated in their cell cycle regulation and 
metabolism [72]. P53 inactivation leads to the promotion of carbohydrate and lipid metabolism 
as well as autophagy and ROS through the up-regulation of the mammalian target of rapamycin 
(mTOR) and AMP-activated protein kinase (AMPK) pathways [73]. Although p53 is most 
notably studied in cancer and other disease models, it is also a crucial protein for regulating self-
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renewal and the metabolic demands of nephron progenitors in the developing kidney. A recent 
study showed that mice with a conditional deletion of p53 specifically in the nephron progenitors 
(under the control of Six2:cre) exhibited renal abnormalities including altered self-renewal and 
nephron deficit as well as dysregulated energy metabolism [11]. P53-depleted nephron 
progenitors exhibited suppression of glucose metabolism pathways, which suggests a cell-type 
specific role for p53 [11]. Together, these studies suggest that p53 is more than a tumor 
suppressor protein and also plays a large role in regulating metabolism in nephron progenitors.  
1.3.8 Nephron metabolism 
The second characterized renal structure that is highly metabolically active is the proximal 
tubules. Proximal tubules are a derivative of nephron progenitors and involved in fluid 
reabsorption driven by sodium transport. Proximal tubular function requires ATP, which is why 
they are the second most abundant sources of mitochondria (with the most abundant source of 
mitochondria being the heart) [50]. Proximal tubules almost exclusively rely on oxidative 
phosphorylation metabolism primarily driven by β-oxidation of fatty acids [74]. Moreover, 
proximal tubules are not known to rely on glycolysis for ATP generation, although the reason 
behind this is not currently understood [50]. One potential reason is that glycolytic metabolism is 
a process reserved for self-renewing and proliferating cell populations. Although the proximal 
tubules are a terminally differentiated structure, they have some capacity to undergo repair when 
damaged such as after ischemic acute kidney injury (AKI). After AKI, the surviving proximal 
tubule epithelial cells initiate a dedifferentiation process to proliferate and replace sloughed and 
damaged cells [74, 75]. The dedifferentiation process, where cells become progenitor-like, is 
characterized by decreased fatty acid oxidation and increased glycolysis and lactate secretion 
 18 
[74]. As the epithelium redifferentiates, the metabolic profile of the tubules returns to primarily 
mitochondrial respiration, however if the metabolic profile is not restored, renal pathologies 
emerge [67, 68, 74].  Other structures that comprise the nephron have not been well 
metabolically characterized. However, some studies predominantly done in the 1980s 
investigated enzyme abundance and function in isolated segments of the nephron. These studies 
found that each segment has a unique metabolic profile, which likely corresponds to its function. 
Based on these investigations, the specific metabolic pathways of each segment can be 
hypothesized. A summary of the predicted metabolic pathways utilized along the nephron is 
shown in Table 1. Although the proteins expressed and their function is known, future 
investigations into kidney metabolism should include experimentation to definitively determine 
the types of metabolisms used along the nephron.    
1.3.9 Metabolism of a diseased kidney 
Wilms Tumor 
Wilms tumor is the most commonly encountered renal tumor in children accounting for 95% of 
all pediatric renal cancers and affecting approximately 650 new patients each year [76]. Two 
tumor-suppressing genes are frequently associated with the development of Wilms tumor: Wilms 
Tumor 1 and 2 (WT1/WT2). These genes are expressed in nephron progenitors and pre-tubular 
aggregates and expression is required for kidney development [77]. However, other genetic and 
epigenetic mutations have also been identified [78]. These tumors are thought to result from 
persistent nephron progenitor cells that remain capable of proliferation and differentiation [78].  
Similar to many other cancers, Wilms tumor exhibits metabolic alterations and the 
Warburg effect [78]
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epithelial, stromal, and blastemal [78]. Interestingly, the mitochondrial energy requirement of 
these three tissue types differs in patients with triphasic Wilms tumor [78]. Wilms tumor stromal 
tissue exhibits severe loss of mitochondria quantity and oxidative phosphorylation capacity [79], 
while the epithelial and blastemal tissues retain normal mitochondrial density [79]. Moreover, in 
addition to mitochondrial suppression, several other metabolic proteins are decreased such as 
those involved in long-chain fatty acid metabolism and amino acid metabolism [80]. Although 
these metabolic differences are known, only limited investigation has been done into the 
mechanisms leading to mitochondrial suppression.  
Approximately 6% of Wilms tumor patients have p53 mutations leading to the repression 
of HIF-1α [78]. In p53 knockout cell lines, pharmacological reactivation of p53 leads to 
suppression of aerobic glycolysis (the Warburg effect) [81]. HIF-1α is primarily localized in the 
nucleus in Wilms tumor tissue [82] suggesting that it contributes to the metabolic dysregulation 
phenotype. Like most cancers, Wilms tumor has a heavy reliance on glycolysis, thus 
pharmacological and molecular targeting of this metabolic pathway may prove successful as a 
novel therapeutic strategy.   
 
Renal Cell Carcinoma  
VHL, the major regulator of HIFs, is a tumor suppressor protein, which is a protein that, when 
mutated, causes tumorigenesis and cancer development, particularly in the kidney [83]. Loss of 
VHL plays a prominent role in the pathogenesis of clear cell renal cell carcinoma (ccRCC), and 
up to 70% of all ccRCC cases are attributed to VHL gene defects [84]. Although ccRCC is 
relatively rare in pediatric patients, it still accounts for up to 2% of pediatric renal cancers and is 
associated with poor prognosis and ineffective treatment options. Similar to other cancer types, 
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ccRCC is highly invasive and characterized by metabolic reprogramming towards glycolysis 
resulting in increased cellular proliferation and evasion of apoptosis to aid in rapid tumor growth 
[38]. In in vitro VHL-/VHL+ model systems, forced VHL expression leads to decreased 
glycolysis and glycolytic activity while TCA enzymes and ETC protein expressions were 
increased [83]. Moreover, VHL-deficient ccRCC cell lines exhibit HIF-dependent decreases in 
mitochondrial content associated with peroxisome proliferator-activated receptor gamma 
coactivator 1α (PGC-1α; mitochondrial biogenesis regulator) suppression [85]. PGC-1α is 
essential for mitochondrial function in proximal tubules and its expression leads to decreased 
tumor growth in ccRCC-derived cell lines [85]. Mice with a nephron progenitor-specific VHL 
deletions did not develop ccRCC or exhibit any tumor growth [86]. However, mice with nephron 
progenitor-specific VHL-BAP1 (a deubiquitinating enzyme that acts as a tumor suppressor) 
deletions, double knockout was sufficient for mice to spontaneously develop a ccRCC phenotype 
[86]. This suggests that the ccRCC phenotype may not present solely from loss of VHL and may 
instead be derived from an accumulation of mutations in multiple tumor suppressor genes. 
Further, research investigating this would shed light on the pathogenicity of these mutations and 
may lead to new therapeutics to treat this aggressive disease. Moreover, current cancer 
treatments have shifted towards targeting the metabolic reprogramming phenotype using 
inhibitors of glycolysis outlined in the following review [87]. These same therapeutics should be 
further investigated for use in invasive cancers such as ccRCC. 
 
Acute Kidney Injury 
Acute kidney injury (AKI) is classified as a sudden loss in kidney function resulting in waste 
buildup and electrolyte imbalance [88]. Although it is a common clinical disorder, it often results 
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in high morbidity and mortality with no effective treatment plan [88]. A recent worldwide study 
into the prevalence of AKI in pediatric patients ages 3 months to 25 years found that the overall 
incidence of AKI in critically ill children was approximately 27% [89]. AKI typically targets the 
proximal tubules and since they have high mitochondrial abundance, it is unsurprising that a 
hallmark of AKI is tubular ATP depletion [88].  
Since mitochondria are implicated in AKI manifestation and current treatments are 
lacking, the mitochondria are promising targets for drug discovery in treating AKI. One such 
target in the mitochondria is the metabolically linked sirtuin protein deacylase family. Sirtuins 
are important regulators of pathways involved in cellular proliferation, cell survival, metabolism, 
apoptosis, and DNA repair [90]. There are seven mammalian sirtuin proteins (SIRT1-SIRT7) 
[91] with SIRT1 and SIRT3 being the most well characterized in the kidney. Of the seven SIRT 
proteins, only SIRT3, SIRT4, and SIRT5 localize to the mitochondria. Although SIRT1 does not 
localize to the mitochondria, it has significant influence on metabolism by mediating 
mitochondrial activity through proteins such as PGC-1α [91]. PGC-1α knockout mice subjected 
to AKI fail to regain normal renal function showing that PGC-1α expression is required for renal 
protection against AKI [92]. This is likely because PGC-1α regulates NAD+, which is consumed 
by SIRT proteins. Mouse models of AKI have shown that SIRT1 and SIRT2 exhibit renal 
protective effects in cisplatin-induced AKI. Moreover, these sirtuins prevent against renal 
fibrogenesis and in addition to SIRT3 have been associated with kidney longevity [93]. Further, 
SIRT1 and SIRT3 are currently being investigated as therapeutic targets for AKI and kidney 
disease as they both have important roles mediating antioxidant and anti-inflammatory effects in 
the kidney [94]. These ongoing studies are critical for the development of new strategies for the 
treatment of kidney diseases. 
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Another repercussion of AKI in the proximal tubules is metabolic reprogramming after 
injury. The proximal tubules are terminally differentiated structures, however they have the 
capacity to undergo repair when damaged. After AKI, the surviving proximal tubule epithelial 
cells initiate a dedifferentiation process to proliferate and replace sloughed and damaged cells 
[74]. The dedifferentiation process where cells become progenitor-like is characterized by 
decreased FAO and increased glycolysis and lactate secretion [74]. As the epithelium 
redifferentiates, the metabolic profile of the tubules returns to primarily mitochondrial 
respiration, however if the metabolic profile is not restored, renal pathologies emerge [67, 68, 
74]. Understanding the metabolic changes associated with injury and repair will greatly benefit 
the field and provide novel molecular targets for AKI treatment.   
 
Polycystic Kidney Disease 
Polycystic kidney disease (PKD) is the fourth leading cause of renal failure (accounts for up to 
10% of end stage renal disease cases worldwide). PKD is characterized by development of fluid-
filled cysts in the kidney, most commonly in tubular regions of the nephron [95]. Although PKD 
symptoms typically present around 35 years of age, symptoms can begin as early as within a few 
months after birth [96]. The most common forms of the disease are caused by mutations in the 
genes polycystin 1 and 2 (PKD1/PKD2) [95]. Recent studies in PKD etiology suggest that 
metabolism may be critical for disease development and progression [95, 97]. Rowe et al found 
that mouse embryonic fibroblasts (MEFs) isolated from kidney-specific Pkd1 knockout mice 
exhibited decreased glucose levels and increased lactate [97]. Furthermore, when these cells 
were glucose deprived, ATP levels decreased, while mitochondrial inhibition had little effect 
[97]. Therefore, it was concluded that glucose metabolism is necessary in cells lacking Pkd1, a 
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phenotype reminiscent of the Warburg effect. Although Rowe et al found that mitochondrial 
inhibition did not alter ATP levels, another recent study found that in mouse models of 
autosomal dominant PKD (ADPKD) and in human ADPKD-derived cells, mitochondrial density 
and biogenesis were significantly decreased [98]. Further, this study showed that mitochondrial 
dysfunction and PGC-1α down regulation likely contribute to pathogenic cyst formation [98]. 
This highly proliferative, cancer-like phenotype with mitochondrial abnormalities should lead 
PKD research towards treatments such as glycolysis inhibition. In fact, Rowe et al generated and 
treated two PKD mouse models with the glycolysis inhibitor 2-deoxyglucose (2DG) and found a 
decrease in disease progression [97], suggesting that glucose metabolism plays a large role in 
disease development. Further, another recent study utilizing the serine-threonine kinase Lkb1 
deficient mouse model found that the kidneys of these mice required glutamine for ureteric bud 
branching and proliferation [99]. This is important because glutamine can be used as a fuel 
source in the TCA and as the carbon backbone for gluconeogenesis. In line with the collective 
findings of these studies on PKD, metabolic reprogramming and altered metabolite utilization is 
a commonality between normal kidney development, cancer, and renal diseases and thus the 
potential of metabolic pathways as therapeutic targets must be interrogated.  
 
Chronic Kidney Disease 
Chronic kidney disease (CKD) is simply defined as any condition that leads to abnormalities in 
kidney function or structure over a period of time greater than 3 months [100]. CKD is a 
common disease affecting more than 10% of adults in the United States [21], however because 
current detection methods are lacking, patients are typically unaware of their CKD until it 
reaches a later stage [101]. Unfortunately, this delay in disease treatment can lead to poor patient 
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prognosis because there is not a known cure. CKD is uncommon in children, however when 
pediatric cases arise, they are at significantly higher risk for health complications and experience 
increased susceptibility to disease later in life [102]. This necessitates research into enhanced 
CKD diagnostics, mechanistic understanding, and treatment options.    
More recently, links between metabolic dysfunction, mitochondrial abnormalities, and 
CKD progression has been investigated. Although these types of studies are increasing in 
popularity, the mechanisms contributing to mitochondrial regulation and kidney function are still 
relatively unknown.   It is now widely accepted that mitochondrial dysfunction plays a role in 
CKD [103-105], however whether is it a driver of pathology or a secondary effect as a 
consequence of the disease has not been completely elucidated. A recent genomic screen 
studying genetic dysregulation in patients with CKD found that out of the 44 most dysregulated 
genes, 11 of those genes were involved in oxidative phosphorylation [104]. Further investigation 
revealed these patients exhibited increased ETC protein expression but these proteins had overall 
decreased activity and high levels of oxidative damage [104]. This led the researchers to 
conclude that ROS is likely a major driver of the disease pathology [104]. Further in a recent 
review by the same group, the authors highlight the involvement of ROS in disease progression 
and interrogate the potential therapeutic benefits of molecules with antioxidant properties in 
targeting the mitochondria and treating CKD [105]. In addition to ROS, a few other pathways 
have been recently investigated for their role in mediating mitochondrial dysfunction in CKD. It 
is well established that the primary function of the kidney is reabsorption, which is done through 
ATP-dependent molecules [103]. In CKD patients and animal models the nuclear receptor called 
the estrogen related receptor gamma (ERRγ) has been found to be an important regulator of 
mitochondrial oxidative phosphorylation and FAO [103]. ERRγ regulates hundreds of genes 
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involved in these metabolic pathways and is decreased in CKD [103]. Therefore, ERRγ may be a 
novel receptor targeted for CKD prevention in the future. Lastly, one pathological symptom of 
severe CKD is fibrosis. Other molecules that regulate mitochondrial function and biogenesis are 
PPARα and PGC-1α (described in more detail above). These molecules are both highly 
expressed in renal tubular cells due to the dense mitochondrial load [106]. Developmental 
pathways, such as Notch, have been linked to the generation of fibrosis as it is highly activated in 
CKD [106]. As such, PPARα and PGC-1α expression is decreased in CKD models as well as in 
cisplatin-induced AKI [106, 107]. Han et al found that forced expression of PGC-1α protected 
mice against Notch-induced kidney fibrosis and could even reverse the mitochondrial defects 
associated with Notch overexpression [106]. Studies such as these are recognizing the 
importance of mitochondria in renal disease and are proposing new mechanisms that will better 
help the field combat and cure CKD. Although there is increased interest in the role of 
metabolism in renal diseases, there are still many gaps in our knowledge and understanding of 
the complex mechanisms contributing to disease. However, studies such as those described have 
presented new, novel targets for drug discovery and potential therapeutics such as antioxidants, 
Notch pathways, and ERRγ expression.  
1.4 HYPOXIA AND THE DEVELOPING KIDNEY 
1.4.1 Hypoxia and kidney development 
It has been previously shown that hypoxia plays a large role in kidney development [205]. In 
fact, the kidney initially develops in a relatively hypoxia environment ranging from 
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approximately 5-8% O2 in utero [10]. Rymer et al (2014) investigated renal vasculature 
development and blood flow and revealed that perfusion of the vasculature likely drives nephron 
progenitor differentiation suggesting that an influx of oxygen is required in order for nephron 
progenitors to receive differentiation cues [205]. This work found that at E15.5 in mice, 
perfusion of the vessels did not cross into the nephrogenic zone where the nephron progenitors 
reside, however the mature nephrons were extensively perfused allowed blood to pass into the 
glomeruli for filtration [205]. It is also thought that this phenomena leads to normal development 
and is essential for establishing nephron number. Mechanistically, this process if facilitated by 
the VHL/HIF pathway (the major oxygen-sensing pathway expressed in the developing kidney) 
described below. 
1.4.2 Hypoxia-inducible factors  
Hypoxia inducible factors (HIFs) are a family of transcription factors highly expressed during 
hypoxia in the kidney [108-110]. Moreover, approximately 2% of all human genes are indirectly 
or directly regulated by HIFs [83]. Three HIF-α and two HIF-E isoforms are currently known 
and are constituted by a basis helix-loop-helix-PAS structure: HIF-1α, HIF-2α, HIF-3α, and HIF-
1E and HIF-2E [110]. Expression of HIF-α molecules is strictly regulated by the E3 ubiquitin 
ligase von Hippel Lindau (VHL) such that VHL targets HIFs for proteasomal degradation when 
oxygen is abundant (Figure 5) [111, 112]. Prior to VHL-mediated degradation, HIF-α proteins 
are hydroxylated by prolyl hydroxylase domain (PHD) proteins [110, 113]. These PHD proteins 
require oxygen, Fe2+, and 2-oxoglutarate for activation [110]. Constitutively expressed HIF-E 
molecules, however, are not oxygen-dependent and are therefore not regulated by PHDs and 
VHL. HIF-1α is the most well characterized developmental isoform and has been heavily 
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implicated in mediating cellular processes during both physiological and pathological hypoxia 
[108, 114, 115].  
Kidney formation is highly dependent on oxygen concentration, and during early fetal 
development the kidneys are initially exposed to a physiologically hypoxic gradient [116, 117]. 
This process of gradual oxygenation likely drives proliferation and then differentiation of the 
nephron progenitor population [108], but the exact mechanism is poorly understood. Most 
notably, HIF-1α is highly expressed when the developing kidney is exposed to physiological 
hypoxia [108, 117-119]. However, as the vasculature of the developing kidney matures, oxygen 
levels increase, facilitating HIF-1α degradation via VHL [117]. Metabolically, HIF expression 
during hypoxia aids in significant increases in anaerobic glycolysis by targeting glucose 
transporters and glycolysis genes [38, 70, 120]. Simultaneously, HIF-1D acts as a genetic 
repressor of enzymes involved in the mitochondrial oxidation of pyruvate, a key step in 
mitochondrial respiration [70, 120, 121]. Up-regulation of glycolysis by HIF-1α allows stem 
cells to rapidly proliferate and self-renew. However, as the vasculature matures, VHL down 
regulates HIF-1α [122] and the cells switch to rely on mitochondrial respiration. Since HIFs have 
been linked to metabolism and nephron progenitors have unique metabolic characteristics and 
high HIF-1α expression [123], it is likely that these proteins facilitate the metabolic profile of 
nephron progenitors during nephrogenesis. HIFs have also been implicated in numerous other 
cellular processes including angiogenesis, vascularization, cell cycle regulation, proliferation, 
and apoptosis [124-129].  Early investigations into HIF-1α attempted to use global knockout 
mouse models, which proved to be embryonic lethal [130], therefore conditional deletions are 
most commonly generated for analysis.  
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1.4.3 Von Hippel Lindau  
VHL, the major regulator of HIFs, is also considered a tumor suppressor protein, which is a 
protein that, when mutated, causes tumorigenesis and cancer development. VHL inactivation in 
humans leads to a phenotype known as autosomal dominant Von Hippel Lindau (VHL) Disease 
and is largely characterized by invasive tumor growth particularly in the kidney [83]. VHL gene 
mutations also play a predominant role in the pathogenesis of clear cell renal cell carcinoma 
(ccRCC), and are often also associated with VHL Disease. In fact, up to 70% of all ccRCC cases 
are attributed to VHL gene defects [84].  
Although HIF-1α is considered the major target of VHL, HIF-2α is more highly 
expressed and implicated in ccRCC [131]. In this case, HIF-2α acts as a metabolic regulator 
leading to increased glycolysis, decreased gluconeogenesis, and increased lactate fermentation in 
the tumor microenvironment (the Warburg effect) [38, 132]. This metabolic reprogramming 
allows for increased cellular proliferation and evasion of apoptosis [38]. In in vitro VHL 
knockdown and knockout model systems, forced VHL expression lead to decreased glycolysis 
and glycolytic activity while TCA enzymes and ETC protein expressions were increased [83]. 
Moreover, VHL-deficient ccRCC cell lines exhibit HIF-dependent decreases in mitochondrial 
content associated with PGC-1α suppression. PGC-1α is a PPARJ co-activator, which is a family 
of transcription factors regulated to coordinate mitochondrial biogenesis [85]. Further, PGC-1α is 
essential for mitochondrial function in proximal tubules and PGC-1α expression decreases tumor 
growth in ccRCC-derived cell lines [85]. Moving into a mouse model, Iyer et al generated a 
global VHL knockout mouse, which resulted in embryonic lethality prior to kidney development 
[108, 133, 134]. Wang et al generated mice with a conditional deletion of VHL specifically in the 
nephron progenitors under a Six2creGFP and found that they did not develop ccRCC or exhibit 
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any tumor growth [86]. However, if VHL is knocked out in conjunction with a nephron 
progenitor-specific BAP1 (tumor suppression protein) deletion, the double knockout was 
sufficient for mice to spontaneously develop kidney tumors and renal cell carcinoma [86]. These 
VHL-BAP1 double knockout mice also exhibited HIF-1 and HIF-2-dependent metabolism gene 
up regulation [86].  
These in vitro and in vivo studies demonstrate the importance of VHL in regulating 
metabolism, although conclusive mechanisms are currently not well known. Although, VHL has 
not been previously characterized as a driver of metabolic processes during kidney development, 
recent investigations in zebrafish demonstrate the importance of VHL in pronephros formation, 
blood vessel formation, and renal function [135, 136].   
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Figure 5: The VHL/HIF pathway 
During normoxia, pVHL is recruited to nephron progenitors to ubiquitinate HIF-1α for proteasomal degradation. 
However, during hypoxia, HIF-1α binds to its β-subunit in the nucleus to initiate transcription of hypoxia response 
elements (HREs) resulting in abnormal nephron differentiation.    
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1.4.4 Causes of pathological prenatal hypoxia 
As previously discussed, the kidneys develop in a relatively hypoxic environment ranging 
anywhere between 1 and 9% O2 [116, 117]. This range constitutes normal physiology hypoxia, 
while O2 < 1% is classified as pathological hypoxia [113, 137, 138]. Exposure to pathological 
hypoxia during embryogenesis has been shown to negatively impact fetal growth and 
development [113]. Moreover, pathological hypoxia during development can increase disease 
susceptibility and lead to adverse health conditions later in life [139]. Fetal hypoxia can be 
caused by a number of insults including: maternal smoking, environmental pollutants, placental 
insufficiency, and fetal anemia to name a few. Placental insufficiency is one of the most common 
(affecting 3-5% of pregnancies) causes of intrauterine hypoxia [139] and, depending on the 
severity, causes defects in metabolic, endocrine, and hematological systems. Specifically in the 
kidney, fetal exposure to pathological hypoxia has been linked to decreased nephron number [10, 
18, 22]. Since the nephron is responsible for a majority of kidney functions, perturbations to 
nephron endowment significantly increase susceptibility to diseases such as CKD and ESRD. 
1.4.5 Introduction to the experimental chapters 
The following experimental chapters are aimed at detailing the relationship between hypoxia, 
metabolism, and kidney development. This work will focus on 1) an in vitro characterization of 
hypoxia adaptation and metabolic reprogramming 2) the effect of prenatal hypoxia exposure on 
the developing kidney and long-term disease susceptibility 3) the role of VHL in mediating 
metabolic switching and nephron progenitor fate and 4) the role of VHL in mitochondrial 
function and metabolism.  
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2.0  THE EFFECT OF HYPOXIA ON RENAL CELL METABOLISM 
This chapter is an ongoing study and more experimentation is required before it can be 
considered for publication. 
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2.1 CHAPTER SUMMARY 
Placental insufficiency, characterized by fetal nutrient and oxygen deprivation, is a leading cause 
of Intrauterine Growth Restriction (IUGR), a condition that affects 12% of deliveries and causes 
75% of perinatal deaths in the United States. For patients diagnosed with IUGR, the developing 
fetus exhibits a preferential redirection of oxygen and blood flow away from the kidney, leading 
to organ underdevelopment and increased risk for disease later in life. Although the kidneys 
initially develop in a hypoxic environment, as its vasculature matures, renal blood flow increases 
to facilitate oxygen delivery. Oxygenation is a process that is closely regulated by transcription 
factors called hypoxia-inducible factors (HIFs), which are highly expressed during hypoxia. 
HIFs help cells adapt to periods of hypoxia by regulating cellular processes such as glucose 
metabolism, mitochondrial respiration, cell division, and apoptosis. Our hypothesis for this 
investigation is that pathological hypoxia results in metabolic reprogramming towards anaerobic 
glycolysis over mitochondrial respiration. To test this hypothesis, Human Embryonic Kidney 
cells (HEK293) were cultured in either normoxia (~20% O2) or hypoxia (1% O2) for 24 or 48 
hours. We evaluated cell viability, cell proliferation, gene expression, and ROS production. 
There were no significant differences in cell viability between normoxic and hypoxic cells. Cells 
exposed to hypoxia exhibited decreased cellular proliferation after 24 hours, however recovered 
by 48 hours of exposure. Our data also revealed metabolic gene expression differences at both 24 
and 48 hours and a decrease in ROS after 48 hours of hypoxia. Together, our data suggests that 
renal embryonic cells exposed to hypoxia exhibit a delay in adaptation to hypoxia that occurs 
after 24 hours and the cells experience metabolic reprogramming towards glycolysis to aid in 
hypoxia adaptation, promote cell survival, and repress harmful ROS.  
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2.2 INTRODUCTION 
Hypoxia is a pathological condition defined as a reduction or lack of oxygen availability [117]. 
In aerobic organisms, such as mammals, oxygen is necessary to facilitate several molecular and 
biological processes including cellular energy production. When oxygen is not available, cells 
undergo complex reprogramming to adapt to the hypoxic insult. Placental insufficiency, a 
disease characterized by fetal oxygen deprivation, is a leading cause of Intrauterine Growth 
Restriction (IUGR) [140, 141], a condition that affects up to 7% of all pregnancies and leads to 
75% of perinatal deaths [142, 143]. In patients suffering from placental insufficiency and IUGR, 
the developing fetus exhibits a preferential redirection of oxygen and blood flow away from the 
kidney in favor of the brain and heart [139], leading to organ underdevelopment and increased 
disease susceptibility in pediatric patients as well as later in life. Although the kidney develops in 
a relatively hypoxia environment, as the vasculature matures to increase blood flow, oxygen 
levels increase [118]. This process is characterized by the expression of hypoxia-inducible 
factors (HIFs), which are highly expressed during developmental and pathological hypoxia 
[117]. HIFs are transcription factors that aid in cellular adaptation and response to low oxygen 
conditions [109, 117]. The primary purpose of HIFs is to facilitate cellular processes that 
increase oxygen flow, but also allow cells to adapt and evade cell death [109].  
In previous stem cell hypoxia studies, it was shown that HIFs have several gene targets 
involved in glycolysis metabolism [120, 121, 144]. It was also shown that HIF-1α specifically 
has a dual role of promoting glycolysis while actively inhibiting oxidative phosphorylation [115, 
121, 145-148]. Anaerobic glycolysis is the primary type of metabolism performed during periods 
of low oxygen. Cells can quickly utilize glucose to generate ATP energy and electron carriers to 
support cellular functions such as self-renewal and proliferation [32]. Stem, progenitor, immune, 
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and cancer cells are most widely associated with using HIFs and glycolysis to rapidly expand 
their populations [32, 69, 149-152]. Moreover, stem and progenitor cells originate during 
development when sufficient oxygen is unavailable, therefore HIFs are expressed to maintain 
metabolism and keep cells from undergoing apoptosis. However, once stem and progenitor cells 
receive signals to undergo differentiation, many switch their metabolisms to the more efficient 
oxidative phosphorylation [17]. We believe this switch in metabolism is due to increased oxygen 
availability.  
This study investigated the influence of hypoxia on cellular processes in renal cells. 
Human Embryonic Kidney cells (HEK293) were cultured in normoxia or hypoxia for 24 or 48 
hours prior to analysis. Previous research suggests that exposure to hypoxia prevents HIF 
degradation and there increases the expression of HIFs. We found that hypoxia exposure did not 
alter cell viability at either time point investigated. Although viability was not unchanged, 
cellular proliferation was significantly decreased at 24 hours but not at 48 hours, which suggests 
that cells do not fully adapt to hypoxia until approximately 48 hours.  Gene expression 
alterations were first observed at 24 hours such that cells cultured in hypoxia were using both 
glycolysis and mitochondrial respiration, however by 48 hours were predominantly using 
glycolysis. Lastly, we measured ROS as a determinant of cellular health and found that at 24 
hours cells had slightly increased, non-significant ROS production, however by 48 hours ROS 
was significantly decreased. Together, this study shows that HEK-293T cells exhibit a delay in 
adaptation to hypoxia that occurs between 24 and 48 hours that involves metabolic 
reprogramming towards glycolysis.  
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2.3 METHODS AND MATERIALS 
2.3.1 Cell culture techniques 
HEK-293 (human embryonic kidney cell line) cells were cultured in T75 flasks in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with high glucose, sodium pyruvate, 
GlutaMAXTM, and phenol red (Thermo Fisher Scientific). Media was also treated with 10% Fetal 
Bovine Serum (FBS) and 1% penicillin/streptomycin antibiotic. Culture conditions were set at 
5% CO2 and in either normoxia (21% ambient oxygen) or hypoxia (1% oxygen) for 24 or 48 
hours. Hypoxic conditions were obtained using a hypoxia chamber (Rangos Research Center 
Esni Laboratory). Cells were passaged at ~80% confluency. Experiments were done in at least 
triplicate in 6-well culture plates. 
2.3.2 Real time quantitative polymerase chain reaction (PCR) 
Cells were harvested after the appropriate culture time and conditions. RNA was isolated using a 
miRNeasy RNA isolation Kit (Qiagen). RNA was quantified using a Nanodrop 2000c (Thermo 
Fisher Scientific). The Superscript First Strand cDNA kit (Invitrogen, CA) was used for cDNA 
synthesis of 500ng of RNA. The cDNA from these samples was analyzed using a C1000 
Thermal Cycler (Bio-Rad, Hercules, CA) to determine the levels of mRNA in the tissues.  The 
following genes were analyzed using this method: GAPDH, LDHA, SIRT3, TOMM20, IDH1, 
KI67, NOX4, and CASP3. All gene expression was normalized to 18S. Primer sequences are 
listed in Appendix B. 
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2.3.3 Lactate production determination 
Lactate in the supernatants was measured using a Lactate Plus meter (Nova Biomedical) and 
Lactate Plus lactate test strips (Nova Biomedical). 
2.3.4 Trypan blue cell viability assay 
Cells were harvested and 1 x 106 cells were stained using 0.4% trypan blue solution (Thermo 
Fisher Scientific). Both viable and non-viable cells were counted on a hemocytometer in 
duplicate and averaged.   The total number of viable cells was divided by the total number of 
both viable and non-viable cells and multiplied by 100 to obtain percent viability for each 
sample.  
2.3.5 Flow cytometry for reactive oxygen species 
Cells were harvested and 1 x 106 cells were stained for 15 minutes at 37°C using 5PM 
MitoSOXTM Red Mitochondrial Superoxide Indicator (Thermo Fisher Scientific; Appendix E) 
per manufacturer’s guidelines. Cells were analyzed on a BD LSRFORTESSA cell analyzer (BD 
Biosciences) through the Flow Cytometry Core at the Rangos Research Center located at the 
UPMC Children’s Hospital of Pittsburgh. Mean fluorescent intensity was determined using 
FlowJo software (v10.1).    
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2.3.6 Cellular proliferation 
1 x 106 cells were stained for 15 minutes at 37°C using 1mM Violet Proliferation Dye (VDP450; 
BD Biosciences; Appendix E) per manufacturer’s guidelines. Cells were then plated in 6-well 
plates and cultured for 24 or 48 hours in either normoxia or hypoxia. Cells were harvested and 
analyzed on a BD LSRFORTESSA cell analyzer (BD Biosciences) through the Flow Cytometry 
Core at the Rangos Research Center located at the UPMC Children’s Hospital of Pittsburgh. 
Data was analyzed using FlowJo software (v10.1).      
2.3.7 Statistical analysis 
Minimums of 3 biological replicates were used for each experiment in at least technical 
duplicate. When comparing two sample groups, statistical significance was determined using a 
two-tailed Student’s t test (α = 0.05). Significance was defined as *P<0.05, **P<0.01, and 
***P<0.001. Where appropriate, data is presented as mean ± standard error of the mean. Data 
was analyzed using Microsoft Excel and figures were generated using GraphPad Prism 7.  
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2.4 RESULTS 
2.4.1 Hypoxia exposure does not alter cell viability 
To begin our investigation into the significance of hypoxia on renal cell metabolism, HEK293 
cells were cultured in normoxia (~21% O2) or hypoxia (~1% O2) for 24 and 48 hours. Previous 
studies have indicated that although hypoxic environments may alter cell viability in certain cell 
types, hypoxia typically does not significantly affect cellular viability in renal cells [153, 154]. 
This is particularly true regarding the hypoxic environment surrounding tumorigenic renal cells. 
In fact, renal cancer cells utilize hypoxia to undergo rapid growth and expansion [154]. In 
HEK293 cells exposed to hypoxia, there were no significant differences in cell viability at either 
24 hours or 48 hours (Figure 6A) Additionally, we did not reveal any significant differences in 
CASP3 gene expression after 48 hours of hypoxia (Figure 6B). This suggests that hypoxia does 
not alter cellular viability in HEK293 cells.  
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Figure 6: Cell viability is not affected by chronic hypoxia 
(A) There were no changes in cell viability after both 24 and 48 hours of 1% O2 exposure as indicated by manual 
counting of cells dyed by trypan blue. Error bars indicated as SEM. 24 hour: P=0.82; N=3. 48 hour: P=0.76; N=4. 
(B) CASP3 (cell death) gene expression was not significantly different between 48-hour normoxia and hypoxia 
exposure. P=0.83; N=3. Error bars indicated as SEM. 
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2.4.2 HEK293 cells exhibit a decrease in proliferation prior to hypoxia adaptation 
Next, we evaluated the effect of hypoxia on cellular proliferation. RCC cells propagate quickly 
in hypoxia, therefore we hypothesized that HEK293 cells exposed to hypoxia would exhibit 
similarly increased proliferation. Cells were stained with proliferation dye and cultured for 24 or 
48 hours prior to analysis using flow cytometry. After 24 hours, HEK293 cells exhibited 
significantly reduced rates of proliferation (average rates are 91% and 82%, respectively) in cells 
cultured in hypoxia. However, after 48 hours in hypoxia, there were no significant differences 
between cells in the two culture conditions (Figure 7A-C). Proliferation was further evaluated 
using KI67 gene expression, which showed similar trends (Figure 7D). This suggests that 
adaptation to hypoxia occurs between 24 and 48 hours after initial exposure. Although a 
reduction in the proliferative rate was not initially anticipated, a period of growth arrest is not 
entirely unexpected as these cells were acclimated to normoxia, and transitioned abruptly into 
severe hypoxia. After this initial delay in proliferation, the cells then rapidly begin dividing after 
adaptation, which is shown by the increase in proliferation that becomes comparable to the 
normoxia control cells after 48 hours.  
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Figure 7: Cells exposed to hypoxia exhibit adaptation delay 
(A-C) Cellular proliferation was significantly decreased 24-hours after hypoxia exposure, however proliferation was 
unaffected by 48 hours as measured by flow cytometry (representative sample shown; averages equal 91% and 82%, 
respectively). 24 hour: P<0.005; N=6. 48 hour: P=0.18; N=5. Error bars indicated as SEM. (D) KI67 (proliferation 
marker) gene expression exhibited similar trends to the proliferation data with decreased expression at 24 hours and 
recovery/adaptation after 48 hours; N=2; significance not determined. Error bars indicated as SEM. 
 
2.4.3 Metabolic gene expression is altered after chronic hypoxia exposure 
Several studies have previously indicated that hypoxia promotes anaerobic glycolysis [17, 36, 
38, 74, 115, 146, 149, 155-159]. To begin our investigation into the role of hypoxia in mediating 
metabolic processes, we analyzed gene expression of known glycolysis and mitochondrial 
metabolic genes. In relation to glycolysis, we saw a significant increase in LDHA expression at 
both 24 and 48 hours and a trending increase in GAPDH expression at both time points (Figure 
8A). In contrast, we observed comparable expression of SIRT3, TOMM20, and IDH1 expression 
at 24 hours and decreased expression in all three mitochondrial genes by 48 hours of hypoxia 
(Figure 8B). This indicates that the HEK293 cells likely undergo metabolic reprogramming 
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towards anaerobic glycolysis between 24 and 48 hours after initial exposure, which is consistent 
with a delay in adaptation to hypoxia. Moreover, lactate secretion in the media supernatants 
show significantly increased lactate levels after both 24 and 48 hours of hypoxia exposure 
(Figure 8C). This suggests that hypoxia leads to an increase in glycolysis in HEK293 cells.  
 
GAPDH LDHA
0
100
200
300
400
%
 N
or
m
al
iz
ed
 to
 C
on
tro
l
Glycolysis Gene Expression
Normoxia 24
Hypoxia 24
Normoxia 48
Hypoxia 48*
*
SIRT3 TOMM20 IDH1
0
50
100
150
200
%
 N
or
m
al
iz
ed
 to
 C
on
tro
l
Mitochondrial Gene Expression
*
*
24 Hours 48 Hours
0
5
10
15
20
m
m
ol
/L
Lactate Secretion
Normoxia
Hypoxia*
*
A 
B 
C 
 
Figure 8: Glycolysis is increased after hypoxia exposure 
(A) Glycolysis genes GAPDH and LDHA are significantly increased after 48-hours of hypoxia exposure. 24 hour: 
P<0.05; N=3. 48 hour: P=0.05; N=3. (B) Mitochondrial genes SIRT3, Tomm20, and IDH1 are decreased after 48-
hours of hypoxia exposure. 48 hour: P=0.05; N=3.  (C) Lactate in the media was significantly increased at both 24 
and 48 hours after hypoxia exposure. P<0.05. Error bars indicated as SEM. 
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2.4.4 Hypoxic cells generate less ROS 
Lastly, we evaluated mitochondrial function by determining ROS levels. Flow cytometry 
staining with MitoSox revealed similar levels of ROS after 24 hours of hypoxia (Figure 9A). By 
48 hours of hypoxia exposure, the cells showed significantly reduced levels of ROS (Figure 9A). 
Decreased ROS would be indicative of a decreased reliance on mitochondrial metabolism, and 
suggests that these cells are in fact utilizing glycolysis. We also believe this further suggests that 
cells exhibit adaptation to hypoxia between 24 and 48 hours of exposure. Additionally, we 
evaluated NOX4 (ROS-producing oxygen sensor) gene expression, which corresponded to the 
flow cytometry data with reduced ROS by 48 hours (Figure 9B).  
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Figure 9: ROS is decreased during hypoxia exposure 
(A) ROS is decreased after 48 hours of hypoxia exposure. 24 hours: P=0.69; N=3. 48 hour: P=0.04; N=3. Error bars 
indicated as SEM. (B) NOX4 (ROS marker) gene expression is trending down in cells exposed to hypoxia. 24 hours: 
P=0.98; N=3. 48 hour: P=0.15; N=3. Error bars indicated as SEM. 
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2.5 DISCUSSION 
Placental insufficiency and IUGR affect up to 7% of all pregnancies in the United States [142, 
143]. Both of these conditions lead to fetal hypoxia, or lack of necessary oxygen supply [117]. 
Pathological fetal hypoxia often leads to preferential redirection of oxygenated blood towards 
organs such as the heart and brain over less vital organs [139]. This redirection of blood often 
leads to kidney underdevelopment and increases susceptibility to kidney disease, diabetes, and 
hypertension. Molecularly, cellular response to hypoxia is mediated by hypoxia-inducible factor 
(HIFs) transcription factors in order to facilitate an influx of oxygen and maintain cellular 
processes [117]. HIFs are highly expressed during hypoxia and regulate genes containing 
hypoxia response elements (HREs) [11, 115, 150]. Many HREs encode proteins involved in 
metabolism, primarily glycolysis, to help sustain energy production in the absence of oxygen 
[144]. Additionally, some HREs are responsible for the down-regulation of oxygen-dependent 
mitochondrial respiration [121]. Therefore, there is a clear link between oxygen availability and 
metabolic regulation. 
Previous studies have shown that kidney “stem” cells, known as nephron progenitors, 
utilize different types of metabolism at different points in development [17]. Specifically, self-
renewing, proliferative nephron progenitors rely more heavily on glycolysis than mitochondrial 
respiration, while nephron progenitors undergoing terminal differentiation utilize oxidative 
phosphorylation to a greater extent [17]. We believe that these differences in metabolism stem 
from the availability of oxygen at certain time points during development. Utilizing HEK293 
cells cultured in normoxia and hypoxia, we found that oxygen availability leads to alterations in 
metabolic gene expression, proliferation, and ROS. Although alterations were revealed, 
sufficient adaptation was not apparent until after 24 hours of exposure. This indicates that 
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adaptation to hypoxia is a complex mechanism that does not occur instantaneously. Indeed, 
adaptation appeared to be sufficient by 48 hours, shown by a decrease in ROS, increase in 
glycolysis gene expression, and similar levels of proliferation between hypoxia and normoxia 
cultured cells. This study raises awareness regarding the interconnectivity between cell growth, 
metabolism, and hypoxia, particularly in development and cancer progression fields. Further 
discussion on the future directions and research limitations of this work are described in Chapter 
6.1.      
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3.0  PRENATAL HYPOXIA INCREASES SUSCEPTILIBILTY TO ACUTE KIDNEY 
INJURY  
This is an adaptation of the author’s version of the work. The definitive version is being prepared 
for publication. 
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3.1 CHAPTER SUMMARY 
Prenatal hypoxia is a gestational stressor that can result in developmental abnormalities or 
physiological reprogramming, and often decreases cellular capacity against secondary stress. 
When a developing fetus is exposed to hypoxia, blood flow is preferentially redirected to vital 
organs including the brain and heart over other organs including the kidney. Hypoxia-induced 
injury can lead to structural malformations in the kidney; however, even in the absence of 
structural lesions, hypoxia can physiologically reprogram the kidney leading to decreased 
function or increased susceptibility to injury. Our investigation in mice reveals that while 
prenatal hypoxia does not affect normal development of the kidneys, it primes the kidneys to 
have an increased susceptibility to kidney injury later in life.  We found that our model does not 
develop structural abnormalities when prenatally exposed to modest 12% O2 as evident by 
normal histological characterization and gene expression analysis. Further, adult renal structure 
and function is comparable to mice exposed to ambient oxygen throughout nephrogenesis. 
However, after treatment with cisplatin, the offspring of mice housed in hypoxia exhibit 
significantly reduced renal function and proximal tubule damage following injury. We conclude 
that exposure to prenatal hypoxia in utero physiologically reprograms the kidneys leading to 
increased susceptibility to injury later in life.   
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3.2 INTRODUCTION 
Intrauterine hypoxia leading to prenatal hypoxia of the fetus is a common gestational stressor 
that can lead to a range of developmental abnormalities [160]. When prenatal hypoxia occurs, the 
developing fetus exhibits a preferential redirection of blood flow, including oxygen and nutrient 
supply, to the brain and heart over organs such as the kidney [139, 161]. Previous studies in 
mouse and rat models of prenatal hypoxia often utilize a chambered hypoxia device, where 
pregnant dams are housed at 12% O2 [162, 163]. These studies show that exposure to mild 
hypoxia in utero can impair pre- and post-natal development [164] and can induce epigenetic 
modifications [165]. Although both structural and non-structural abnormalities can arise from 
prenatal exposure to hypoxia, the long-term effect of this stressor in the kidneys is still largely 
unknown. 
The kidneys are the filtration units of the body and the nephron is the functional unit of 
the kidney responsible for blood filtration, removal of toxic wastes, and regulation of several 
important physiological functions [6, 7, 16]. Kidney development in the mouse takes place from 
embryonic day 10.5 (E10.5) through postnatal day 3 (P3) corresponding to approximate 
gestational weeks 5 through 35 in humans [166]. During this time, a population of self-renewing 
cells called nephron progenitors rapidly proliferate then undergo differentiation to give rise to the 
glomerular and renal tubular epithelia of the mature nephron [167]. This process of nephron 
development occurs under physiological hypoxia (~1-9% O2) [162], and although temporary 
changes in oxygen tension are normal, chronic hypoxia can be detrimental [168]. Maternal 
chronic prenatal hypoxia of less than 10% oxygen has been shown to lead to physical and 
structural abnormalities [139, 160, 169, 170]. In one study, pregnant dams with a CD1 
background housed in 12% O2 from E14.5 to P1 found that female offspring were unaffected, 
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however male offspring exhibited decreased body weight, decreased kidney weight, and 
alterations in tubular development and in the corticomedullary ratio [171]. Although structural 
abnormalities can arise due to hypoxia exposure, we hypothesize that even in the absence of 
structural malformations, the kidneys are more susceptible to disease later in life. This increased 
susceptibility may be a result of physiological reprogramming, a phenomena that decreases 
cellular functionality of the kidneys to be more susceptible to injury later in life.   
One such injury that affects both pediatric and adult patient populations is acute kidney 
injury (AKI). AKI is an abrupt loss of kidney function characterized by significant decreases in 
glomerular filtration as well as increases in serum creatinine and blood urea nitrogen (BUN) 
levels, which lead to high morbidity and mortality rates [172, 173]. It is also a risk factor for 
progression to chronic kidney disease (CKD) and eventually end-stage renal disease (ESRD) 
[174]. It is known that AKI is multifactorial and caused by distinct insults including ischemia, 
nephrotoxins, and sepsis [175]. Cisplatin is a widely used cytotoxic chemotherapeutic agent and 
is a known nephrotoxin that causes acute and chronic injury in the kidneys [176, 177]. A major 
complication of cisplatin treatment is AKI, which occurs in up to 30% of patients [176]. 
Cisplatin targets both nuclear and mitochondrial DNA and for this reason primarily affects the 
highly metabolically active proximal tubules [177, 178]. While multiple conditions such as aging 
and CKD also predispose to AKI [179, 180], there is little known about the effect of prenatal 
hypoxia on susceptibility to AKI.   
Herein, we generated a mouse model of prenatal hypoxia and uncovered a sub-
pathological role for hypoxia as a mediator of susceptibility to kidney injury. Our study reveals 
that mice exposed to prenatal hypoxia during nephrogenesis exhibit exacerbated cisplatin-
induced AKI in adulthood. Our study highlights the importance of strict regulation of 
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oxygenation in the developing kidney and suggests prenatal hypoxia may physiologically 
reprogram the nephrons, leaving them more susceptible to injury. 
3.3 METHODS AND MATERIALS 
3.3.1 Prenatal hypoxia in mice 
C57BL/6 wild type time-mated females (gestation age E10.5; Charles River) were placed in a 
hypoxia chamber. The chamber was equipped with a purge airlock system, CO2 and O2 control 
indicators, and humidity and gas monitoring control systems designed for live animal 
experiments. Exposure to 12% hypoxia was initiated on embryonic day 10.5 (E10.5), which 
coincides with the induction of nephrogenesis. Hypoxia exposure was terminated on postnatal 
day 3 (P3), which coincides with the conclusion of nephrogenesis. Control mice with normoxia 
treatment were housed in ambient conditions at 21% O2. For embryonic renal assessments, 
pregnant dams were sacrificed on E16 by CO2 inhalation followed by cervical dislocation. For 
post-natal renal assessment, hypoxia-exposed pups were transferred to ambient O2 on P3 and 
sacrificed at 7 weeks of age by CO2 inhalation followed by cervical dislocation. Kidney tissue 
was immediately collected and stored for analysis. The University of Pittsburgh Institutional 
Animal Care and Use Committee approved all experiments (Approval No. 16088935). 
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3.3.2 Cisplatin-induced AKI in mice 
For the secondary stressor model, another cohort of time-mated female C57BL/6 wild type mice 
gestation age E10.5 were used following the same normoxia and hypoxia conditions from E10.5 
through P3. The mice exposed with hypoxia or normoxia were maintained in regular vivarium 
with 21% O2 ambient conditions until 7 weeks of age. At 7 weeks of age, the mice were treated 
with cisplatin (APP NDC 63323-103-64, 20mg/kg bw, ip; Appendix F) in normal saline or with 
normal saline vehicle control. The mice were sacrificed 72 hours after cisplatin treatment by 
cervical dislocation after isoflurane anesthesia. Blood and kidney tissue were immediately 
collected and stored for analysis. The University of Pittsburgh Institutional Animal Care and Use 
Committee approved all experiments (Approval No. 16088935). 
3.3.3 Tissue collection and histological assessment 
Tissue was collected at E16.5 and 7 weeks and immediately flash frozen in liquid nitrogen or 
fixed in 4% paraformaldehyde (PFA). Fixed tissue was processed and embedded in paraffin. 
Embedded tissue was sectioned at 4 μm thickness and stained with hematoxylin and eosin 
(H&E) for histological examination. Renal tubular pathology was semiquantitvely scored in a 
blind fashion on corticomedullary fields (40x magnification). Samples were imaged using a 
Leica DM 2500 microscope (Leica) and LAS X software (Leica). Histological scoring was 
performed in a blinded fashion at 40x magnification on corticomedullary regions of the tissue 
sections from N=4 animals. Eight sections were evaluated for injury per sample. Glomerular 
quantification was performed blinded using a low power field. Manual counting was done on the 
corticomedullary regions of the tissue sections from N=4 animals. Corpuscle and glomerular 
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quantification was done using ImageJ Software using at least N=4 animals. Lengths were 
measured in triplicate and averaged per glomeruli or corpuscle. The glomerular-to-corpuscle 
ratio was done by dividing the average glomerular length per glomeruli by the average corpuscle 
length per corresponding corpuscle.   
3.3.4 Serum analysis 
7 week old pups were subjected to cardiac punctures prior to sacrifice for the collection of blood. 
Blood was subsequently centrifuged for 10 minutes at 10,000rpm to collect serum. Serum was 
analyzed for blood urea nitrogen and creatinine at the Kansas State Veterinary Diagnostic 
Laboratory. 
3.3.5 Immunofluorescent staining 
Immunofluorescent staining was performed on paraffin embedded samples as described above. 
Sections were deparafinized and rehydrated according to the following: 100% xylene for 5 min, 
100% ethanol for 5 minutes, 70% ethanol for 5 minutes, 50% ethanol for 5 minutes. Each step 
was done in duplicate. Antigen retrieval was done using citrate buffer buffered to pH=6. Slides 
were put into a pressure cooker and microwaved for approximately 17 minutes. Samples were 
probed using primary antibodies or lectins (1:100; Appendix D): neural cell adhesion molecule 
(Ncam; Sigma-Aldrich), sine oculis homeobox homolog 2 (Six2; Proteintech), phosphor-histone 
H3 (Phh3; Cell Marque), endomucin (Santa Cruz Biotechnology), Wilm’s tumor 1 (WT1; Santa 
Cruz Biotechnology), Lotus tetragonolobus (LTL; Vector Laboratories), Organic anion 
transporter 1 (OAT1; Alpha Diagnostic International), Dolichos biflorus agglutinin (DBA; 
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Vector Laboratories), Kidney injury molecule 1 (Kim1; R&D Systems), and Terminal 
deoxynucleotidyl transferase dUTP nick-end labeling kit (TUNEL; EDM Millipore) all co-
stained with DAPI (Thermo Fisher Scientific). Samples were imaged using a Leica microscope 
(Leica Microsystems) and LAS X software (Leica Microsystems).    
3.3.6 Real time quantitative polymerase chain reaction (PCR) 
RNA was extracted from the flash frozen kidney tissue at E16.5, E18.5 and 7 weeks using the 
miRNAeasy Mini Kit (Qiagen). Synthesis of cDNA was done as preciously described in 2.3.2. 
The following genes were analyzed using this method: Cited1, Lhx1, Pax2, and Wnt4. Gene 
expression was normalized to Rn18s. Primer sequences are listed in Appendix B. 
3.3.7 Statistical analysis 
Minimums of 3 biological replicates were used for each experiment in at least technical 
duplicate. When comparing two sample groups, statistical significance was determined using a 
two-tailed Student’s t test (α = 0.05). Significance was defined as *P<0.05, **P<0.01, and 
***P<0.001. Where appropriate, data is presented as mean ± standard error of the mean. Data 
was analyzed using Microsoft Excel and figures were generated using GraphPad Prism 7.  
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3.4 RESULTS 
3.4.1 Prenatal hypoxia does not alter embryonic kidney development 
To investigate the effect of hypoxia during kidney development, time-mated C57B/6 female 
mice were placed into hypoxia chambers with 12% oxygen beginning on embryonic day 10.5 
(E10.5) and maintained in hypoxia until the conclusion of nephrogenesis on postnatal day 3 (P3) 
(Figure 10A). Pregnant control females were housed in ambient oxygen (normoxia) for the 
duration of their pregnancy. Litter sizes between dams housed in normoxia and hypoxia were 
similar (P=0.67) with a mean litter size of 4 pups. Hypoxia exposed E16.5 kidneys appeared to 
undergo normal developmental processes and histological examination did not reveal any 
significant abnormalities (Figure 10B-E). A cohort of the pups exposed to prenatal hypoxia were 
transferred to normoxia at P3 and at 7 weeks of age those mice also did not exhibit any 
significant alterations in renal histology (Figure 10F-I).  
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Figure 10: Prenatal hypoxia exposure does not alter histological structure of the kidneys 
(A) Schematic illustration for the mouse model of prenatal exposure to hypoxia during kidney development. (B-E) 
H&E staining from E16.5 prenatal hypoxia exposed kidneys exhibit normal development. (F-I) H&E staining from 
7-week mice shows no significant structural abnormalities. 
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To further investigate whether any developmental defects were present, we performed 
immunofluorescent staining on E16.5 kidneys to evaluate kidney development using markers for 
nephron progenitor self-renewal (Sine oculis homeobox homolog 2; Six2) and developing 
structures (Neural cell adhesion molecule; Ncam). Neither Six2 nor Ncam immunostaining 
revealed any structural malformations or alterations in nephron number. Proliferation of the 
nephron progenitors was evaluated by immunostaining against phospho-histone H3 (pHH3), 
which appeared to be occurring at comparable rates in both normoxia and hypoxia-exposed 
kidneys. Apoptosis analysis through TUNEL immunostaining showed that cell death was 
confined to the renal stroma [181] and appeared comparable between normoxia and hypoxia 
exposed kidneys (Figure 11A-F). Additionally, mRNA levels of nephron progenitors (Cited1 and 
Pax2) and nephron differentiation (Wnt4 and Lhx1) were not altered between the two cohorts 
(Figure 11G). Likewise, we performed immunostaining to observe proximal tubule development 
and ureteric branching, neither of which revealed any abnormalities (Figure 11H-O). Together, 
this suggests that prenatal exposure to 12% oxygen in the C57B/6 background strain does not 
lead to alterations in structural kidney development by mid-nephrogenesis.  
We next evaluated the progression of renal development at E18.5. Similarly, we 
immunostained again Six2, Ncam, Phh3, and TUNEL and did not observe any abnormalities at 
this later stage of nephrogenesis (Figure 12A-F). Gene expression of Cited1, Pax2, Wnt4, and 
Lhx1 also remained unchanged between the two groups (Figure 12G). Lastly, we quantified the 
kidney length and body length of E18.5 animals and did not reveal any differences in the size of 
the kidneys or bodies of offspring exposed to hypoxia (Figure 12H-I). The kidney-to-body length 
ratios also remained consistent (Figure 12J). Therefore, there are no structural differences in 
early, mid, or late kidney development in mice exposed to pre-natal hypoxia.    
 58 
 
Figure 11: Prenatal hypoxia exposure does not alter development of the kidneys at E16.5 
(A-B) Immunofluorescent staining with antibodies against Six2 (red) and Ncam (green) show no differences in 
nephron progenitor differentiation when exposed to prenatal normoxia (top) versus hypoxia (bottom) at E16.5. (C-
D) Immunofluorescent staining with antibodies against pHH3 (red) and Ncam (green) reveal no differences in cell 
proliferation in cells exposed to normoxia (top) and hypoxia (bottom). (E-F) TUNEL (green) staining exhibits 
similar apoptosis levels in hypoxic (top) and normoxic cells (bottom). (G) RT-qPCR analysis of genes associated 
with nephron progenitors (Cited1, Pax2) and differentiation (Wnt4 and Lhx1) have similar levels of mRNA 
expression between prenatal normoxia- (black) and hypoxia- (grey) exposed kidneys. N=4. Error bars indicated as 
SEM. (H-K) Immunofluorescent staining with LTL at E16.5 shows no differences in proximal tubule formation 
between normoxic (top) and hypoxic (bottom) kidneys. (L-O) Immunofluorescent staining against DBA at E16.5 
exhibits no developmental phenotype during ureteric bud branching and differentiation. 
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Figure 12: Prenatal hypoxia exposure does not alter development of the kidneys at E18.5 
(A-B) Immunofluorescent staining with antibodies against Six2 (red) and Ncam (green) show no differences in 
nephron progenitor differentiation when exposed to prenatal normoxia (top) versus hypoxia (bottom) at E18.5. N=3. 
(C-D) Immunofluorescent staining with antibodies against pHH3 (red) and Ncam (green) reveal no differences in 
cell proliferation in cells exposed to normoxia (top) and hypoxia (bottom). (E-F) TUNEL (green) staining exhibits 
similar apoptosis levels in hypoxic (top) and normoxic cells (bottom). (G) RT-qPCR analysis of genes associated 
with nephron progenitors (Cited1, Pax2) and differentiation (Wnt4 and Lhx1) have similar levels of mRNA 
expression between prenatal normoxia- (black) and hypoxia- (grey) exposed kidneys. N=4. Error bars indicated as 
SEM. (H-J) No differences in kidney length (P=0.21), body length (P=0.34), or the kidney-to-body length ratio 
(P=0.96) of E18.5 embryos; Normoxia N=3; Hypoxia N=7. 
 
3.4.2 Prenatal hypoxia alone does not disrupt adult renal function 
Next, we assessed renal structure and function at 7 weeks of age. Immunofluorescent staining 
using LTL and Oat1 (markers of proximal tubule brush borders and proximal tubule epithelial 
cells, respectively) did not reveal the development of structural abnormalities by 7 weeks of age 
(Figure 13A-B). There were also no significant differences in glomerular structure (Figure 13C-
D) or vascularization (Figure 13E-F) in 7-week mice exposed to prenatal hypoxia compared to 
normoxia-exposed controls. BUN and creatine measurements were also not significantly altered 
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in prenatal hypoxia exposed mice (Figure 13G; data not shown). Creatinine levels were all below 
a detectable 0.5 mg/dL concentration. To confirm that nephrogenesis occurred normally, we 
quantified the number of glomeruli using unbiased manual counting of glomerular structures. 
Both mouse cohorts had similar numbers of formed glomeruli (Figure 13H). Further, we 
quantified the corpuscle and glomerular size, which again did not reveal any differences in 
nephron development (Figure 13I). Lastly, the weight of the animals did not differ between 
exposure groups (Figure 13J). Therefore, prenatal hypoxia alone does not lead to major 
alterations in renal structure or function in C57B/6 adult mouse kidneys.  
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Figure 13: Prenatal hypoxia exposure does not alter structure or function of adult kidneys 
(A-B) Immunofluorescent staining with antibodies against Oat1 (red) and LTL (green) do not reveal any differences 
in the proximal tubules of prenatal hypoxia-exposed kidneys (bottom) when compared to normoxia-exposed kidneys 
(top) at 7 weeks. (C-D) Immunofluorescence staining with antibodies against Wt1 (red) and LTL (green) reveal no 
difference in glomerular structure at 7 weeks. (E-F) Immunofluorescence staining with antibodies against 
endomucin (Endo; green) indicates similar levels of vascularization. (G) Levels of renal functional marker, blood 
urea nitrogen (BUN), is not altered by prenatal hypoxia exposure; Normoxia N=6; Hypoxia N=7; P>0.99. Error bars 
indicated as SEM. (H) Quantification of the glomeruli indicated no differences in nephron number; N=4; P=0.62; 
Error bars indicated as SEM. (I) There were no differences in the size of the glomeruli or corpuscles of animals 
exposed to prenatal hypoxia compared to controls; Normoxia N=7; Hypoxia N=4; P=0.81. Error bars indicated as 
SEM. (J) There were no differences in the body weight of animals exposed to prenatal hypoxia compared to 
controls; Normoxia N=10; Hypoxia N=7; P=0.43. Error bars indicated as SEM. 
 62 
3.4.3 Prenatal hypoxia increases susceptibility to cisplatin-induced AKI 
Next, we aimed to determine whether prenatal hypoxia in the absence of structural abnormalities 
led to increased kidney injury susceptibility. Another cohort of mice that were exposed to 
prenatal hypoxia were subjected to a single injection of the nephrotoxin cisplatin (20mg/kg bw, 
ip) and were sacrificed 3 days post injury (3 dpi) (Figure 14A). The prenatal hypoxia kidneys 
exhibited exacerbated cisplatin-induced injury. Injury included increased formation of 
proteinaceous casts and severe dilation of the proximal tubules (Figure 14B-E) when compared 
to normoxia-exposed kidneys. Histopathological scoring revealed a significantly higher level of 
injury severity (P=0.038). Scoring was done such that a 1 indicated insignificant injury while 5 
indicated severe injury. Kidneys that were prenatally exposed to hypoxia had significantly more 
regions that were designated a 5 compared to normoxia-exposed controls (Figure 14F). 
Accompanying the tubular injury, these mice exhibited significantly increased levels of blood 
urea nitrogen (BUN) and creatinine in serum indicating reduced kidney function (Figure 14G-H). 
Furthermore in the prenatal hypoxia exposed kidneys, immunofluorescent staining with LTL and 
Oat1 revealed increased frequency of epithelial sloughing and dilation in the proximal tubules 
(Figure 15A-B). Proximal tubule dilation was quantified and quantification revealed prenatal 
hypoxia-exposed kidneys treated with cisplatin had significantly increased dilation compared to 
both baseline hypoxia and prenatal normoxia-exposed kidneys treated with cisplatin (Figure 
15C). Hypoxia-exposed kidneys treated with cisplatin also had significantly increased expression 
of kidney injury marker 1 (Kim1) (Figure 15D-H). Together, this data reveals that although 
prenatal oxygen levels do not contribute to developmental structural abnormalities, low oxygen 
conditions prime the kidneys for injury later in life.  
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Figure 14: Prenatal hypoxia exposure decreases renal function after cisplatin-induced kidney injury 
(A) Schematic illustration for mouse model of prenatal hypoxia, coupled with cisplatin-induced AKI in the adult 
stage. The mice were sacrificed at 3 days post-injury with cisplatin (3 dpi). (B-E) H&E staining of kidneys exposed 
to prenatal hypoxia and treated with cisplatin at 7 weeks (bottom panels) shows increased formation of 
proteinaceous casts (arrows) and dilation of the proximal tubules compared to prenatal exposure to normoxia with 
cisplatin treated kidneys (top panels). (F) Mice exposed to prenatal hypoxia exhibited a significantly higher injury 
severity score; P<0.05, N=4. (G) Hypoxia-exposed mice (grey) have significantly higher BUN levels; Normoxia 
N=7; Hypoxia N=4. P<0.05. Error bars indicated as SEM. (H) Hypoxia-exposed mice (grey) show a significant 
increase in creatinine levels; Normoxia N=4; Hypoxia N=4. P<0.01. Error bars indicated as SEM.  
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Figure 15: Prenatal hypoxia exposure increases proximal tubular injury after cisplatin-induced kidney injury 
(A-B) Immunofluorescence staining with antibodies against Oat1 (red) and LTL (green) at 3 dpi reveals further 
increased rate of epithelial sloughing in the proximal tubules in prenatal hypoxia exposed mice after cisplatin 
treatment. (C) Proximal tubule dilation was quantified at baseline and 3dpi. Prenatally hypoxia-exposed mice 
exhibited significantly increased tubular dilation compared to control animals; ANOVA and student t-test: *P<0.05, 
**P<0.01; N=3; Error bars indicated as SEM. (D-G) Immunostaining with antibodies against Kim1 (red) and LTL 
(green) at 7 weeks shows further increased injury marker expression (arrows) in prenatal hypoxia-exposed kidneys 
(bottom). (H) Quantification of Kim1-positive area shows further increased Kim1 expression in prenatal hypoxia 
exposed kidneys (grey); P<0.01, N=3. Error bars indicated as SEM. 
3.5 DISCUSSION 
Prenatal hypoxia is a multifactorial condition and can be caused by a variety of factors including 
placental insufficiency, pre-eclampsia, malnutrition, and even high altitude living during 
pregnancy [163, 182]. Prenatal hypoxia results in decreased blood and nutrient flow to the fetus 
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leading to decreased oxygen availability in the kidney [139, 161]. In consequence, any 
complication resulting in prenatal fetal hypoxia can cause changes in fetal growth or organ 
functionality thereby increasing the risk for diseases later in life [182]. In this study, we 
interrogated the role of prenatal hypoxia on long-term susceptibility to cisplatin-induced kidney 
injury.  
Our study did not reveal any structural developmental kidney defects in offspring of 
dams exposed to hypoxia. At both 12% O2 and ambient oxygen (~21% O2), the kidneys 
exhibited a comparable degree of differentiation, proliferation and apoptosis of E16.5 and E18.5 
nephron progenitors regardless of oxygen treatment. Although this finding differs slightly from 
previous investigations utilizing similar hypoxia oxygen concentrations [10, 183, 184], we 
hypothesize that the lack of developmental defect could be explained by the difference of 
hypoxic conditions and by the mouse strain used in previous studies. Our study used a modest 
hypoxia model with an oxygen concentration set at 12% O2 to maximize survival by treatment. 
Other studies often use a more severe oxygen concentrations. One study using 12% O2 and mice 
with a CD-1 background showed that 12% O2 was sufficient to mediate structural abnormalities 
during development, however our investigation utilized mice with a C57B/6 background. The 
CD-1 mouse strain also exhibits higher mortality in response to hypoxia [185] by activating a 
maladaptive hypoxia response through HIF-1 up regulation [186]. Therefore, this is a 
plausible reason behind the lack of structural abnormalities in our model, thus allowing for an 
interrogation of physiological reprogramming in the absence of structural abnormalities. 
Less is currently known about the sub-pathological role of prenatal hypoxia on organ 
injury later in life. It has previously been shown that prenatal hypoxia decreases adaptive 
potential of the brain and subsequently increases the risk of neurodegenerative disorders such as 
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Parkinson’s disease in late adulthood [187, 188]. Further the heart has been shown to undergo 
physiological reprogramming in relation to in utero hypoxia leading to injury susceptibility later 
in life [125, 189, 190]. However, prenatal hypoxia in the absence of structural defects has not 
been well studied in kidney injury models.   
To precisely dissect the effect from prenatal hypoxia in susceptibility to kidney disease 
later in life, we challenged the offspring mice that were exposed to prenatal hypoxia with acute 
nephrotoxicity via a high dose of cisplatin treatment. Mice subjected to prenatal hypoxia 
displayed increased susceptibility to cisplatin injury despite the absence of clear developmental 
defects. Cisplatin causes cellular damages in the S3 segment of renal proximal tubular epithelial 
cells in mice [191]. Our data demonstrated that cisplatin treatment increased expression of 
proximal tubule specific injury marker, Kim-1, in the group exposed to prenatal hypoxia as well 
as increased renal functional markers, creatinine and BUN. This study acts as a proof of principle 
by clearly showing that strict regulation of developmental oxygenation is critical for long-term 
renal function. Although prenatal hypoxia exposure leads to exacerbated kidney injury, the 
mechanism leading to this finding is still unclear.  
Although this study does not delve into the mechanisms leading to disease, we 
hypothesize that a physiological reprogramming event occurs during development that primes 
the kidneys for injury after secondary insult, in this case cisplatin treatment. One possible 
mechanism that leaves the tubules susceptible to injury may be, at least in part, through 
stimulation of pathological reactive oxygen species (ROS). ROS is a consequence of incomplete 
oxygen reduction during mitochondrial respiration [192]. Aberrant ROS production has also 
been previously implicated as a marker of severe kidney injury and chronic kidney disease [104, 
193, 194]. In kidneys after ischemia-reperfusion injury, damaged proximal tubules shift their 
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major energy production from oxidative phosphorylation to glycolysis as part of the de-
differentiation process [74]. There has been some interrogation into the relationship between 
hypoxia pathways and ROS, however the mechanisms of action are currently inconclusive [147, 
195-198]. Although these mechanisms are currently unknown, it is clear that hypoxia and ROS 
influence adaptive gene expression and may be responsible for the phenotype shown in the 
present study. Another potential mechanisms that has been implicated in cisplatin-induced 
kidney injury is the Renin-Angiotensin System.  The Renin-Angiotensin System is involved in 
blood pressure regulation and vascularization and has been previously investigated in prenatal 
hypoxia and cisplatin studies [199-201]. Independent of vascular roles, cisplatin is known to 
increase its nephrotoxicity via interaction with Renin-Angiotensin System in T lymphocytes and 
kidney epithelial cells [201] and could be a pathway of future investigation in developmental 
physiological reprogramming of the kidneys.  
The present study has several limitations and raises a number of questions. It has been 
previously proposed that age and sex play a role in hypertension pathology after prenatal hypoxia 
[199]. For this reason, it will be important to evaluate the role of age and sex in susceptibility to 
cisplatin injury of the offspring after prenatal hypoxia. Further, hypoxia inducible factors (HIFs) 
and the hypoxia inducible microRNA, miR-210, are regulated in the kidneys after AKI, and thus 
should also be robustly evaluated [182]. In rats, development of pre-eclampsia-like symptoms of 
pregnant dam by prenatal hypoxia is mediated by Endothelin-1 (ET-1) signaling [202] and ET-1 
interacts with the Renin-Angiotensin system [203]. Therefore, it is also important to assess the 
role of the Renin-Angiotensin system in pregnant dams and evaluate the effect of this system on 
developing kidneys in order to explore therapeutic targets.  
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In conclusion, we show that embryonic hypoxia exposure predisposes mice to enhanced 
kidney injury after cisplatin treatment during adulthood even in the absence of initial structural 
abnormalities. This study suggests that sub-pathologically low oxygen concentrations during 
fetal development may play a critical role in the physiological programming of the nephron in 
the absence of structural abnormalities and could be used as a prognosticator for kidney disease 
susceptibility in adults. Further discussion on the future directions and research limitations of this 
work are described in Chapter 6.2.      
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4.1 CHAPTER SUMMARY 
Kidney development is a tightly regulated process that is necessary for normal long-term kidney 
function. Nephron progenitors are a stem cell population that exists within the developing kidney 
and give rise to the functional unit of the kidney, the nephron. Nephron progenitors are a 
metabolically active cell population and self-renew under glycolytic conditions. A switch from 
glycolysis to mitochondrial respiration drives these cells towards differentiation. However, the 
mechanisms that control this switch are poorly defined. Here, we explore von Hippel Lindau 
(VHL) as a regulator defining nephron progenitor self-renewal versus differentiation. This 
investigation reveals a previously unknown mechanism controlling the balance between nephron 
progenitor self-renewal and differentiation. In nephron progenitor specific VHL knockout mice, 
differentiated nephron progenitors exhibit persistent Six2 expression ultimately leading to 
decreased nephron endowment and renal dysfunction. Furthermore, we found that nephron 
progenitors with a VHL deletion favor glycolytic metabolism and rely less on mitochondrial 
respiration for energy production. This suggests that VHL normally serves to promote a switch 
from glycolysis towards oxidative phosphorylation, which is critical for nephron progenitors to 
undergo differentiation.  
 
 
 71 
4.2 INTRODUCTION 
Nephron development initially involves reciprocal signaling between the ureteric epithelium 
(UE) and the cap mesenchyme (CM), a region comprised of renal cells known as nephron 
progenitors [5]. These nephron progenitors are under strict regulation either to maintain a 
progenitor state or differentiate [18]. The transcription factor Six2 plays a major role in the 
maintenance of the proliferating progenitor population [11, 27, 204]. In self-renewing nephron 
progenitors, both Six2 and the cofactor Cited1 are initially expressed, however Cited1 expression 
becomes down regulated at the beginning of differentiation [18, 27, 205, 206]. As nephron 
progenitors mature, Six2 also becomes down regulated and the cells begin to express 
differentiation markers indicating commitment to a mesenchyme to epithelial transition (MET) 
[11, 31]. This transition, marked by Wnt4 expression, occurs as CM cells make mature cell-cell 
contacts and ultimately form functional nephrons [30]. The maturing nephron progenitors give 
rise to the nephron: a complex structure comprised of a glomerulus and epithelialized tubules 
that are connected to the collecting duct system [6].  
Kidney formation is highly dependent on oxygen concentration [117] and previous 
studies show that low levels of oxygen (hypoxia) can result in renal malformations including 
nephron deficit [183, 207]. The kidney initially develops in a relatively hypoxic environment and 
as the vasculature perfuses, oxygen levels increase [118]. This tightly regulated change in 
oxygenation coordinates with the inductive signals from the UE to drive proliferation and 
subsequent differentiation of the nephron progenitors. Hypoxia inducible factors (HIFs) play a 
large role in mediating cellular responses to oxygen fluctuations. Although there are three HIF 
isoforms (HIF-1α, HIF-2α, and HIF-3α), HIF-1α is considered the master regulator of 
developmental responses to hypoxia [109]. HIF-1α is known to stimulate angiogenesis and 
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maturation of the vasculature, which drives blood flow into hypoxic areas, thereby increasing 
oxygen concentration [108, 118]. Increases in oxygen facilitate HIF-1α’s degradation via 
recruitment of von Hippel-Lindau (VHL) [108, 118]—a protein component of a ubiquitin ligase 
complex. If prenatal exposure to pathological hypoxia occurs in the nephron progenitors, VHL is 
not recruited to degrade HIF-1α allowing for its sustained expression and transcriptional 
activation of genes containing hypoxia response elements (HREs) [11-13].  
Many confirmed HREs are found in genes that encode glycolytic enzymes [11, 12, 14]. 
High rates of glycolysis allow progenitor cells to rapidly undergo expansion through 
proliferation and nucleotide generation [15-17]. However as differentiating cells mature, they 
utilize mitochondrial respiration to maintain energy demands of the cell [120, 121, 144]. HIF-1α 
is largely responsible for the metabolic profile of progenitor cells and functions in a dual role by 
promoting glycolysis while suppressing mitochondrial respiration [84, 85, 121]. It has also been 
shown that nephron progenitors exhibit a gradual, decreased reliance on glycolysis between 
embryonic day 13.5 (E13.5) and 19.5 (E19.5) [17]. While early stage nephron progenitors rely 
heavily on glycolysis [17], terminally differentiated nephrons have a unique metabolic profile 
depending on the particular nephron segment [208]. The proximal tubule segment, which is 
responsible for a majority of the reabsorption performed by the kidney, utilizes fatty acids, 
oxidative phosphorylation, and gluconeogenesis to support these critical functions [50, 208, 
209]. For these reasons, we hypothesize that the switch from glycolysis to mitochondrial 
respiration is regulated via VHL-mediated HIF-1α degradation in nephron progenitors during 
development.  
Herein, we report an interrogation into the role of VHL/HIF signaling in mediating 
nephron progenitor differentiation. Global VHL knockout mice are embryonic lethal [108], 
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suggesting that VHL plays a critical role in embryonic development. To circumvent embryonic 
lethality, we generated nephron progenitor-specific VHL knockout mice (VHLNP-/-) to interrogate 
the role of VHL in nephron development. Our investigation reveals that loss of VHL results in 
metabolic dysregulation, which inhibits nephron progenitor differentiation.  
4.3 METHODS AND MATERIALS 
4.3.1 Experimental mouse model 
We bred transgenic Six2EGFPcre mice (JAX009606) [210] with VHL-floxed mice (JAX12933) 
[211] to generate mice with conditionally deleted VHL in Six2cre+ cells. This generated mice 
that conditionally delete VHL in the Six2cre-positive nephron progenitors. The University of 
Pittsburgh Institutional Animal Care and Use Committee approved all experiments (Approval 
No. 16088935). 
4.3.2 Mouse model genotyping  
The presence of GFP in the dissected kidneys was visualized with a fluorescent microscope and 
confirmed using PCR. Embryonic tissue or tail clippings from postnatal animals were collected 
and genomic DNA was extracted. The primers used for the Six2EGFPcre allele and VHL allele 
can be found in Appendix C. The cre-positive band is at 350 basepairs while cre-negative mice 
had no band. The VHL homozygous band is around 500 basepairs and heterozygous bands at 
307 base pairs and around 500 basepairs.   
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4.3.3 Western blotting 
Whole kidneys were lysed in radioimmunoprecipitation assay buffer (RIPA buffer; Thermo 
Scientific) and the homogenates were plated in triplicate to measure protein concentration using 
a Bradford assay kit (Bio-Rad). Samples were electrophoresed on BoltTM 4-12% Bis-Tris Plus 
Gels (ThermoFisher Scientific) for approximately 1 hour at 100V and transferred to 0.2 μm pore 
size nitrocellulose membranes using the Bolt Western blotting system (ThermoFisher Scientific) 
for 1 hour at 10V per manufactures guidelines. Antibodies used include (Appendix D): anti-VHL 
(Santa Cruz Biotechnology, 1:250), anti-HIF-1α (Novus, 1:250), anti-α/β tubulin (Cell Signaling 
Technology, 1:1000) Secondary antibodies include: anti-IgG rabbit HRP (Cell Signaling 
Technology, 1:1000) and anti-IgG mouse HRP (Cell Signaling Technology, 1:250). Blots were 
imaged using a ProteinSimple FluoroChem M System (ProteinSimple) and quantified using 
ImageJ software (ImageJ/NIH Image).    
4.3.4 Tissue collection and histological assessment 
Renal histology was assessed at E13.5, E15.5, P1, P21, and P30 in VHLNP+/- and VHLNP-/- mice. 
At the indicated time points, embryos (E15.5) or dissected kidneys (P1, P21, P30) were fixed, 
processed, and sectioned as previously described in 3.3.3. Samples were stained with 
Hematoxylin and Eosin (H&E) for histological examination or used for immunostaining. The 
following primary antibodies or lectins were used at a 1:100 dilution unless indicated (Appendix 
D): anti-Six2 (Proteintech), anti-Ncam (Sigma-Aldrich), anti-Glut1 (Abcam), anti-phospho-
histone H3 (pHH3; Cell Signaling), Terminal deoxynucleotide transferase dUTP Nick End 
Labeling (TUNEL; EMD Millipore), anti-Lef1 (Cell Signaling), anti-Sall1 (Abcam), anti-Wt1 
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(Santa Cruz Biotechnology), anti-Jag1 (Santa Cruz Biotechnology; 1:20), anti-Pck1 
(Proteintech), dolichos biflorus agglutinin (DBA; Vector Laboratories) and lotus tetragonolobus 
lectin (LTL; Vector Laboratories).  Samples were imaged using a Leica microscope (Leica 
Microsystems) and LAS X software (Leica Microsystems).    
4.3.5 3-Dimensional (3D) reconstruction 
E13.5 embryos were collected for 3D reconstructions of VHLNP+/- and VHLNP-/- kidneys.  
Embryos were fixed as previously described [212]. Five embryos for each genetic group were 
evaluated via 3D reconstruction as described [212]. A Zeiss Model Axio Imager M1 (Zeiss) 
microscope with Stereo Investigator Stereology image tracing software (MBF Bioscience) was 
used for analysis. 
4.3.6 Flow cytometry  
Kidneys were dissecte from P1 VHLNP+/- and VHLNP-/- mice. Kidneys were digested using 0.3% 
collagenase and forced through needlepoint to create a single cell suspension. For cell cycle 
analysis: Cells were fixed using cold 75% methanol for four hours then stained with Propidium 
Iodide FxCycle PI/RNase Staining Solution (Thermo Fisher Scientific; Appendix E). For 
mitochondrial density: 1 x 106 cells were stained for 30 minutes at 37°C using 200nM 
MitoTrackerTM Red FM (Thermo Fisher Scientific; Appendix E). The cells were analyzed on a 
BD LSRFORTESSA cell analyzer (BD Biosciences) (BD Biosciences) through the Flow 
Cytometry Core at the Rangos Research Center located at the UPMC Children’s Hospital of 
Pittsburgh. Mean fluorescence intensity (MFI) was determined using FlowJo software (v10.1). 
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4.3.7 Physical dissector/fractionator combination method  
P21 kidneys were dissected from VHLNP+/- and VHLNP-/- mice then fixed and processed as 
described previously. Embedded samples were completely sectioned at 4 μm thickness. All P1 
kidney slides were stained with anti-WT1 (Thermo Fisher Scientific, 1:100) while every 3 slides 
of P21 samples were subjected to H&E staining [213, 214]. The nth (reference section) and nth + 
2 (lookup section) sections were counted for glomeruli as described [213] using Stereo 
Investigator Stereology Software (MBF Bioscience) on a Zeiss Model Axio Imager M1 (Zeiss) 
microscope.   
4.3.8 Quantification of P1 nephron number 
P21 VHLNP+/- and VHLNP-/- P1 kidneys were dissected, fixed, and processed as described 
previously. The entire kidney was serially sectioned at 4μm and immunostained with rabbit anti-
WT1 antibody and visualized using a Vectastain ABC Kit (Vector Laboratories), per 
manufacturer’s guidelines [215]. For quantification, consecutive sections from every 20 were 
selected and WT1+ structures were identified using a Wacom drawing tablet (Wacom) and 
Stereoinvestigator v.9.04 software [215]. Glomerular number was calculated according to the 
equation by Cullen-McEwen et al [213].  
4.3.9 Serum analysis 
P21 VHLNP+/- and VHLNP-/- mice were subjected to cardiac puncture for blood collection. Serum 
was analyzed as previously described in 3.3.4.  
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4.3.10 RNA-sequencing analysis 
RNA sequencing was performed on E17.5 isolated nephron progenitors. E17.5 kidneys were 
dissected and screened using the GFP expression. Dissected kidneys that expressed GFP were 
dissociated into single cell suspensions and sorted using a BD FACsaria II cell sorter (Flow 
Cytometry Core, Rangos Research Center. Each sample consisted of approximately 150,000 
pooled control or mutant nephron progenitor cells. RNA was extracted using the miRNeasy Mini 
Kit (Qiagen). The Health Sciences Sequencing Core at Children’s Hospital of Pittsburgh 
performed library construction and RNA sequencing (single-end reads, 75bp). Bioinformatics 
quality control was performed using FastQC (version 0.11.5) [216], and adapters were trimmed 
using BBDuk from the BBMap software package (version 37.41) [217]. Reads were aligned to 
transcripts assembled from the mm10 genome (GRCm38, GENCODE M17) [218] using the 
Spliced Transcripts Alignments to a Reference software package (STAR, version 2.5.3a) [219]. 
Data analysis was performed using the R programming language (version 3.4.3) [220]. Reads 
aligned to known transcripts were counted using the Bioconductor [221] GenomicAlignments 
package (version 1.10.1) [221], and differential expression between VHLNP+/- and VHLNP-/- 
kidney samples was calculated using the DESeq2 R package (version 1.18.1) [222]. Functional 
annotation analysis was performed using the DAVID database (release 6.8, 
https://david.ncifcrf.gov/) [223, 224]. Data deposited into Gene Expression Omnibus (GEO 
Accession Number: GSE122900). 
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4.3.11 Real-time quantitative polymerase chain reaction (PCR) 
E17.5 whole kidney RNA was used to validate the E17.5 isolated nephron progenitor RNA 
sequencing as described in 2.3.2. The following genes were analyzed: Pgk1, Gapdh, Tpi1, Bnip3, 
Ddit4, Pdk1, Eno1, Slc16a3, Cited1, Six2, Lef1, Sall1, Osr1, Eya1, Jag1, Sox9, Foxd1 and Wnt4. 
Primer sequences are listed in Appendix B. 
4.3.12 Magnetic activated cell sorting (MACS) nephron progenitor isolation 
Nephron progenitors were isolated from VHLNP+/- and VHLNP-/- kidneys using magnetic-activated 
cell sorting (MACS, Mitenyi Biotec; [17, 27]). The kidney capsule and ureters were removed 
from P1 kidneys to expose the nephrogenic zone and washed with Hank’s balanced salt solution 
(HBSS). Kidneys were digested with 0.25% collagenase and 1% pancreatin [27]. Cells were 
isolated by negative selection via incubation with antibodies against endothelial progenitors 
(anti-CD105), RBCs and erythroid cells (anti-TER119), cortical interstitium (anti-CD140a), and 
renal epithelial cells (anti-CD326) following manufactures instruction (Mitenyi Biotec) [27]. 
Isolated nephron progenitors were seeded in a monolayer on Matrigel-coated (Corning) culture 
plates at 100,000 cells per well with APEL-based (Stem Cell Technologies) NPME media as 
previously described [27]. Cells were incubated overnight then subjected to extracellular flux 
analysis.   
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4.3.13 Seahorse extracellular flux mitochondrial stress test 
Kidneys were pooled from multiple litters for P1 MACS nephron progenitor isolation. Cells were 
seeded at 100,000 cells per well on Matrigel-coated Seahorse microplates for flux analysis on the 
XF24 Extracellular Flux Analyzer (Aligent Seahorse Technologies) [17]. VHLNP+/- and VHLNP-/- 
nephron progenitors were subjected to a mitochondrial stress test via the sequential 
administration of specific metabolic pathway inhibitors. The XF sensor cartridges were hydrated 
overnight at 37q C without carbon dioxide in Seahorse XF calibrant solution. The assay medium 
was Seahorse XF unbuffered DMEM supplemented with 3-5 mM pyruvate, 5mM D-glucose, and 
2 mM L-glutamine (pH 7.4) [17]. Metabolic profiling was performed by measuring basal 
respiration for 25 minutes followed by the sequential injection of the substrates oligomycin (1 
Pg/mL; Appendix F), cyanide p-trifluoromethoxy-phenylhydrazone (FCCP, 0.3 PM; Appendix 
F), and rotenone (0.1 PM; Appendix F) with antimycin A (1PM; Appendix F) [17]. 
Measurements were taken at eight-minute intervals for 3 hours. Basal respiration, ATP 
production, maximal respiration, and glycolysis ratios were calculated from a total of three 
biological data sets done in at least technical duplicate. Data normalized to cell number.   
4.3.14 Pyruvate oxidation assay 
VHLNP+/- and VHLNP-/- P1 mouse kidneys were dissected and homogenized in serum-free 
Dulbecco’s modified Eagle’s medium (DMEM) without glucose supplementation. To determine 
pyruvate oxidation, tissue homogenates were incubated at 37q C with uniformly labeled 14C-
pyruvate in sealed in glass tubes sealed with rubber stoppers fitted with hanging baskets. The 
hanging baskets held 1cm square filter paper inserts soaked in potassium hydroxide (1M). After 
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30 minutes, perchloric acid (0.5M) was introduced by needle to acidify the media and the 
reactions were incubated for at 37q C for 1hr to collect 14C-CO2 [225, 226]. 14C-pyruvate 
incorporation was measured by scintillation counting and normalized to cellular protein content.   
4.3.15 Kidney explant glycolysis inhibition 
E13.5 kidneys were cultured on 0.4Pm polyethylene terephthalate membrane inserts as 
previously done [215]. One kidney from each embryo was cultured in improved minimal 
essential media (IMEM; containing 50 Pg/mL transferrin) alone and the other was cultured in 
media containing 10 PM YN1 inhibitor (Appendix F) [17, 215]. After 72 hours kidneys were 
fixed in 4% paraformaldehyde for 1 hour. Kidneys were immunostaining with antibodies against 
Six2 and Jag1 following the previous methods [215].  
4.3.16 Statistical analysis 
A minimum of 3 biological replicates was used for each experiment in at least technical 
duplicate. When comparing two sample groups, statistical significance was determined using a 
two-tailed Student’s t test (α = 0.05). Significance was defined as *P<0.05, **P<0.01, and 
***P<0.001. Where appropriate, data is presented as mean ± standard error of the mean analyzed 
with figures generated using GraphPad Prism 7.  
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4.4 RESULTS 
4.4.1 VHL expression is required for differentiation of nephron progenitors 
To determine the functional significance of VHL in nephron progenitors, we conditionally 
deleted VHL from Six2+ nephron progenitors by crossing transgenic Six2-TGCtg mice [210] to 
VHLlox/lox mice [211] (Figure 16A). This produced VHL wild type (Six2-TGC+/+; VHLlox/lox 
(VHLNP+/+)), heterozygous knockout (Six2-TGC tg/+; VHL+/lox (VHLNP+/-)), and homozygous 
knockout (Six2-TGC tg/+; VHLlox/lox (VHLNP-/-)) genotypes. Six2-TGCtg/+ embryos enabled GFP 
visualization in VHLNP+/- and VHLNP-/- animals. Due to a slight hypoplastic phenotype associated 
with the Six2GFPcre transgene [227], we used VHLNP+/- littermate controls for all experiments. 
VHL protein expression (Figure 16B) and HIF-1α protein stabilization (Figure 15C) in VHLNP+/- 
and VHLNP-/- kidneys confirmed sufficient knockdown and stabilization, respectively. Moreover, 
subsequent RNA-sequencing analysis (see results below) validated VHL knockout specifically in 
the nephron progenitors.  
Histological examination of VHLNP-/- kidneys did not reveal any significant alterations in 
development at embryonic day 13.5 (E13.5; Figure 16D-E). However, by E15.5 the VHLNP-/- 
kidneys begin to exhibit reduced maturation of the nephron progenitors (Figure 16F-G). By 
postnatal day 1 (P1) VHLNP-/- kidneys are smaller and remain developmentally delayed (Figure 
16H-I) with fewer nephron progenitor-derived structures (see results below).  
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Figure 16: Conditional deletion of VHL from Six2+ nephron progenitors 
(A) Experimental breeding strategy to obtain successful VHL deletion in nephron progenitors using Six2-TGCtg and 
VHLlox/lox mice (B) Whole kidney homogenates from P1 VHLNP+/- and VHLNP-/- mice subjected to Western blotting 
with antibodies against VHL and α/β-tubulin to confirm VHL deletion; ***P<0.0001; VHLNP+/- N=3; VHLNP-/- N=5. 
Error bars indicated as SEM. (C) Whole kidney homogenates from P1 VHLNP+/- and VHLNP-/- mice subjected to 
Western blotting with antibodies against HIF-1α and α/β-tubulin to confirm HIF-1α stabilization; *P<0.05; N=4. 
Error bars indicated as SEM. (D-E) Hematoxylin and Eosin (H&E) staining of kidneys sectioned at E13.5 appears 
developmentally normal. (F-I) H&E staining of kidneys sectioned at E15.5 and P1 exhibit hypoplasia and reduced 
developing glomeruli (arrows). 
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To determine the onset of the developmental phenotype, we performed 3-Dimentional 
(3D) reconstructions of E13.5 kidneys to evaluate kidney size and maturation, which supported 
the histological examination. The number of glomerular structures, renal vesicles, and immature 
glomeruli were not significantly altered nor were there differences in kidney volume, ureteric 
epithelium volume, or glomerular volume (Figure 17A-H).  
Next, we evaluated the expression of nephron progenitor and renal vesicle markers 
through immunofluorescent staining of E15.5 and P1 VHLNP+/- and VHLNP-/- kidneys as E15.5 is 
when we first observe a phenotype and P1 is largely an older progenitor population. Staining 
against the nephron progenitor marker Six2 with Ncam to mark the nascent nephrons at E15.5 
(Figure 18A-B) and P1 (Figure 18C-D) revealed that VHLNP-/- kidneys have persistent Six2 
expression in Ncam+ structures. Further, Ncam expression was also decreased at both E15.5 and 
P1 suggesting there may be alterations in cell adhesion between nephron progenitors (Figure 
18A-D). For these reasons, we quantified the number of Six2+ cells per cap at P1 and found a 
increase (P=0.006; Figure 18I). Next, we performed immunostaining against Jag1 
(differentiating structures) and saw a reduction in the number of Jag1+ structures (P=0.008; 
Figure 18E-H;J), which further suggests that VHLNP-/- kidneys exhibit decreased differentiation.  
To evaluate differentiation capacity, we performed unbiased, stereological counting of 
Wt1+ glomeruli at P1 and found a 30% decrease (P=0.01; Figure 19A). Although there is a 
significant decrease in the number of nephrons, the kidney-to-body weight ratio at P1 was 
unchanged between VHLNP+/- and VHLNP-/- mice (Figure 19B).  
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Figure 17: VHLNP-/- mice exhibit altered kidney development after E13.5 
(A) 3-Dimensional (3D) reconstruction of E13.5 VHLNP+/- and VHLNP-/- kidneys showing glomerular structure 
formation. No significant differences in glomerular structure (P=0.47), renal vesicle formation (P=0.81), or 
immature glomeruli number (P=0.39). VHLNP+/- N=3; VHLNP-/- N=5. Error bars indicated as SEM. (B) 3D 
reconstruction of E13.5 VHLNP+/- and VHLNP-/- kidneys showing tissue volume. No significant differences in kidney 
volume (P=0.75), ureteric epithelium volume (P=0.78), or glomerular volume (P=0.87). VHLNP+/- N=3; VHLNP-/- 
N=5. Error bars indicated as SEM. (C-H) 3D images depicting all glomerular structures (green), ureteric branching 
patterns (pink), and a reconstruction of the kidneys.  
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Figure 18: VHLNP-/- kidneys exhibit Six2 mis-expression, decreased cell adhesion, and fewer Jagged1+ 
structures 
(A-D) E15.5 and P1 immunofluorescent staining with antibodies against Six2 (red) and Ncam (green) showed 
prolonged expression of Six2 in Ncam+ structures (arrow head). Reduced Ncam staining was also shown in VHLNP-/- 
kidneys (asterisk). (E-H) Six2 (red) and Jag1 (green) staining reveals expansion of Six2+ cells (plus sign) and fewer 
Jag1+ structures (arrows). (I) The number of Six2+ cells per cap was significantly increased in P1 VHLNP-/- kidneys. 
**P<0.01; N=3. Error bars indicated at SEM.  (J) The number of Jag1+ structures is significantly decreased in P1 
VHLNP-/- kidneys. **P<0.01; N=3. Error bars indicated as SEM. 
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Figure 19: VHLNP-/- kidneys have decreased differentiation in nephron progenitors 
(A) VHLNP-/- kidneys have significantly fewer glomeruli (30% reduction) compared to littermate controls. *P<0.05; 
N=4. Error bars indicated at SEM. (B) No significant differences in the kidney-to-body weight ratio at P1. P=0.33. 
N=3. (C) No significant differences in nephron progenitor gene expression (Cited1, Sall1, Eya1, Six2, Osr1). Renal 
vesicle genes (Lef1, Wnt4, Jag1) were all significantly increased. *P<0.05; N=4. Error bars indicated at SEM. 
 
 
 
 
Gene expression analysis of whole E17.5 kidneys showed no differences in several 
nephron progenitor markers, including Cited1, Sall1, Eya1, Six2, and Osr1 (Figure 19C). Gene 
expression analysis of the differentiation markers Lef1, Wnt4, and Jag1 revealed significant 
decreases in expression reflecting an inability to properly undergo differentiation (Figure 19C). 
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There were no changes in Foxd1 (stromal progenitors) or Sox9 (ureteric tip identity) gene 
expression (Figure 19C). Together, this suggests that VHL does not induce profound alterations 
during the self-renewal phase and likely plays a larger role in the regulation of nephron 
progenitors that are poised to exit the progenitor niche. 
To explore alterations in proliferation and cell death as a possible causes of decreased 
differentiation, we performed immunofluorescent staining with anti-pHH3 and TUNEL, 
respectively. There were no differences in proliferation or apoptosis (Figure 20A-P). We also 
performed cell cycle analysis on P1 nephron progenitors using propidium iodide to investigate 
potential irregularities in the cell cycle or senescence. Cell cycle analysis showed no differences 
in G1/G0, S, or G2/M phases (Figure 20Q-R). Collectively, these data indicate that reductions in 
nephron number do not likely stem from decreased proliferation, increased cell death, cell cycle 
dysregulation, or cellular senescence prior to cessation of nephrogenesis in VHLNP-/- kidneys. 
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Figure 20: VHLNP-/- kidneys do not exhibit alterations in proliferation or apoptosis across development 
(A-H) Kidneys at E13.5, E15.5, E18.5, and P1 were immunostained for phospho-histone H3 (pHH3; red) and Ncam 
(green), which did not reveal any alterations in proliferation. (I-P) E13.5, E15.5, E18.5, and P1 kidneys were 
subjected to TUNEL staining (green) and no significant differences were detected. (Q-R) P1 VHLNP+/- and VHLNP-/- 
kidneys were subjected to cell cycle analysis, which did not reveal any significant differences. VHLNP+/- N=4; 
VHLNP-/- N=5. 
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4.4.2 VHLNP-/- nephron progenitors display metabolic gene dysregulation 
To better understand the mechanisms underlying how VHL contributes to development, we 
performed RNA-sequencing (RNA-seq) on E17.5 GFP+ nephron progenitors using FACS. 
Hierarchical distance clustering and principal component analysis (PCA) showed clear grouping 
of VHLNP+/- and VHLNP-/- samples (N=4; Appendix G). Variance and expression of distribution 
were estimated using DESeq2 and minus-average plotting (Appendix G). We observed a down 
regulation of VHL, confirming efficient deletion of this loxP-flanked fragment by Cre 
recombinase (Appendix G). Controlling the false discovery rate at 5% and focusing on genes 
with at least two-fold up or down regulation, we found that 245 known genes were significantly 
altered: 222 of these genes were up regulated and only 23 were down regulated in VHLNP-/- 
nephron progenitors (Figure 21A). The top most dysregulated genes included Bnip3l, Bnip3, 
Pgm2, Fam162a, Pfkp, Slc2a3, Kbtbd11, Stc2, Adamts13, and Mgarp (Appendix G). Functional 
enrichment analysis using DAVID (http://david.ncifcrf.gov) generated the top most affected 
Gene Ontology (GO) term pathways, which included glycolysis (16 genes; 45.7% of KEGG 
Glycolysis/Gluconeogenesis genes; P=1.13x10-21), cellular response to hypoxia (13 genes; 
12.6% of KEGG HIF-1 genes; P=6.65x10-10), and HIF-1α signaling pathway (12 genes; 11.4% 
of KEGG HIF-1α genes; P=3.78x10-8) among others (Figure 21B). HIFs, the main targets of 
VHL, are known to transcriptionally activate genes containing HREs. Of which, several were 
found to be altered including those associated with glycolysis (Pgk1, Gapdh, and Tpi1), hypoxia 
response (Bnip3 and Ddit4), and HIF-1α signaling (Pdk1 and Eno1) (Figure 21C; Appendix G) 
in VHLNP-/- nephron progenitors. Additionally, we validated several of the RNA-seq data results 
by real time quantitative PCR using cDNA from VHLNP+/- and VHLNP-/- whole kidneys (Figure 
21D).   
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Figure 21: RNA-sequencing reveals genetic dysregulation in isolated VHLNP-/- nephron progenitors 
(A) Heat map showing differential gene expression in VHLNP+/- and VHLNP-/- nephron progenitors. Cutoff for 
significance was set to LFC>2 and P<0.05. (B) DAVID functional annotation enrichment analysis showing the 
pathways associated with the gene expression data. (C) Annotation-associated gene expression showing Glycolysis 
gene dysregulation using DAVID analysis (Gene Ontology terms). (D) Real time RT-qPCR validation of 
significantly dysregulated genes in the glycolysis, cellular response to hypoxia, and HIF-1α signaling pathways. 
*P<0.05. RNA-sequencing N=4. RT-qPCR validation N=3. Error bars indicated as SEM. 
4.4.3 VHLNP-/- nephron progenitors exhibit decreased mitochondrial oxygen consumption 
RNA-seq data analysis implicated metabolic dysregulation as a potential driver of defective 
nephron progenitor differentiation in VHLNP-/- kidneys. To compare overall mitochondrial 
function, P1 VHLNP+/- and VHLNP-/- nephron progenitors were MACS-isolated and subjected to a 
mitochondrial stress test using a Seahorse XF24 extracellular flux analyzer to measure oxygen 
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consumption [17, 27]. Oxygen consumption is an indicator of mitochondrial respiration in the 
presence of a series of metabolic inhibitors and uncoupling agents [225, 228]. Overall oxygen 
consumption, both before and after substrate addition, resulted in decreased OCR (Figure 22A). 
Basal oxygen consumption was significantly decreased in VHLNP-/- nephron progenitors 
compared to VHLNP+/- littermate controls (Figure 22B). Moreover, mitochondrial ATP-linked 
respiration was significantly decreased (Figure 22C). Non-mitochondrial respiration was also 
calculated by averaging the oxygen consumption after addition of rotenone/antimycin A and was 
increased in VHLNP-/- nephron progenitors (P=0.016). This indicates decreased reliance on the 
mitochondria for energy production. P1 VHLNP-/- kidneys also exhibited decreased mitochondrial 
pyruvate oxidation to CO2 (Figure 22D), further confirming decreased mitochondrial 
metabolism. To better understand the decrease in mitochondrial respiration, we analyzed 
mitochondrial density by flow cytometry using MitoTracker Red. There were no significant 
differences at P1 in mitochondrial density in the GFP+ cell population (Figure 22E). This data 
indicates that P1 VHLNP-/- nephron progenitors exhibit decreased dependency on mitochondrial 
ATP for energy production, which is not due to mitochondrial insufficiency.  
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Figure 22: VHL deletion suppresses cellular oxygen consumption 
(A) P1 MACS-isolated nephron progenitors were subjected to oxygen consumption (OCR) measurements in a 
Seahorse XF24 extracellular flux analyzer. Measurements of OCR were taken prior to and after sequential 
administration of the metabolic inhibitors oligomycin (ATP synthase inhibitor), FCCP (mitochondrial oxidative 
phosphorylation uncoupler), and rotenone/antimycin A (respiratory chain inhibitors). (B) The average oxygen 
consumption over the first 30 minutes produced the basal oxygen consumption, which was significantly decreased in 
VHLNP-/- nephron progenitors. *P<0.05; N=3. Error bars indicated as SEM. (C) ATP-linked respiration was 
calculated by subtracting basal respiration by the average OCR after oligomycin addition. ATP-linked respiration 
was significantly decreased in VHLNP-/- nephron progenitors. *P<0.05; N=3. Error bars indicated as SEM. (D) 
Pyruvate oxidation to 14CO2 was significantly decreased in VHLNP-/- whole tissue homogenates. *P<0.05; VHLNP+/- 
N=4; VHLNP-/- N=3. Error bars indicated as SEM. (E) Mitochondrial density was not significantly altered P1 
nephron progenitors. P=0.39. Error bars indicated as SEM. 
 
4.4.4 VHLNP-/- nephron progenitors exhibit increased glycolysis 
In addition to oxygen consumption, the Seahorse XF24 extracellular flux analyzer monitors the 
extracellular acidification rate (ECAR), as an indicator of anaerobic glycolysis. VHLNP-/- MACS-
isolated nephron progenitors demonstrated increased glycolysis both before and after substrate 
administration (Figure 23A). Basal ECAR was increased (Figure 23B). Moreover, the glycolytic 
response to oligomycin (mitochondrial respiration inhibitor) was significantly higher in VHLNP-/- 
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nephron progenitors compared to VHLNP+/- nephron progenitors demonstrating increased 
glycolytic capacity (Figure 23C). We evaluated glycolytic dependence by culturing E13.5 kidney 
explants in media alone or media containing 10μM Y1N (glycolysis inhibitor) for 72 hours. 
Explants were then subjected to immunostaining against Six2 and Jag1 to mark the nephron 
progenitors and developing structures, respectively. Visual identification of the number of 
differentiating structures revealed 1) VHLNP-/- kidneys cultured in YN1 were capable of 
differentiating while VHLNP-/- kidneys cultured in media alone underwent minimal differentiation 
and 2) VHLNP+/- and VHLNP-/- kidneys cultured in YN1 differentiated similarly (Figure 23D-G). 
This suggests that the differentiation phenotype arises from an inability of VHLNP-/- nephron 
progenitors to metabolically switch from glycolysis to mitochondrial respiration during 
nephrogenesis, further validating the importance of VHL during kidney development.   
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Figure 23: VHL deletion leads to increased glycolysis 
(A) P1 MACS-isolated nephron progenitors were subjected to extracellular acidification (ECAR) measurements in a 
Seahorse XF24 extracellular flux analyzer as done in Figure 21. (B) Basal glycolysis was determined by averaging 
the extracellular acidification over the first 30 minutes and exhibited an up-regulated trend (P=0.09) in VHLNP-/- 
nephron progenitors. (C) Oligomycin-stimulated glycolysis was calculated by subtracting the basal ECAR from the 
average of the values obtained after oligomycin addition. Oligomycin-stimulated glycolysis was significantly 
increased in VHLNP-/- nephron progenitors. **P<0.01; N=3. Error bars indicated as SEM. (D) Glycolysis pathway 
showing the target of the glycolysis inhibitor YN1. (E-H) Immunofluorescent staining of kidney explants revealed 
that in media alone VHLNP-/- kidneys differentiated less than VHLNP+/- kidneys in media alone. When cultured in the 
presence of the glycolysis inhibitor YN1 both VHLNP-/- and VHLNP+/- kidneys underwent similar levels of 
differentiation.  
4.4.5 VHL deletion results in abnormalities of juvenile mouse kidneys 
VHLNP-/- mice experience premature death around P30; therefore we characterized the renal 
phenotype at P21. To assess renal structure and function of the juvenile (P21) mice, we 
performed gross and histological examinations, which revealed smaller kidneys with fewer 
glomerular structures (Figure 24). The VHLNP-/- kidneys appeared to have decreased glomeruli 
and dilation of the proximal tubules (Figure 24A-D), which is likely due to a compensatory 
 95 
mechanism to overcome the reduction in nephron number [229]. In fact, we found that the 
VHLNP-/- kidneys have a 50% reduction in nephron number (P<0.0001; Figure 24I). Although 
VHLNP-/- kidneys were smaller than VHLNP+/- kidneys, the kidney-to-body weight ratio was not 
different (Figure 24K-M). Additionally, blood urea nitrogen (BUN) concentration was 
significantly increased in VHLNP-/- mice (Figure 24J), which we hypothesized was due to 
glomerular insufficiency and not a result of tubular malfunction. To evaluate this hypothesis, we 
performed immunostaining against Glut1 (glycolysis) and Pck1 (gluconeogenesis), which did not 
reveal differences in protein expression between the VHLNP+/- and VHLNP-/- kidneys (Figure 24E-
H), suggesting that the developed tubules are functional.  
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Figure 24: VHLNP-/- mice exhibit a glomerular deficit at P21 
(A-D) H&E staining of kidneys sectioned at P21 showing reduced nephron number (black arrows). (E-H) There are 
no differences in Glut1 or Pck1 expression in P21 kidneys. LTL staining reveals proximal tubule dilation in VHLNP-/-
kidneys. (I) VHLNP+/- and VHLNP-/- glomerular counts at P21 revealed approximately 50% reduction in glomerular 
number. ****P<0.0001; N=4. Error bars indicated as SEM. (J) Blood urea nitrogen levels are significantly higher in 
VHLNP-/- mice compared to littermate controls. ****P<0.0001; VHLNP+/- N=8; VHLNP-/- N=6. Error bars indicated as 
SEM. (K) Gross comparison of kidney size. (L) VHLNP-/- kidneys are significantly smaller in length at P21. 
***P<0.0005; N=4. Error bars indicated as SEM. (M) The kidney-to-body weight ratio was similar between control 
and VHLNP-/- mice. P=0.07. N=4. Error bars indicated as SEM. 
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4.5 DISCUSSION 
From our study it is clear that the VHL/HIF pathway plays a major role in differentiation 
decisions during nephron progenitor maturation. Our data reveals a previously unknown role for 
VHL in mediating metabolic switching during kidney development that is broadly applicable to 
other developing systems. Mechanistically, our data suggests that VHL is required for nephron 
progenitors to adapt to increasing oxygenation and, in response, alter their primary metabolism 
from glycolysis to oxidative phosphorylation. Moreover, we propose this metabolic switching is 
an essential process for differentiating nephron progenitors. Specifically, nephron progenitors 
lacking VHL exhibit up regulated glycolysis and down regulated mitochondrial respiration. 
Although mitochondrial respiration was suppressed, mitochondrial density did not differ between 
VHLNP+/- and VHLNP-/- nephron progenitors. We conclude that the mitochondria are healthy and 
retain the ability to function normally, however they lack substrate (i.e. pyruvate) due to the HIF-
mediated up regulation of PDK, which effectively blocks pyruvate utilization by the 
mitochondria. Instead of pyruvate shuttling into the mitochondria, it is preferentially converted 
into lactate and recycled back into the glycolytic pathway. The profound metabolic alteration 
leads to decreased differentiation indicated by reduced nephron numbers at both P1 and P21. 
This model simulates pathological hypoxia, which has previously shown to cause a reduction in 
nephrons [183], however the underlying mechanisms have not been previously identified.       
It is well known that kidney formation is highly dependent on oxygen concentration, 
which is largely regulated by VHL and HIFs. Of particular interest, VHLNP-/- nephron progenitors 
have access to oxygen, but remain unable to respond to the oxygen. We hypothesize that the 
VHLNP-/- differentiation phenotype is due to prolonged maintenance of a progenitor niche as 
demonstrated by persistent Six2 and Wt1 expression and decreased nephron number. Six2-
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expressing cells represent a multipotent nephron progenitor population expressed throughout 
kidney development [230, 231] and Six2 must be down regulated to initiate MET [231, 232]. 
Furthermore, another study has shown that HIF-1α blocks MET [233]—a necessary process for 
differentiating nephron progenitors—which serves as another potential mechanism leading to 
decreased nephron number. Although our model has a significant reduction in nephron number, 
our data suggests that either a subset of nephron progenitors remain capable of maturing into 
nephrons or that the differentiation process is not as efficient in VHLNP-/- mice. Similarly, when 
VHL is deleted from Foxd1-expressing stromal progenitors, the resulting offspring exhibit 
nephron deficit and postnatal death by 14 days of age, which was attributed to increased HIF 
expression [234].  Our data shows that the nephrons that do form are either derived from nephron 
progenitors that underwent differentiation early (prior to E15.5) or due to inefficient nephron 
progenitor differentiation. The VHLNP-/- mice do not exhibit a profound phenotype until E15.5, 
which we hypothesize is due to the physiologically hypoxic environment the kidneys are 
subjected to in early development, and is prior to when VHL is critical. Therefore in the absence 
of VHL prior to E15.5, the nephron progenitors are capable of normal differentiation, however 
after this time they fail to undergo sufficient differentiation. A previous study by Wang et al also 
investigated renal structure and function in Six2creEGPF-VHL null mice for the purpose of 
studying renal cell carcinoma [86]. Although our model exhibits profound abnormalities 
correlating to significantly decreased renal function by P21, their mice are histologically normal 
and do not exhibit any malformations or dysfunction until approximately 4 months of age [86]. 
We see an accelerated phenotype, which we attribute to differences in mouse background strains. 
Our model was generated using a B6/129S4 mixed background, while Wang et al used a 
BALB/c background. Previous studies have shown that there are significant mouse strain 
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differences, particularly in the kidney and in the progression of diseases such as renal fibrosis, 
hypertension, and kidney disease [235-237].  
Another significant function of VHL-mediated HIF degradation is the regulation of 
metabolism. Previous interrogations of HIF implicate it in the regulation of glycolysis and 
oxidative phosphorylation [121, 144]. While VHL has not been interrogated as a regulator of 
metabolism in nephron progenitors, HIF-1α is a known mediator in other cell types, suggesting 
that VHL must also play an important role in regulating the metabolic profile of these 
progenitors. Moreover, VHL-related cancers exhibit similarly decreased mitochondrial 
respiration in favor of glycolic metabolism even in the presence of oxygen, a phenomenon 
known as the Warburg effect [157, 238, 239]. Although our VHLNP-/- model is not a cancer 
model, these mice do exhibit severe alterations in the nephron progenitor metabolic profile 
consistent with the Warburg effect. In addition to enhanced glycolysis, a previous study 
investigated the metabolic profiles of E13.5 and P0 nephron progenitors and showed that 
younger progenitors demonstrate a higher dependence on glycolysis while older progenitors are 
more dependent on oxidative phosphorylation [17]. Our study suggests that the phenotype 
associated with the VHLNP-/- mice can be attributed to metabolic alterations leading to an inability 
of the cells to transition from glycolysis to oxidative phosphorylation.  
In summary, our study suggests that VHL is crucial for the metabolic switching required 
during progenitor cell differentiation and validates that strict regulation of oxygenation is vital 
for cellular differentiation. Thus, VHL is also an essential mediator dictating proliferative, 
poised, and differentiating nephron progenitors and likely plays a critical role in cell fate 
decisions. Further discussion on the future directions and research limitations of this work are 
described in Chapter 6.3.      
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5.0  VON HIPPEL LINDAU DOES NOT ALTER MITOCHONDRIAL FUNCTION IN 
THE DEVELOPING KIDNEY 
This chapter is an ongoing study and more experimentation is required before it can be 
considered for publication.   
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5.1 CHAPTER SUMMARY 
Von Hippel-Lindau (VHL) is a component of an ubiquitin ligase complex. A major target of 
VHL is a family of transcription factors known as hypoxia inducible factors (HIFs). One member 
of the HIF family is HIF-1α, which is highly expressed in the developing kidney. Both VHL and 
HIFs are critical for development and global deletion of either of these proteins is embryonic 
lethal. One such process that the VHL/HIF axis has been implicated in is metabolic regulation. 
HIF-1α has been previously shown to mediate metabolic processes, however the role of VHL in 
regulating metabolism and mitochondrial function has not been well characterized. A recent 
study into VHL localization found that VHL directly localizes to the mitochondria, but further 
characterization of its role in the mitochondria is unknown. This study aims to investigate the 
role of VHL in mitochondrial function using a mouse model with a conditional deletion of VHL 
specifically in nephron progenitors (VHLNP-/-). A previous investigation by our laboratory 
revealed that the VHLNP-/- nephron progenitors exhibit profound metabolic dysregulation 
glycolysis was up regulated while mitochondrial respiration was significantly down regulated. 
Herein, we found that in the absence of VHL in the nephron progenitors, mitochondrial density, 
dynamics, biogenesis, and ROS production are not altered. This suggests that oxidative 
phosphorylation is inhibited due to HIF-stabilization leading to a lack of substrate availability for 
normal mitochondrial respiration.  
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5.2 INTRODUCTION 
The tumor suppressor and ubiquitin ligase von Hippel-Lindau (VHL) is most well studied in the 
context of hypoxia [117, 129], renal cell carcinoma [86, 240, 241], and Von Hippel-Lindau 
Disease [242]. Many of these pathologies arise from mutations in the VHL gene rendering a 
nonfunctional protein. In a normal cell supplied with ample oxygen, VHL predominantly targets 
the transcription factor family of hypoxia inducible factors (most notably HIF-1α and HIF-2α) 
[117]. HIF-1α is highly expressed in developing cells including stem and progenitor cells, 
however often becomes down regulated (via VHL) for cellular differentiation. Pathologies result 
from prolonged or inappropriate expression of HIFs due to the up regulation of genes containing 
hypoxia response elements (HREs). Overexpression of HREs alters cellular processes 
contributing to cell cycle dysregulation, aberrant proliferation, metabolic irregularities, and 
immunological reprogramming.  
    Metabolic dysregulation is a hallmark of many diseases including cancer, autoimmune 
diseases (diabetes mellitus and rheumatoid arthritis), and kidney disorders (polycystic kidney 
disease, acute kidney injury, and chronic kidney disease) [152, 208]. Unsurprisingly, the 
VHL/HIF-1α axis is also commonly disrupted in these diseases. Previous studies have shown 
that HIF-1α contributes to the metabolic profile of a cell such that high HIF-1α expression results 
in increased glycolytic metabolism [69, 243]. Additionally, HIF-1α expression also results in the 
active down regulation of oxidative phosphorylation of the mitochondria [69, 243]. Although the 
mechanism of HIF-1α in metabolism is well understood, recent studies have also investigated the 
direct role of VHL in mediating metabolism (as opposed to VHL-mediated HIF-1α metabolic 
regulation).  
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A previous study by Shiao et al (2000) revealed that, in addition to cytoplasmic 
localization, VHL localizes to mitochondria in some tissues including the kidney [244]. 
Moreover, mutated VHL resulted in an abnormal mitochondrial phenotype in adult rat kidneys 
[244]. Further, another study interrogated the role of VHL in mitochondrial function and found 
that while oxidative phosphorylation activity and protein content was increased, there were no 
differences in mitochondrial membrane potential [238]. Although this was an interesting finding, 
it is likely that the data was due to the regulation of HIFs and not a direct effect of VHL. Studies 
such as these raise the question: If VHL localizes to the mitochondria, what function does it 
serve?  
To investigate this phenomenon, we used a mouse model (VHLNP-/-) with a conditional 
deletion of VHL specifically in the nephron progenitors (self-renewing cell that forms the 
nephron). A previous study done by our laboratory revealed that VHLNP-/- kidneys have 
prolonged reliance on glycolysis metabolism and inefficiently undergo metabolic switching. 
Although this was largely attributed to the VHL/HIF-1α pathway, herein we investigate 
mitochondrial properties contributing to function including: biogenesis, mitophagy, 
fission/fusion dynamics, ROS, and mitochondrial density. We found that the mitochondria 
appear healthy and retain the ability to function normally, however they lack substrate (i.e. 
pyruvate) due to the HIF-mediated up regulation of PDK, which effectively inhibits pyruvate 
utilization by the mitochondria. Instead of pyruvate migration into the mitochondria, it is 
preferentially converted into lactate and recycled back into the glycolytic pathway.   
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5.3 METHODS AND MATERIALS 
5.3.1 Experimental mouse model and genotyping 
VHLNP+/- and VHLNP-/- mice were generated using the same breeding strategy described in 4.3.1. 
Genotypes were determined as described in 4.3.2. 
5.3.2 Real time quantitative polymerase chain reaction (PCR) 
E17.5 kidneys were dissected and screened using the GFP expression. Dissected kidneys that 
expressed GFP were dissociated into single cell suspensions and FACS sorted (Flow Cytometry 
Core, Rangos Research Center. Each sample consisted of approximately 150,000 pooled control 
or mutant nephron progenitor cells. RNA isolation and cDNA synthesis was done as previously 
described in 2.3.3. The following genes were analyzed using this method: Glut1, Ldha, Pdk1, 
Tomm20, Tfam, Sirt1, Drp1, Opa1, Bcl2, Lc3, Nox4. All gene expression was normalized to 
Rn18s. Primer sequences are listed in Appendix B. 
5.3.3 Western blotting 
Immunoblots were prepared as done in 4.3.3. Antibodies used include (Appendix D): Pgc-1a 
(Novus), Dnm1l (Thermo Fisher Scientific), Tomm20 (Santa Cruz), and anti-α/β tubulin (Cell 
Signaling Technology, 1:1000). Secondary antibodies include: anti-IgG rabbit HRP (Cell 
Signaling Technology, 1:1000) and anti-IgG mouse HRP (Cell Signaling Technology, 1:250). 
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Blots were imaged using a ProteinSimple FluoroChem M System (ProteinSimple) and quantified 
using ImageJ software (ImageJ/NIH Image).    
5.3.4 Flow cytometry for mitochondrial density 
Samples were analyzed using MitoTrackerTM Red FM (Thermo Fisher Scientific; Appendix E) as 
previously described in 4.3.6.  
5.3.5 Flow cytometry for reactive oxygen species 
Samples were analyzed using MitoSOXTM Red Mitochondrial Superoxide Indicator (Thermo 
Fisher Scientific; Appendix E) as previously described in 2.3.5.  
5.3.6 Flow cytometry for lysosome formation 
Kidney tissue was harvested from P1 VHLNP+/- and VHLNP-/- mice. Kidneys were digested using 
0.3% collagenase and forced through needlepoint to create a single cell suspension. 1 x 106 cells 
were stained for 1 hour at 37°C using 50nM LysoTrackerTM Red DND-99 (Thermo Fisher 
Scientific; Appendix E) per manufacturer’s guidelines. Cells were analyzed on a BD 
LSRFORTESSA cell analyzer (BD Biosciences) through the Flow Cytometry Core at the 
Rangos Research Center located at the UPMC Children’s Hospital of Pittsburgh 
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5.3.7 Immunofluorescent staining 
Immunofluorescent staining was performed on paraffin embedded samples as previously 
described in 3.3.5. Samples were probed using primary antibodies or lectins (1:100; Appendix D) 
against: Tomm20 (Santa Cruz), LTL (Gibco), and DAPI. Samples were imaged using a Leica 
microscope (Leica Microsystems) and LAS X software (Leica Microsystems).    
5.3.8 Statistical analysis 
A minimum of 3 biological replicates was used for each experiment in at least technical 
duplicate. When comparing two sample groups, statistical significance was determined using a 
two-tailed Student’s t test (α = 0.05). Significance was defined as *P<0.05, **P<0.01, and 
***P<0.001. Where appropriate, data is presented as mean ± standard error of the mean. Data 
was analyzed using Microsoft Excel and figures were generated using GraphPad Prism 7.  
5.4 RESULTS 
To interrogate the role of VHL in mitochondrial function, we utilized our previously published 
mouse model with a conditional deletion of VHL specifically in nephron progenitors under a 
Six2cre [245]. This model exhibits profound developmental kidney defects due to an inability to 
undergo metabolic switching from glycolysis to mitochondrial respiration during nephron 
progenitor differentiation [245]. We hypothesize that this could be due to three potential 
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mechanisms: 1) decreased mitochondrial density 2) mitochondrial dysfunction 3) or lack of 
substrate utilization.  
5.4.1 Mitochondrial density is not altered in VHLNP-/- kidneys 
To determine mitochondrial quantity, we performed immunofluorescent staining against 
Tomm20, an outer mitochondrial membrane protein that can be visualized and quantified as an 
indicator of mitochondrial mass. Immunofluorescent staining revealed that P1 VHLNP-/- kidneys 
appeared to have decreased mitochondrial density (Figure 25A-B). Further, P21 VHLNP-/- kidneys 
also exhibited decreases in mitochondrial density (Figure 25C-D). Although there were 
differences in mitochondrial densities at both P1 and P21, it was previously shown that VHLNP-/- 
kidneys have significantly decreased nephron number at both time points, which would lead to a 
decreased number of proximal tubules [245]. The proximal tubules are highly metabolically 
active and utilize mitochondrial fatty acid oxidation to a high extent [208]. For this reason, we 
believe that the decrease in Tomm20 expression in VHLNP-/- kidneys was due simply to reduced 
proximal tubule load and not due to inherently decreased mitochondrial density. To test this, we 
quantified Tomm20 gene and protein expression using real time quantitative PCR and Western 
blotting. Tomm20 expression was comparable between FACs sorted nephron progenitors from 
VHLNP+/- and VHLNP-/- kidneys (Figure 25F). Tomm20 protein expression also appeared similar 
Figure 25E;G). Moreover, we evaluated mitochondrial density by flow cytometry using 
MitoTracker straining and again did not see any significant differences in mitochondrial density 
(Figure 25H). Together, this suggests that the reduced mitochondrial utilization by VHLNP-/- 
kidneys is not due to decreased mitochondrial density.  
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Figure 25: Mitochondrial density is decreased in VHLNP-/- kidneys but not in VHLNP-/- nephron progenitors 
(A-B) P1 kidneys were immunostained against Tomm20 (red) and Ncam (green) and VHLNP-/- kidneys appear to 
have reduced mitochondria indicated by Tomm20 reduction. (C-D) Similarly, P21 VHLNP-/- kidneys appear to have 
reduced mitochondria indicated by Tomm20 (red) reduction. No alterations observed in DBA immunostain (green). 
(E) Tomm20 immunoblot against Tomm20 from P1 whole kidney lysates. (F) Tomm20 gene expression was not 
altered in E17.5 isolated nephron progenitors. P=0.09; N=4. Error bars indicated as SEM. (G) Quantification of the 
immunoblot shown in E revealed no difference in protein expression between control and VHLNP-/- whole kidney 
lysates. P=0.93; N=4. Error bars indicated as SEM. (H) Mitochondrial density is not different in VHLNP-/- nephron 
progenitors. P=0.39; VHLNP+/- N=11; VHLNP-/- N=10. Error bars indicated as SEM. 
 
5.4.2 VHLNP-/- kidneys do not exhibit mitochondrial dysfunction 
Previous hypoxia studies have shown that cells can adapt to oxygen level fluctuations by altering 
their metabolism [246], which can lead to significant alterations in mitochondrial biogenesis, 
fission/fusion dynamics, and autophagy. For these reasons, we evaluated gene and protein 
expression of several key molecules involved in these processes.  
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Gene expression of the mitochondrial biogenesis genes Tfam and Sirt1 did not show any 
abnormalities in the rate of mitochondrial formation (Figure 26A) in P1 nephron progenitors. 
Likewise, Western blotting for PGC-1α, a protein essential for mitochondrial biogenesis, did not 
reveal any differences in expression (Figure 26B-C) in P1 whole kidney homogenates. 
Therefore, we do not believe that the mitochondria are undergoing abnormal rates of turnover. 
Similarly, we evaluated mitochondrial dynamics in P1 nephron progenitors and kidneys 
by determining gene and protein expression of Opa1 (inner mitochondrial membrane fusion) and 
Drp1 (mitochondrial fission). Neither gene nor protein expression of these mitochondrial 
dynamic markers were altered in VHLNP-/- kidneys (Figure 27A-D).  
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Figure 26: Mitochondrial biogenesis is not altered in VHLNP-/- nephron progenitors  
(A) Mitochondrial biogenesis genes Tfam and Sirt1 do not exhibit dysregulation in VHLNP-/- nephron progenitors at 
E17.5. Tfam P=0.22; Sirt1 P=0.51; N=4. Error bars indicated as SEM. (B) Pgc1D protein quantification did not 
reveal any significant differences in expression. P=0.94; N=4. Error bars indicated as SEM. (C) Immunoblot for 
Pgc1D shows similar expression both kidneys.  
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Figure 27: Mitochondrial dynamics are unchanged in VHLNP-/- nephron progenitors  
 (A) Mitochondrial dynamics genes Drp1 (mitochondrial fission; P=0.20) and Opa1 (mitochondrial fusion; P=0.09) 
are not differentially expressed in VHLNP-/- nephron progenitors. N=4. Error bars indicated as SEM. (B) 
Immunoblots of Drp1 and Opa1. (C-D) Drp1 (P=0.11) and Opa1 (P=0.66) protein expressions were not significantly 
altered. N=4. Error bars indicated as SEM. 
 
Next, we performed gene expression analysis to determine whether VHLNP-/- kidneys 
experienced increased mitophagy—mitochondrial degradation by autophagy. We found that Bcl2 
and Lc3 gene expression were not significantly different (Figure 28A). We also utilized 
LysoTracker staining and analyzed expression in P1 nephron progenitors by flow cytometry. 
LysoTracker is a dye that localizes to lysosomes, and during mitophagy the degraded 
mitochondria are engulfed by autophagosomes that fuse with lysosomes; Therefore, this is a 
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technique that indicates the level of autophagy that is occurring.   There were no differences in 
lysosomal formation as indicated by LysoTracker flow cytometry (Figure 28B).  
Finally, we evaluated ROS generation as an output of mitochondrial dysfunction. Nox4 
(oxidative stress indicator) gene expression was determined to be similar between both VHLNP+/- 
and VHLNP-/- kidneys from P1 animals (Figure 29A). Further, MitoSox (ROS indicator) 
fluorescence as determined by flow cytometry did not reveal any differences between the P1 
control and VHLNP-/- kidneys (Figure 29B).  
Together, this data reveals that in developing nephron progenitors, HIF-1α stabilization 
does not significantly impact mitochondrial function. Similarly, although it has been shown that 
VHL may localize to the mitochondrial, it is unlikely that VHL in nephron progenitors plays a 
significant role in the differentiation process. For these reasons, we believe our data indicates 
that the mitochondria are functional and capable of performing oxidative phosphorylation, 
however are not utilized for energy generation due to the preferential conversion of pyruvate to 
lactate in the cytosol. 
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Figure 28: VHLNP-/- nephron progenitors have similar levels of autophagy as compared to VHLNP+/- nephron 
progenitors 
(A) Mitophagy genes Bcl2 (P=0.11) and Lc3 (P=0.13) are not dysregulated in VHLNP-/- nephron progenitors. N=4. 
Error bars indicated as SEM. (B) Lyso tracker analysis by flow cytometry revealed that there is not significant 
difference in lysosome formation in VHLNP-/- nephron progenitors. P=0.81; VHLNP+/- N=5; VHLNP-/- N=7. Error bars 
indicated as SEM. 
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Figure 29: VHLNP-/- nephron progenitors do not exhibit aberrant ROS 
(A) Nox4 (ROS marker) gene expression was not significantly altered in VHLNP-/- nephron progenitors compared to 
controls. P=0.06; N=4. Error bars indicated as SEM. (B) MitoSox (ROS indicator) staining and flow cytometry 
analysis did not reveal any differences (student t-test) in ROS generation in VHLNP-/- nephron progenitors. P=0.64; 
N=4. Error bars indicated as SEM. 
5.5 DISCUSSION 
Metabolic processes are an important component of normal cellular function. Any disruption in 
metabolism can lead to reduced energy production, irregularities in cellular function, and 
ultimately disease pathologies. The kidney functions to eliminate waste and maintain salt-water 
balance. More than 70% of the kidney’s function is performed by the nephron, which is the 
functional unit of the kidney. The kidney is a highly metabolically active organ and relies on 
mitochondrial metabolic pathways used by the nephron to filter blood and produce waste (urine). 
The proximal tubule is one epithelialized segment of the nephron that is involved in filtrate 
generation and requires an abundance of ATP to transport ions and small molecules from the 
tubules into the blood system. The required ATP is produced by mitochondria, and as such the 
proximal tubules are the second most abundant sources of mitochondria in the body. Therefore, 
mitochondrial function is pertinent to kidney function.  
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Both developmental processes and normal kidney function utilize ATP, a mechanism that 
inherently necessitates oxygen since oxygen is considered the final electron acceptor in the 
electron transport chain. Oxygenation of the kidney occurs during embryonic development and is 
regulated by the suppression of hypoxia inducible factors (HIFs; particularly HIF-1α) by the 
ubiquitin ligase Von Hippel-Lindau (VHL). HIF-1α is a known mediator of metabolism by 
promoting glycolysis and inhibiting mitochondrial respiration. Therefore, as development 
progresses and renal oxygen availability increases, HIF-1α expression decreases allowing for a 
metabolic switch from glycolysis to oxidative phosphorylation, which drives nephron progenitor 
differentiation. Although the occurrence of a metabolic switch is known, the role of the 
VHL/HIF axis in mitochondrial function has not been well characterized, particularly during 
kidney development.  
Previous studies have shown the VHL directly localizes to the mitochondria [244]. 
Moreover, another study has shown that loss of VHL in the nephron progenitors leads to 
suppression of mitochondrial oxygen utilization [245]. In the present study, we interrogated 
mitochondrial function in nephron progenitors with a VHL deletion. Previous investigations in 
other organs and disease states have found profound irregularities in mitochondrial biogenesis 
and autophagy, fission/fusion dynamics, and ROS production. For example, tumorigenic cells—
which are often located in a hypoxic environment—exhibit enlarged mitochondria due to 
decreased fission/increased fusion mediated through interactions with the Bcl-2 family proteins 
Bnip3 and Bnip3l that serve to protect the cells from undergoing apoptosis [247]. Further, 
mitochondrial function has been directly related to morphology to allow for optimal cellular 
energy generation and conservation [53]. In addition to morphological changes during adaptation 
of cellular activity, many cell types including cancer cells can regulate mitochondrial number 
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through biogenesis and mitophagy depending on the energy demands and oxygen availability 
[68]. Since several studies have performed in-depth investigations into mitochondrial function, 
morphology, and density, we aimed to characterize the mitochondrial phenotype in nephron 
progenitors with a VHL deletion. We hypothesized that, similarly to cancer cells, we would find 
mitochondrial abnormalities in the absence of VHL. However, based on gene and protein 
expression of molecules involved in these processes, those abnormalities do not appear to occur 
in nephron progenitors lacking VHL. Likewise, we also investigated the role and production of 
ROS in our model. The current literature is split in terms of the purpose of ROS and it’s 
interactions with HIFs. One study suggests that ROS is an important signaling molecule for HIF 
activation [248], however another study shows that HIF activity effectively decreases ROS 
generation [195]. Contradictory studies such as these indicate that the interaction between 
VHL/HIFs and ROS is multifaceted and likely is cell-type and disease specific. Therefore, 
conclusions regarding mitochondrial function and hypoxia cannot simply be applied to other 
model organisms or cell-specific systems without proper interrogation. 
Although these previous studies have shown abnormalities in mitochondrial function, we 
believe that loss of VHL in our model suppresses mitochondrial respiration due to a lack of 
pyruvate available and transported in the mitochondria. We hypothesize that this is because the 
nephron progenitors are maintaining a progenitor metabolic profile and are responding to the 
maintenance cues of their niche. Nephron progenitors are initially exposed to a hypoxic 
environment and, with the loss of VHL, these cells are programmed to remain in genetically-
simulated hypoxia. Other models of VHL loss typically include tumorigenic cells, which are not 
representative of developmental hypoxia and often experience reprogramming through HIF-2α 
expression. Although HIF-1α and HIF-2α can act redundantly, an increasing number of studies 
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are showing that the HIFs have their own unique target genes and can act either synergistically or 
antagonistically. Moreover HIF-2α behaves as an oncogene while HIF-1α behaves as a tumor 
suppressor further validating that developmental hypoxia mechanism and pathogenic hypoxia 
cellular responses are different. Based on these overwhelming differences in hypoxia adaptation, 
further research is required to characterize the cellular cues of developmental versus pathological 
hypoxia responses. Further discussion on the future directions and research limitations of this 
work are described in Chapter 6.4.       
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6.0  FUTURE DIRECTIONS AND IMPLICATIONS 
6.1 ELUCIDATING THE CELLULAR MECHANISMS OF ADAPTATION TO 
HYPOXIA  
6.1.1 Future experimental methodology 
This brief project served to characterize the adaptation mechanisms used by kidney cells when 
exposed to hypoxia. We aimed to determine the proliferative, apoptotic, and metabolic affects of 
1% oxygen (O2) on HEK-293T cells. Although we made some interesting findings—such as 
hypoxia adaptation is a process that occurs between 24 and 48 hours after initial exposure—we 
failed to fully characterize the metabolic profile of these cells during the adaptive process. The 
experiments outlined in Chapter 2 would benefit from an increased sample sizes for gene 
expression, ROS generation, and lactate determination. Additionally, gene expression data 
should be confirmed by analysis of protein expression. A time course experiment from 24 to 72 
hours should also be done to analyze gene and protein expression every 6 hours and definitively 
ascertain the adaptation process.  
As stated, this project did not fully characterize the metabolic phenotype and although the 
present data suggests that a metabolic reprogramming even occurs, further experimentation is 
necessary. Mitochondrial stress tests and glycolysis stress tests using Seahorse extracellular flux 
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analysis would significantly improve this study. It is known that cells have an innate ability to 
adapt to low oxygen concentrations using HIF signaling and that one mechanism mediated by 
HIFs is metabolic reprogramming. Metabolic reprogramming during hypoxia usually consists of 
a switch from oxidative phosphorylation performed by the mitochondria to cytosolic anaerobic 
glycolysis. Seahorse extracellular flux would provide information regarding the ability of the 
mitochondria to function at 1% O2 in a kidney-derived cell line. Further, a time course assay 
every 12 hours would allow us to determine whether metabolic switching is necessary for 
adaptation or whether it is a consequence that occurs after adaptation. Data obtained from the 
Seahorse should then be confirmed by a pyruvate oxidation assay to quantify the level of 
pyruvate actively being converted acetyl-CoA and CO2.  
HEK-293T cells are an easily established cell line, which was ideal for the time 
constraints of the present study. However, the use of human embryonic fetal kidney tissue would 
greatly benefit the conclusions made from the present investigation. We have preliminary 
Oroboros data suggesting that human fetal kidneys rely substantially on non-mitochondrial 
metabolism to meet the energy demands of the developing organ. Repetition of all experiments 
outlined in Chapter 2 and in this experimental discussion using human fetal kidneys from various 
gestational ages should be done to determine the ability of primary human kidney cells to adapt 
to the ever-changing oxygen conditions occurring in utero. Additionally, in both HEK-293T and 
primary human progenitors, it would be advantageous to better understand whether glycolysis is 
required for cellular maintenance (such as self-renewal of progenitor cells) or if it is merely a 
consequence of hypoxia. To investigate this mechanistic question, the cells would be treated with 
a glycolysis inhibitor and then evaluated for basic cellular functions such as cellular 
proliferation, apoptosis, and metabolism.  
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Finally, mouse nephron progenitor metabolism has been well studied [11, 17, 245], 
however other renal progenitor cell metabolism and the role of hypoxia has not been as 
extensively studied. It has previously been shown in vivo that maternal exposure to hypoxia 
(<7.5% O2) significantly reduces ureteric branching and β-catenin signaling in the ureteric tree 
[10] suggesting that hypoxia does contribute to alterations in early ureteric epithelium 
development. Further, renal stromal progenitors with Vhl depletion under a Foxd1:cre results in 
impairment of kidney development and postnatal death that can be rescued by co-depletion of 
Vhl and Hif-2α [234]. The drastic phenotypes that appear in Vhl-depleted stromal progenitors and 
in hypoxia-exposed ureteric epithelium have been well characterized, however further insight 
into the mechanism driving these phenotypes should be aimed at metabolic profiling of the 
specific cell types. The work herein serves as a basis for future hypoxia investigations and 
suggests that metabolism plays a major role in normal progenitor cell development.     
6.1.2 Expected outcomes and research limitations 
Based on our current experimental data, we would predict that glycolytic metabolism would be 
favored during extended hypoxia exposure, which would be indicated by increased glycolysis 
gene and protein expression as well as increased lactate secretion in the media supernatants. 
Therefore, it is expected that a metabolic switching event between 24 and 48 would be confirmed 
using the rigorous additional experimentation outlined above. This metabolic switch likely 
occurs as a protective mechanism for the cells to evade apoptosis as previously shown [53, 246, 
247, 249].  
One major limitation to the present study is the small sample sizes. Although we reached 
a samples size of three per condition group of each experiment, additional samples should be 
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generated to determine whether significance would be reached for the experiments that were 
conducted.  
Additionally, another major limitation was due to the use of HEK-293T cells. This cell 
line was originally established in 1973 from normal human embryonic kidney cells. Through 
decades of propagation, it is likely that these cells have acquired mutations allowing them to 
easily grow. Cellular division utilizes numerous mechanisms to produce the required nucleotides 
and proteins to sustain life, and some of these mechanisms are likely metabolic in nature. 
Immortalized cell lines often resemble other cell lineages or tumorigenic cells and HEK cells in 
particular have been shown to have dysregulated apoptotic mechanisms and cell cycle 
dysregulation [250]. Moreover, due to the abnormal karyotype, expression of cancer-associated 
proteins, and neuronal cell characteristics [250, 251], the behavior of these cells may not be 
entirely indicative of how the kidney would respond and adapt to hypoxia. Genomic 
investigation has previously shown that the HEK cell transcriptome shows expression of adrenal, 
kidney, and pituitary tissue [251] and expresses genes such as NF-L, NF-M, Vim, and several 
neuronal keratins [252]. Further, the adrenal tissue is of neural crest origin, which is 
hypothesized to be the reason that HEK cells has a unique “neuronal” phenotype compared to 
kidney specific cells lines. For these reasons, the experiments outlined in Chapter 2 and above 
should be repeated in more suitable cells such as MK3, MK4, or primary human kidney cells, 
which would be more indicative of developmental renal cell behavior.  
6.1.3 Global implications  
Intrauterine hypoxia is a common gestational stressor that can lead to developmental 
abnormalities of the fetus. Placental insufficiency is one type of intrauterine hypoxia-related 
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condition and is characterized by fetal oxygen deprivation [139, 253]. Moreover, placental 
insufficiency is a leading cause of Intrauterine Growth Restriction (IUGR) [254]. IUGR is a 
condition that affects 12% of deliveries and causes 75% of perinatal deaths in the United States. 
When disorders such as these present in the clinic, one concern of the physician is failure to 
thrive and decreased organ development due to the preferential redirection of blood and oxygen 
to the brain and heart [139, 161]. The kidney is a highly perfused organ that requires oxygen to 
develop and function normally. If prenatal hypoxia exposure occurs, the risk for long-term 
kidney disease is significantly increased. Due to the high prevalence of gestational hypoxia 
disorders and prenatal complications, research into the effect of hypoxia on kidney development 
and disease is critical.  
Not only is oxygen availability important for kidney development, but also it is critical 
for normal kidney function. The kidney is a highly metabolically active organ and requires an 
abundance of oxygen to supply mitochondrial energy and facilitate blood filtration. Without 
oxygen, the kidney cannot transport ions and small molecules across the epithelium, thus leading 
to damage of the renal tubules. The nephron is the functional unit of the kidney and is comprised 
of the proximal and distal tubules among other segments. These tubular segments perform more 
than 70% of all renal function; therefore damage greatly increases susceptibility to kidney 
disease and injury. In fact, hypoxia is considered a major driver of chronic kidney disease and 
end stage renal failure (ESRF) [255].  Causes of hypoxia-induced kidney disease include: 
anemia, hyperglycemia, hypertension, hypercholesterolemia, sleep apnea, and environmental 
factors (cigarette smoking and air pollution) [255]. Unfortunately, there is no known cure for 
kidney disease and the treatment options include dialysis or kidney transplant, both of which 
significantly reduce lifespan. Current investigations into alternative treatments are aimed at 
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oxygenation such as erythropoietin injections, renal angioplasty, whole body oxygen chambers, 
and various drug therapies [255]. 
6.2 INTERROGATING PHYSIOLOGICAL REPROGRAMMING IN THE KDINEYS 
AFTER HYPOXIA EXPOSURE 
6.2.1 Future experimental methodology  
The focus of Chapter 3 was to characterize the phenotype, both pre- and post-natally, of mice 
that were exposed to hypoxia in utero. Previous investigations into the effect of hypoxia failed to 
determine the role of strict oxygenation on embryonic development, or more specifically on 
kidney development. Some studies have suggested that hypoxia exposure may lead to decreased 
nephron endowment and structural abnormalities in the kidney and other organs, but a complete 
characterization has not currently been done. We aimed to determine the effect of prenatal 
hypoxia exposure on kidney development by housing pregnant dams in hypoxia (12% O2) or 
normoxia (ambient oxygen) during nephrogenesis. Although we evaluated renal histology, 
developmental gene expression, protein expression, and renal function our sample sizes were not 
ideal and several additional parameters should be assessed.  
Future work should first focus on repeating the experiments outlined in Chapter 3. 
Numbers should be increased to four pregnant dams per condition group and time point—
normoxia embryonic development, hypoxia embryonic development, normoxia P1 development, 
hypoxia P1 development, normoxia baseline 7 week, hypoxia baseline 7 week, normoxia 
cisplatin treated, and hypoxia cisplatin treated. During the oxygenation treatment period (E10.5-
 124 
P3), maternal parameters such as food intake, water intake, urine output, weight gain, litter sizes, 
and placental weights should all be measured. At the appropriate embryonic and postnatal 
collection periods, pup weight, kidney weight, pup length, and kidney length should be 
determined. To better define the lack of structural abnormalities, glomerular number should be 
quantified at all time periods, as should proximal tubule and corpuscle parameters. Moreover, 
this study primarily utilized male mice for post-natal characterization at baseline and after injury. 
In future experiments, ideally both males and females should be used, particularly because 
kidney injury is know to have sex-related differences [199, 256-258].  
Additionally, as our laboratory has previously shown that the major developmental 
hypoxia pathway (VHL/HIF) mediates metabolism [245], the HIF pathway should be 
interrogated for its contribution in priming a physiological reprogramming response that 
increases kidney injury susceptibility, especially since hypoxia has been correlated to kidney 
disease incidence [255]. It is likely that the HIF pathway, or HIF-mediated mechanisms leading 
to alterations in post-translational modifications, is at play in the physiological adaptation and 
priming of the offspring to a secondary insult later in life. To further this investigation, HIF 
protein expression should be evaluated through Western blotting and immunohistochemistry to 
determine both quantity and localization in the kidneys. Since the proximal tubules perform a 
majority of blood filtration and because cisplatin preferentially targets the proximal tubules, it 
would be interesting to assess localization of HIF expression.  
6.2.2 Expected outcomes and research limitations 
Our experimental design utilizes moderate hypoxia as a maternal stressor during gestation. It is 
possible that 12% O2 is not severe enough to induce structural abnormalities in the offspring of 
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dams exposed to the hypoxia. However, this also leads to a potential limitation of the study in 
that a more severe prenatal hypoxia model (which may cause structural lesions) could lead to 
death. For this reason, we selected the more modest oxygen dosing. However, increasing the 
number of samples and the parameters assessed in the study should not change the fundamental 
conclusions that were previously drawn in Chapter 3.  
In the present study, one drawback to using hypoxia is that this treatment must be done in 
a contained apparatus. These devices are small, thus making it difficult to collect the maternal 
parameters such as food/water intake and urine output, which must be done using individual 
metabolic cages. Additionally, another potential drawback to the study is the use of cisplatin, 
however we elected to use this method of injury because we did not want to use both primary 
and secondary hypoxia-based injury models (ischemic reperfusion injury) so that we could 
attribute any differences in phenotype to developmental hypoxia exposure. Further, cisplatin 
usage at an incorrect dosage has been shown to cause systemic toxicity, which can occur when 
an incorrect dosage or evaluation time is selected [259]. Therefore, a baseline study should have 
first been conducted to ensure optimal dosing and timing was chosen for C57BL/6 mice.   
The final major limitation to this investigation was that a mechanism was not established. 
In addition to an interrogation into the hypoxia pathways, several other mechanisms could be 
contributing to the phenotype and should be evaluated. Pathological ROS have been previously 
implicated in severe kidney injury and kidney disease [104, 193, 194]. The role of ROS in 
contributing to the robust injury found in the prenatal hypoxia-exposed mice should be 
conducted. Further, the Renin-Angiotensin System should be of primary interest in this 
investigation as the regulation of blood pressure by Renin-Angiotensin System can play an 
important role in cisplatin susceptibility after prenatal hypoxia. In humans, lower blood pressure 
 126 
and the use of Renin-Angiotensin system inhibitors have also been associated with incidence of 
cisplatin nephrotoxicity [200]. Therefore based on the current literature, these pathways should 
be investigated for their potential role in physiological priming of injury after hypoxia exposure.  
6.2.3 Global implications  
This investigation has important implications in the study of placental insufficiency and IUGR 
even though our model was not specifically evaluated for placental abnormalities due to hypoxia. 
Further, our model may be more indicative of  “preplacental” hypoxia, which has been shown to 
changes in placental blood flow, oxygenation, and nutrient availability [260]. This preplacental 
maternal hypoxia can also lead to alterations such as epigenetic modifications and developmental 
delay, both of which contribute to increased disease susceptibility [260]. Causes of preplacental 
hypoxia include: maternal diabetes, cardiovascular disease, anemia, asthma, and others. 
Although there are several causes of maternofetal hypoxia, it is best exemplified in studies 
investigating high altitude living.  Previous studies interested in individuals residing at high 
altitudes have shown that for every 1,000-meter altitude increase, the resulting offspring have a 
100-gram decrease in birth weight [260, 261]. Further, the placental-to-fetal weight ratio is also 
skewed in these populations [260]. These statistics solidify the importance of research into 
maternal and prenatal hypoxia exposure and its effect on offspring development.  
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6.3 UTILIZING THE VHL/HIF AXIS TO REGULATE METABOLISM AND 
NEPHRON DEVELOPMENT 
6.3.1 Future experimental methodology 
Chapter 4 investigated the role of VHL in kidney development. We found that VHL is critical for 
normal nephron differentiation and its loss leads to decreased nephron endowment. Further, we 
revealed that the decreased nephron endowment associated with VHL loss was due to a failure of 
nephron progenitors to switch their metabolic profile to induce differentiation. Although the 
work done in this project went through several revisions and reviewer critiques prior to its 
publication, further experiments could be done to utilize our findings as precursors to 
therapeutics and disease prevention.  
We propose that future investigations should be aimed at rescuing the characterized 
phenotype of VHLNP-/- mice. This includes utilizing both pharmacological and genetic rescue 
techniques. In the present study, we performed an in vitro rescue on whole kidney explants using 
the glycolysis inhibitor YN1. This experiment allowed us to show that VHLNP-/- kidneys do not 
undergo sufficient differentiation, however when glycolysis is inhibited the nephron progenitors 
can differentiate to a similar extent as the control kidneys. The first experiment that should be 
done in this rescue investigation is to metabolically profile the nephron progenitors after 
glycolysis is inhibited in culture to determine whether these cells switched to mitochondrial 
energy generation. Next, similar experimentation in vivo should be conducted. Glycolysis 
inhibitors—including YN1—have been previously studied as cancer therapies to inhibit high 
rates of glycolysis [262, 263]. This treatment could also be used as a potential strategy to 
enhance nephron number in individuals with VHL mutations. A preclinical trial using VHLNP-/- 
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mice should be done using a low dose of YN1 in an attempt to enhance nephrogenesis. 
Optimization of dosing and timing of treatment would first need to be conducted, however, if 
possible this should be done postnatally but prior to P3 (the conclusion of nephrogenesis) to 
reduce maternal side effects.  
Another important rescue experiment that should be done is a genetic rescue using a 
mouse model with both a nephron progenitor-specific VHL deletion as well as a double deletion 
with HIF-1α knocked out as well. This would help us more definitively determine whether HIF-
1α stabilization is resulting in the observed phenotype. However, one apparent drawback to this 
model is that there is a possibility that HIF-2α could compensate for HIF-1α loss [264, 265]. 
Although there is also literature that suggests there is not redundancy between the two HIF 
molecules [266, 267], this still may be a concern of the outlined experiment.  
6.3.2 Expected outcomes and research limitations 
The present study shows that nephron progenitors require a metabolic switch from glycolysis to 
mitochondrial respiration in order to undergo normal differentiation. Therefore, the addition of 
the experiments outlined above would serve to further validate the mechanistic pathway and 
necessitate the occurrence of a metabolic switch. We hypothesize that glycolysis inhibition in 
vitro will force the VHLNP-/- nephron progenitors to switch from glycolysis to oxidative 
metabolism, which would be shown through metabolic profiling using Seahorse extracellular 
flux analysis. Moreover, we would expect that in vivo treatment of newborn pups with YN1 
would promote nephron differentiation, which could be quantified by stereological counting of 
the glomeruli. Although this appears feasible, pup treatment would likely have several 
limitations including maternal rejection and pup death. If the experiment were manageable, 
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further drawbacks of using systemic YN1 treatment may be failure to thrive and cell cycle arrest 
leading to organ failure and disease. Due to these potential complications, optimal dosing and 
treatment strategy would need to be determined.               
6.3.3 Global implications  
Previous work aimed at understanding the metabolic requirements of nephron progenitors 
revealed that self-renewing progenitors relied more heavily on glycolysis while progenitors 
poised to exit the niche preferred oxidative metabolism [17]. This study aimed to attribute the 
metabolic profiles to a mechanism. We found that hypoxia is a likely contributor to the metabolic 
switching event that occurs. Similar to nephron progenitors, other stem and progenitor cells also 
reside in a hypoxic environment prior to differentiation [124, 234, 243, 268]. Further, stem cell 
metabolism has also been readily studied and these studies have attributed metabolic regulation 
to hypoxia [32, 269]. Although the role of hypoxia and metabolism in stem cell population has 
been greatly studied, with the kidney being a particularly metabolic organ with high 
developmental HIF expression, it was crucial to interrogate these conditions in relation to 
nephron progenitor maintenance and differentiation cues. More broadly however, this study 
shows the importance of oxygen in cellular differentiation and is likely applicable to other 
models. Further, diseases—such as VHL disease, ccRCC, and end stage renal disease—may be 
preventable in the future based on data from hypoxia studies such as this. Identification of 
critical HIF targets aberrantly expressed in these disease systems could be offered as therapeutic 
targets, however further investigation should be done to characterize potential targets.       
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6.4 DETERMINING THE FUNCTIONAL ROLE OF VHL IN THE 
MITOCHONDRIA 
6.4.1 Future experimental methodology 
One study has previously shown that VHL localizes to the mitochondria [244]. Based on this 
finding and our interest in the role of VHL in metabolism, we hypothesized that if VHL localizes 
to the mitochondria then it must serve a function in the mitochondria. The present study 
investigated this hypothesis by defining mitochondrial density, dynamics, biogenesis, death, and 
ROS production and did not find any significant differences between VHLNP+/- and VHLNP-/- 
mitochondrial properties. Additional experimentation that should be included in this study is 
confirmation of VHL localization to the mitochondria in nephron progenitors. This could be 
done following the same experimental outline as in Shiao et al (2000) such as 
immunofluorescent staining of VHL and mitochondria or gold bead-tagged VHL visualized by 
electron microscopy [244]. Further, electron microscopy should be used to phenotype 
mitochondrial morphology, another characterization that was not analyzed in the interrogation 
outlined in Chapter 5.   
6.4.2 Expected outcomes and research limitations 
In this study, we examined several characteristics of mitochondrial health and function and did 
not reveal any significant findings. This led us to conclude that the mitochondria are functional 
in VHLNP-/- nephron progenitors but not utilized due to the up regulation of HIF-mediated 
glycolysis. Performing the experiments outlined above would likely confirm that VHL does 
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indeed localize to the mitochondria. In cancer cell lines, VHL’s role in mitochondrial function 
has been shown to be dependent on the specific mutation and cell type [270], therefore we do not 
believe that it serves a prominent functional role in differentiating nephron progenitors.  
One limitation of this portion of the study is the abundance of literature describing VHL, 
HIF, and metabolism. Although several of these studies were done in cancer cell lines, many of 
them are contradictory suggesting that this pathway may behave differently (or different VHL 
targets are implicated) depending on the specific cell type analyzed. It is also known that VHL 
has non-HIF related targets. Although HIFs re the most well characterized and hypothesized to 
be the major targets of VHL, non-HIF signaling could also be involved in regulating 
mitochondrial function in certain cell types. Several online databases, such as VHLdb, currently 
monitor published VHL target proteins and catalogue the function of those proteins [271].  
Future work on this project should take these alternative pathways into consideration, as it would 
be beneficial to the investigation to explore other target pathways for involvement in 
mitochondrial metabolism.  
6.4.3 Global implications  
Similarly to the previous VHL/HIF chapter, this study has important implications in disease 
treatment for conditions including VHL disease and cancer. These diseases arise from mutations 
in the VHL gene leading to a nonfunctional VHL protein. One study aimed to determine whether 
VHL mutations in ccRCC resulted in mitochondrial dysfunction or if the other accumulated 
mutations in tumorigenic cells lead to the mitochondrial phenotype [238]. It was shown that 
when VHL was present, mitochondrial DNA and oxidative metabolism was utilized and 
therefore in diseases with abnormal VHL expression oxidative phosphorylation was inhibited 
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[238]. One limitation of this study was that it was conducted using commercially available cell 
lines. We believe that our mouse model offers a more translational approach to investigate 
VHL’s role in mitochondrial function even though our model does not develop renal cancer. 
Wang et al (2014) also interrogated VHL and renal cancer and found that VHL deletion (in 
nephron progenitors) alone was not sufficient to cause a renal cancer phenotype, and they 
concluded that renal cancer arises from the accumulation of multiple mutations [86]. Although 
there is not cancer presentation by one month of age in our VHLNP-/- model, we can still 
effectively characterize the mitochondria. Further interrogation into a mitochondrial phenotype 
should be done using VHL-specific knockout mouse models and in primary human renal cancer 
cells in order to delineate VHL’s role in cancer progression and treatment resistance. An 
investigation such as this should also be aimed at defining potential therapeutic targets, which 
may include use of antimetabolites (category of drug used to inhibit metabolism).   
6.5 SUMMARY AND CONCLUSION 
Our investigation aims to elucidate the connection between hypoxia, metabolism, and kidney 
development. We utilized cell lines and mouse models of developmental and genetic hypoxia in 
order to establish the role of the major hypoxia pathway—the VHL/HIF pathway—in regulating 
metabolism and ultimately nephron differentiation. We found that exposure to hypoxia in vitro 
promotes glycolysis and inhibits mitochondrial respiration and we mirrored those experiments 
and conclusions in vivo using the VHLNP-/- mouse model. The experiments performed in vivo 
highlight the importance of strict oxygen regulation during development and show the necessity 
for proper nephron formation. Although our work is not without limitation, we believe that our 
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hypoxia studies have laid the foundation for future work in developmental biology, disease 
etiology, and therapeutic investigations.  
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APPENDIX A 
LIST OF ABBREVIATIONS 
2-DG – 2-Deoxyglucose 
3D – Three-dimensional 
Acetyl-coA – Acetyl-coenzyme A 
Acyl-coA – Acyl-coenzyme A 
ADAMTS13 – A disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 
AKI – Acute kidney injury 
AMPKα – Protein kinase AMP-activated catalytic subunit alpha 1 
ATP – Adenosine triphosphate 
BAP1 – BRCA1 associated protein 1 
BCL2 – B cell lymphoma 2  
BNIP3 – BCL2 interacting protein 3 
BUN – Blood urea nitogen 
CAKUT – Congenital anomalies of the kidney and urinary tract  
CASP3 – Caspase 3 
ccRCC – Clear cell renal cell carcinoma 
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cDNA – Complementary DNA 
CITED1 – Cbp/P300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1 
CKD – Chronic kidney disease 
CO1 – Cytochrome c oxidase subunit I 
CO2 – Carbon dioxide 
DAVID – The database for annotation, visualization and integrated discovery 
DDIT4 – DNA damage inducible transcript 4 
DMEM – Dulbecco’s modified eagle media 
DNA – Deoxyribonucleic acid 
DNM1L/DRP1 – Dynamin family member proline-rich carboxyl-terminal domain less 
ENO1 – Enolase 1 
ESRD – End stage renal disease 
ETC – Electron transport chain 
FACS – Fluorescence-activated cell sorting 
FADH/FADH2 – Flavin adenine dinucleotide 
FAM162A – Family with sequence similarity 162 member A 
FBS – Fetal bovine serum 
FCCP – Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
Fe2+ – Ferrous cation (iron) 
FIS1 – Mitochondrial fission 1 protein 
GAPDH – Glyceraldehyde-3-phosphate dehydrogenase 
GDNF – Glial cell derived neurotrophic factor 
GFP – Green fluorescent protein 
 136 
GO – Gene ontology 
H&E – Hematoxylin and eosin 
H2O – Dihydrogen monoxide (water)  
HBSS – Hank’s balanced salt solution 
Hek293 – Human embryonic kidney 293 cell line 
Hif1α – Hypoxia-inducible factor 1α 
Hif1E – Hypoxia-inducible factor 1E 
Hif2α – Hypoxia-inducible factor 2α 
Hif2E – Hypoxia-inducible factor 2E 
Hif3α – Hypoxia-inducible factor 3α 
HIFs – Hypoxia-inducible factors 
HK2 – Hexokinase 2 
HREs – Hypoxia response elements 
HRP – Horseradish peroxidase 
KBTBD11 – Kelch repeat and BTB domain containing 11 
KI67 – Protein phosphatase 1, regulatory subunit 105: protein marker protein Ki-67 
LC3 I/MAP1LC3A – Microtubules associated protein 1 light chain 3 alpha 
LC3 II/MAP1LC3B – Microtubule associated protein 1 light chain 3 beta 
LDHA – Lactate dehydrogenase A 
LEF1 – Lymphoid enhancer binding factor 1 
LHX1 – LIM homeobox protein 1 
MACS – Magnetic-activated cell sorting 
MET – Mesenchyme to epithelial transition 
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MFN1 – Mitofusin 1 
MFN2 – Mitofusin 2 
MGARP – Mitochondria localized glutamic acid rich protein 
MM – Metanephric mesenchyme  
mtDNA – Mitochondrial DNA 
NAD/NADH – Nicotinamide adenine dinucleotide 
NCAM – Neural cell adhesion molecule 
nDNA – Nuclear DNA 
NDUFV1 – NADH:ubiquinone oxioreductase core subunit V1 
NIX/BNIP2L – BCL2 interacting protein 3 like 
NOX4 – kidney superoxide-producing NADPH oxidase 
pAMPKα – Phosphorylated protein kinase AMP-activated catalytic subunit alpha 1 
PCA –Principal component analysis 
PCR – Polymerase chain reaction 
PDK1 – Pyruvate dehydrogenase kinase 1  
PFKFB3 – 6-Phosphofructo-2-kinase/Fructose-2,6-biphosphtase 3 
PFKP – Phosphofructokinase, platelet-isoform 
PGK1 – Phosphoglycerate kinase 1 
PHD genes – Prolyl hydroxylase domain containing proteins 
pHH3 – Phosphohistone H3 
PI – Propidium iodide 
PPARGC-1α/PGC-1α – Peroxisome proliferator-activated receptor gamma coactivator 1 alpha 
PPARγ – Peroxisome proliferator-activated receptor gamma 
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RBCs – Red blood cells 
RCC – Renal cell carcinoma 
RIPA – Radioimmunoprecipitation  
RN18S – 18s ribosomal RNA  
RNA – Ribonucleic acid 
ROS – Reactive oxygen species 
SIX2 – Sine oculis homeobox homolog 2 
SLC16A3/MCT4 – Solute carrier family 16 member 3 (Monocarboxylate transporter 3) 
SLC2A1/GLUT1 – Solute carrier family 2 member 1 (Glucose transporter type 1) 
SLC2A3 – Solute carrier family 2 member 3 (Glut3) 
TCA – Tricarboxylic acid  
TFAM – Transcription factor A, mitochondrial 
TMRM – Tetramethylrhodamine, methyl ester, perchlorate 
TPI1 – Triosephosphate isomerase 1 
TUNEL – Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling 
UB – Ureteric bud 
UE – Ureteric epithelium 
VHL – Von Hippel Lindau 
WNT4 – Wingless-type MMTV integration site family member 4 
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APPENDIX B 
LIST OF REAL TIME PCR PRIMERS 
Table 2: List of real time PCR primers 
Gene  Species Sense Primer Antisense Primer 
18S Human TCGATGCTCTTAGCTGAGTGTC TGGCAAATGCTTTCGCTCTG 
CASP3 Human ATTATTCAGGCCTGCCGTGG GACTGGATGAACCAGGAGCC 
GAPDH Human AAAATCAAGTGGGGCGATGC TCTCATGGTTCACACCCATGAC 
IDH1 Human TCCATTTTTGCCTGGACCAG TCAGAACGTTGCACATTGGG 
KI67 Human TCCAAAGAAGGCTGAGGACA TGAAGCCGATTCAGACCCAG 
LDHA Human TCTCCCACCCTGCTTTTTCTG 
 
AAGCATTCAAATGCAGCGTATC 
 
NOX4 Human TTTGCCATGAAGCAGGACTC ACGGTCATCTTGCCACATTC 
SIRT3 Human CTGCTCATCAACCGGGACTT TGGTCCATCAAGCTTCCCAG 
TOMM20 Human AGGCTTCGAGAACGAAGAAAGA TGTCAGATGGTCTACGCCCT 
Bcl2 Mouse GAGGCTGGGATGCCTTTGT GCAGGTTTGTCGACCTCACT 
Bnip3 Mouse TTTAAACACCCGAAGCGCAC CCAATGTAGATCCCCAAGCCA 
Cited1 Mouse CCAACCAGGAGATGAACT AGAGCCTATTGGAGATGTC 
Ddit4 Mouse AGGAATTTCTGTGGTGGAGACC AAGCCTGTGTGACTCCTAAGC 
Drp1 Mouse TTCTGAGCTATGCGGTGGTG CTCATGGACCAGCTCCACAC 
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Table 2 Continued: List of real time PCR primers 
Gene  Species Sense Primer Antisense Primer 
Eno1 Mouse CTACCCAGTGGTGTCCATCG TTACACGCCTGCAGGGATTC 
Eya1 Mouse GGAATGCTATTATGAGGTAGAA ATCCTTGTTGACACTTGAC 
Foxd1 Mouse TGTGGAGAACTTTACTGCTA AAATAGATGGACCCTCTGAG 
Gapdh Mouse AACCTGCCAAGTATGATGA GGAGTTGCTGTTGAAGTC 
Jag1 Mouse ACAACACCACCAACAATG GTCATCCTCCTCCACTTC 
Lc3 Mouse GAACCGCAGACGCATCTCT ATGATCACCGGGATCTTACTGG 
Ldha Mouse TGGAGTGGTGTGAATGTTGC ATGGTGGAAATGGGATGCAC 
Lef1 Mouse AGCTTGTTGAAACCCCAGAC TTTTTGGAAGTCGGCGCTTG 
Lhx1 Mouse CTACATCATAGACGAGAACAAG TCATTACTACCACCTTCCTTAT 
Nox4 Mouse TCAAACAGCTGTGCTATGCC ATCAACAGCGTGCGTCTAAC 
Opa1 Mouse CTTGCCAGTTTAGCTCCCGA GTCTGACACCTTCCTGTAATGCT 
Osr1 Mouse ACTGATGAGCGACCTTAC TTGTGAGTGTAGCGTCTT 
Pax2 Mouse GCTAAGGAAAGGACTTTGTG TAGGCAGTTCAGGTGGAT 
Pdk1 Mouse GCGAGGAGGATCTGACTGTG GATAACCGCATCTGTCCCGT 
Pgk1 Mouse AGAAATATGCCGAGGCTGTG TGTGTTCCATTTGGCACAGC 
Rn18s Mouse GACAGGATTGACAGATTGATAG CCAGAGTCTCGTTCGTTA 
Sall1 Mouse GGACTATGAACTACACTATGAAG CAACTTGCGATTGCCATA 
Six2 Mouse GCAGGACTCCATACTCAA GATACCGAGCAGACCATT 
Slc2a1 Mouse ACTTCATTGTGGGCATGTGC TCGGGTGTCTTGTCACTTTG 
Sox9 Mouse AAGGAAGGAAGGAAGGAAG AGGCACAGTGAATGTTCTA 
Tfam Mouse AAGTCTTGGGAAGAGCAGATGGCT AGACCTAACTGGTTTCTTGGGCCT 
Wnt4 Mouse TCTCTGCTCATTGTCCAT TGCTGAACTAAGTCTACCA 
 
 141 
APPENDIX C 
LIST OF GENOTYPING PRIMERS 
Table 3: List of genotyping primers 
Gene  Sense Primer Antisense Primer 
Six2-TGCtg allele ATGCTCATCCGGAGTTCCGTATG CACCTTGTCGCCTTGCGTATAA 
Vhl allele AAGAGCACGCAGCTTAGGAG TTTCTGAGTCCTGGGGATTG 
 142 
APPENDIX D 
LIST OF ANTIBODIES AND LECTINS 
Table 4: List of antibodies and lectins 
Protein/antibody  Company  Catalog # Concentration 
α/β tubulin Cell Signaling Technology 2148 1:1000 
CD105 R&D Systems AF1320  1:10 
CD140a R&D Systems AF1061 1:10 
CD326 BD Biosciences 552370 1:50 
DAPI Thermo Fisher Scientific D1306 1:3000 
DBA Vector Laboratories B-1035 1:!00 
Dnm1l Thermo Fisher Scientific PA1-16987 1:250 
Donkey anti-mouse Jackson ImmunoResearch Laboratories 715-475-150 1:200 
Donkey anti-rabbit Rockland antibodies & assays 612-446-026 1:200 
Endomucin Santa Cruz Biotechnology sc-65495 1:100 
Glut1 Abcam ab652 1:100 
Hif-1α Novus Biologicals NB100-105 1:250 
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Table 4 Continued: List of antibodies and lectins 
Protein/antibody  Company  Catalog # Concentration 
Protein/antibody  Company  Catalog # Concentration 
IgG-Mouse-HRP Cell Signaling Technology 7076 1:1000 
IgG-Rabbit-HRP Cell Signaling Technology 7074 1:1000 
Jagged1 Santa Cruz Biotechnology sc-390177 1:20 
Lef1 Cell Signaling 2230 1:100 
LTL Vector Laboratories L-1320 1:100 
Ncam Millipore Sigma C9672 1:100 
Oat1 Alpha Diagnostic International OAT11-A 1:100 
Pck1 Proteintech 16754-1-AP 1:100 
pHH3 Cell Signaling Technology 9701 1:100 
Pgc-1α Novus Biologicals 4676 1:250 
Sall1 Abcam ab31526 1:100 
Six2 Proteintech 11562-1-AP 1:100 
TER119 R&D Systems MAB1125 1:10 
Tomm20 Santa Cruz Biotechnology sc-11415 1:500 
Vhl Santa Cruz Biotechnology sc-5575 1:250 
Wt1 Santa Cruz Biotechnology sc-393498 1:100 
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APPENDIX E 
LIST OF FLUORESCENT DYES 
Table 5: List of fluorescent dyes 
Dye  Concentration  Company Catalog # 
LysoTracker 65nM Thermo Fisher Scientific L7528 
MitoSox 5PM Thermo Fisher Scientific M36008 
MitoTracker 200nM Thermo Fisher Scientific M22425 
Propidium Iodide 0.5mL Thermo Fisher Scientific F10797 
VPD450 1mM BD Biosciences 562158 
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APPENDIX F 
LIST OF INHIBITORS 
Table 6: List of inhibitors 
Inhibitor  Concentration  Company Catalog # 
Antimycin A 1PM Agilent 103015-100 
Cisplatin 20mg/kg bw APP NDC 63323-103-64 
FCCP 0.3 PM Agilent 103015-100 
Oligomycin 1 Pg/mL Agilent 103015-100 
Rotenone 0.1 PM Agilent 103015-100 
YN1 10 PM Millipore Sigma CAS 75187-63-2 
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APPENDIX G 
SUPPLEMENTAL DATA 
RNA-sequencing supplemental data  
Table 7: Complete list of significantly dysregulated genes 
ID Definition
mmu:100042025 K00134 glyceraldehyde 3-phosphate dehydrogenase [EC:1.2.1.12] | (RefSeq) Gapdh-ps15, Gm20899
mmu:105244208 K02991 small subunit ribosomal protein S6e | (RefSeq) 40S ribosomal protein S6 
mmu:10805 K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2d
mmu:112405 K09592 hypoxia-inducible factor prolyl hydroxylase [EC:1.14.11.29] | (RefSeq) Egln1, AI503754, C1orf 
mmu:112406 K09592 hypoxia-inducible factor prolyl hydroxylase [EC:1.14.11.29] | (RefSeq) Egln2, 0610011A13Rik
mmu:112407 K09592 hypoxia-inducible factor prolyl hydroxylase [EC:1.14.11.29] | (RefSeq) Egln3, 2610021G09Rik
mmu:11600  K05465 angiopoietin 1 | (RefSeq) Angpt1, 1110046O21Rik, Ang-1, Ang1; angiopoietin 1 
mmu:11601  K05466 angiopoietin 2 | (RefSeq) Angpt2, Agpt2, Ang-2, Ang2; angiopoietin 2 
mmu:11602     K05467 angiopoietin 4 | (RefSeq) Angpt4, ANG-3, ANG-4, Agpt4, Ang3; angiopoietin 4 
mmu:11651            K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] | (RefSeq) Akt1, Akt, LTR-akt, PKB, PKB/Akt 
mmu:11652         K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] | (RefSeq) Akt2, 2410016A19Rik, AW554154
mmu:11674            K01623 fructose-bisphosphate aldolase, class I [EC:4.1.2.13] | (RefSeq) Aldoa, Aldo-1, Aldo1; aldolase 
mmu:11863            K09097 aryl hydrocarbon receptor nuclear translocator | (RefSeq) Arnt, D3Ertd557e, Drnt, ESTM42, Hif 
mmu:12043            K02161 apoptosis regulator Bcl-2 | (RefSeq) Bcl2, AW986256, Bcl-2, C430015F12Rik, D630044D05Rik, D83 
mmu:12322            K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2a
mmu:12323            K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2b
mmu:12325            K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2g
mmu:12575            K06625 cyclin-dependent kinase inhibitor 1A | (RefSeq) Cdkn1a, CAP20, CDKI, CIP1, Cdkn1, P21, SDI1
mmu:12576           K06624 cyclin-dependent kinase inhibitor 1B | (RefSeq) Cdkn1b, AA408329, AI843786, Kip1, p27, p27Kip 
mmu:12914            K04498 E1A/CREB-binding protein [EC:2.3.1.48] | (RefSeq) Crebbp, AW558298, CBP, CBP/p300, KAT3A, p30 
mmu:13058            K21421 NADPH oxidase 2 [EC:1.-.-.-] | (RefSeq) Cybb, C88302, CGD91-phox, Cgd, Cyd, Nox2, gp91-1, gp9 
mmu:13614            K16366 endothelin-1 | (RefSeq) Edn1, ET-1, PPET1, preproET; endothelin 1 
mmu:13645            K04357 epidermal growth factor | (RefSeq) Egf, AI790464; epidermal growth factor 
mmu:13649           K04361 epidermal growth factor receptor [EC:2.7.10.1] | (RefSeq) Egfr, 9030024J15Rik, AI552599, Erbb 
mmu:13684            K03259 translation initiation factor 4E | (RefSeq) Eif4e, EG668879, Eif4e-ps, If4e, eIF-4E; eukaryot 
mmu:13685            K07205 eukaryotic translation initiation factor 4E binding protein 1 | (RefSeq) Eif4ebp1, 4e-bp1, AA 
mmu:13806           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno1, 0610008I15, AL022784, Eno-1, MBP-1; enolase 1
mmu:13807            K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno2, AI837106, D6Ertd375e, Eno-2, NSE; enolase 2
mmu:13808           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno3, Eno-3, MSE; enolase 3, beta muscle 
mmu:13856            K05437 erythropoietin | (RefSeq) Epo; erythropoietin 
mmu:13866            K05083 receptor tyrosine-protein kinase erbB-2 [EC:2.7.10.1] | (RefSeq) Erbb2, Erbb-2, HER-2, HER2
mmu:14254            K05096 FMS-like tyrosine kinase 1 [EC:2.7.10.1] | (RefSeq) Flt1, AI323757, Flt-1, VEGFR-1, VEGFR1, s 
mmu:14433            K00134 glyceraldehyde 3-phosphate dehydrogenase [EC:1.2.1.12] | (RefSeq) Gapdh, Gapd; glyceraldehyde 
mmu:15251            K08268 hypoxia-inducible factor 1 alpha | (RefSeq) Hif1a, AA959795, HIF-1-alpha, HIF1-alpha, HIF1alpha 
mmu:15275            K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hk1, BB404130, Hk-1, Hk1-s, dea, mHk1-s; hexokinase 1 
mmu:15277            K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hk2, AI642394, HKII; hexokinase 2 
mmu:15368            K00510 heme oxygenase 1 [EC:1.14.14.18] | (RefSeq) Hmox1, D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32
mmu:15978            K04687 interferon gamma | (RefSeq) Ifng, IFN-g, Ifg; interferon gamma K04687 interferon gamma | (RefSeq) Ifng, IFN-g, Ifg; interferon gamma 
mmu:15979           K05132 interferon gamma receptor 1 | (RefSeq) Ifngr1, CD119, IFN-gammaR, Ifgr, Ifngr, Nktar
mmu:15980            K05133 interferon gamma receptor 2 | (RefSeq) Ifngr2, Ifgr2, Ifgt; interferon gamma receptor 2 
mmu:16000            K05459 insulin-like growth factor 1 | (RefSeq) Igf1, C730016P09Rik, Igf-1, Igf-I
mmu:16001            K05087 insulin-like growth factor 1 receptor [EC:2.7.10.1] | (RefSeq) Igf1r, A330103N21Rik, CD221
mmu:16193            K05405 interleukin 6 | (RefSeq) Il6, Il-6; interleukin 6 
mmu:16194            K05055 interleukin 6 receptor | (RefSeq) Il6ra, CD126, IL-6R, IL-6R-alpha, IL-6RA, Il6r
mmu:16333            K04526 insulin | (RefSeq) Ins1, Ins-1, Ins2-rs1
mmu:16334            K04526 insulin | (RefSeq) Ins2, AA986540, Ins-2, InsII, Mody, Mody4; insulin II 
mmu:16337            K04527 insulin receptor [EC:2.7.10.1] | (RefSeq) Insr, 4932439J01Rik, CD220, D630014A15Rik
mmu:16828            K00016 L-lactate dehydrogenase [EC:1.1.1.27] | (RefSeq) Ldha, Ldh1, Ldhm, l7R2; lactate dehydrogenase 
mmu:17000            K03159 lymphotoxin beta receptor TNFR superfamily member 3 | (RefSeq) Ltbr, AI256028, LTbetaR, Ltar
mmu:170768           K01103 6-phosphofructo-2-kinase / fructose-2,6-biphosphatase 3 [EC:2.7.1.105 3.1.3.46] | (RefSeq) Pf 
mmu:17346            K04372 MAP kinase interacting serine/threonine kinase [EC:2.7.11.1] | (RefSeq) Mknk1, 2410048M24Rik
mmu:17347           K04372 MAP kinase interacting serine/threonine kinase [EC:2.7.11.1] | (RefSeq) Mknk2, 2010016G11Rik
mmu:18033            K02580 nuclear factor NF-kappa-B p105 subunit | (RefSeq) Nfkb1, NF-KB1, NF-kappaB, NF-kappaB1, p105
mmu:18126            K13241 nitric-oxide synthase, inducible [EC:1.14.13.39] | (RefSeq) Nos2, MAC-NOS, NOS-II, Nos-2
mmu:18127            K13242 nitric-oxide synthase, endothelial [EC:1.14.13.39] | (RefSeq) Nos3, 2310065A03Rik, Nos-3
mmu:18597            K00161 pyruvate dehydrogenase E1 component alpha subunit [EC:1.2.4.1] | (RefSeq) Pdha1, Pdha-1
mmu:18598            K00161 pyruvate dehydrogenase E1 component alpha subunit [EC:1.2.4.1] | (RefSeq) Pdha2, Pdhal
mmu:18641            K00850 6-phosphofructokinase 1 [EC:2.7.1.11] | (RefSeq) Pfkl, AA407869, ATP-PFK, PFK-B, PFK-L
mmu:18655            K00927 phosphoglycerate kinase [EC:2.7.2.3] | (RefSeq) Pgk1, Pgk-1; phosphoglycerate kinase 1 
mmu:18706            K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta
mmu:18707            K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta
mmu:18708            K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | (RefSeq) Pik3r1, PI3K
mmu:18709            K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | (RefSeq) Pik3r2, p85beta
mmu:18710            K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | (RefSeq) Pik3r3, AA414954
mmu:18750            K02677 classical protein kinase C alpha type [EC:2.7.11.13] | (RefSeq) Prkca, AI875142, Pkca
mmu:18751            K19662 classical protein kinase C beta type [EC:2.7.11.13] | (RefSeq) Prkcb, PKC-B, PKC-Beta, Pkcb
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mmu:100042025 K00134 glyceraldehyde 3-phosphate dehydrogenase [EC:1.2.1.12] | (RefSeq) Gapdh-ps15, Gm20899
mmu:105244208 K02991 small subunit ribosomal protein S6e | (RefSeq) 40S ribosomal protein S6 
mmu:10805 K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2d
mmu:112405 K09592 hypoxia-inducible factor prolyl hydroxylase [EC:1.14.11.29] | (RefSeq) Egln1, AI503754, C1orf 
mmu:112406 K09592 hypoxia-inducible factor prolyl hydroxylase [EC:1.14.11.29] | (RefSeq) Egln2, 0610011A13Rik
mmu:112407 K09592 hypoxia-inducible factor prolyl hydroxylase [EC:1.14.11.29] | (RefSeq) Egln3, 2610021G09Rik
mmu:11600  K05465 angiopoietin 1 | (RefSeq) Angpt1, 1110046O21Rik, Ang-1, Ang1; angiopoietin 1 
mmu:11601  K05466 angiopoietin 2 | (RefSeq) Angpt2, Agpt2, Ang-2, Ang2; angiopoietin 2 
mmu:11602     K05467 angiopoietin 4 | (RefSeq) Angpt4, ANG-3, ANG-4, Agpt4, Ang3; angiopoietin 4 
mmu:11651            K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] | (RefSeq) Akt1, Akt, LTR-akt, PKB, PKB/Akt 
mmu:11652         K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] | (RefSeq) Akt2, 2410016A19Rik, AW554154
mmu:11674            K01623 fructose-bisphosphate aldolase, class I [EC:4.1.2.13] | (RefSeq) Aldoa, Aldo-1, Aldo1; aldolase 
mmu:11863            K09097 aryl hydrocarbon receptor nuclear translocator | (RefSeq) Arnt, D3Ertd557e, Drnt, ESTM42, Hif 
mmu:12043            K02161 apoptosis regulator Bcl-2 | (RefSeq) Bcl2, AW986256, Bcl-2, C430015F12Rik, D630044D05Rik, D83 
mmu:12322            K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2a
mmu:12323            K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2b
mmu:12325            K04515 calcium/calmodulin-dependent protein kinase (CaM kinase) II [EC:2.7.11.17] | (RefSeq) Camk2g
mmu:12575            K06625 cyclin-dependent kinase inhibitor 1A | (RefSeq) Cdkn1a, CAP20, CDKI, CIP1, Cdkn1, P21, SDI1
mmu:12576           K06624 cyclin-dependent kinase inhibitor 1B | (RefSeq) Cdkn1b, AA408329, AI843786, Kip1, p27, p27Kip 
mmu:12914            K04498 E1A/CREB-binding protein [EC:2.3.1.48] | (RefSeq) Crebbp, AW558298, CBP, CBP/p300, KAT3A, p30 
mmu:13058            K21421 NADPH oxidase 2 [EC:1.-.-.-] | (RefSeq) Cybb, C88302, CGD91-phox, Cgd, Cyd, Nox2, gp91-1, gp9 
mmu:13614            K16366 endothelin-1 | (RefSeq) Edn1, ET-1, PPET1, preproET; endothelin 1 
mmu:13645            K04357 epidermal growth factor | (RefSeq) Egf, AI790464; epidermal growth factor 
mmu:13649           K04361 epidermal growth factor receptor [EC:2.7.10.1] | (RefSeq) Egfr, 9030024J15Rik, AI552599, Erbb 
mmu:13684            K03259 translation initiation factor 4E | (RefSeq) Eif4e, EG668879, Eif4e-ps, If4e, eIF-4E; eukaryot 
mmu:13685            K07205 eukaryotic translation initiation factor 4E binding protein 1 | (RefSeq) Eif4ebp1, 4e-bp1, AA 
mmu:13806           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno1, 0610008I15, AL022784, Eno-1, MBP-1; enolase 1
mmu:13807            K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno2, AI837106, D6Ertd375e, Eno-2, NSE; enolase 2
mmu:13808           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno3, Eno-3, MSE; enolase 3, beta muscle 
mmu:13856            K05437 erythropoietin | (RefSeq) Epo; erythropoietin 
mmu:13866            K05083 receptor tyrosine-protein kinase erbB-2 [EC:2.7.10.1] | (RefSeq) Erbb2, Erbb-2, HER-2, HER2
mmu:14254            K05096 FMS-like tyrosine kinase 1 [EC:2.7.10.1] | (RefSeq) Flt1, AI323757, Flt-1, VEGFR-1, VEGFR1, s 
mmu:14433            K00134 glyc raldehyde 3-phosphate ehydrogenase [EC:1.2.1.12] | (RefSeq) Gapdh, Gapd; glyceraldehyde 
mmu:15251            K08268 hypoxia-inducible factor 1 alpha | (RefSeq) Hif1a, AA959795, HIF-1-alpha, HIF1-alpha, HIF1alpha 
mmu:15275            K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hk1, BB404130, Hk-1, Hk1-s, dea, mHk1-s; hexokinase 1 
mmu:15277            K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hk2, AI642394, HKII; hexokinase 2 
mmu:15368            K00510 heme oxygenase 1 [EC:1.14.14.18] | (RefSeq) Hmox1, D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32
mmu:15978            K04687 interferon gamma | (RefSeq) Ifng, IFN-g, Ifg; interferon gamma K04687 interferon gamma | (RefSeq) Ifng, IFN-g, Ifg; interferon gamma 
mmu:15979           K05132 interferon gamma receptor 1 | (RefSeq) Ifngr1, CD119, IFN-gammaR, Ifgr, Ifngr, Nktar
mmu:15980            K05133 interferon gamma receptor 2 | (RefSeq) Ifngr2, Ifgr2, Ifgt; interferon gamma receptor 2 
mmu:16000            K05459 insulin-like growth factor 1 | (RefSeq) Igf1, C730016P09Rik, Igf-1, Igf-I
mmu:16001            K05087 insulin-like growth factor 1 receptor [EC:2.7.10.1] | (RefSeq) Igf1r, A330103N21Rik, CD221
mmu:16193            K05405 interleukin 6 | (RefSeq) Il6, Il-6; interleukin 6 
mmu:16194            K05055 interleukin 6 receptor | (RefSeq) Il6ra, CD126, IL-6R, IL-6R-alpha, IL-6RA, Il6r
mmu:16333            K04526 insulin | (RefSeq) Ins1, Ins-1, Ins2-rs1
mmu:16334            K04526 insulin | (RefSeq) Ins2, AA986540, Ins-2, InsII, Mody, Mody4; insulin II 
mmu:16337            K04527 insulin receptor [EC:2.7.10.1] | (RefSeq) Insr, 4932439J01Rik, CD220, D630014A15Rik
mmu:16828            K00016 L-lactate dehydrogenase [EC:1.1.1.27] | (RefSeq) Ldha, Ldh1, Ldhm, l7R2; lactate dehydrogenase 
mmu:17000            K03159 lymphotoxin beta receptor TNFR superfamily member 3 | (RefSeq) Ltbr, AI256028, LTbetaR, Ltar
mmu:170768           K01103 6-phosphofructo-2-kinase / fructose-2,6-biphosphatase 3 [EC:2.7.1.105 3.1.3.46] | (RefSeq) Pf 
mmu:17346            K04372 MAP kinase interacting serine/threonine kinase [EC:2.7.11.1] | (RefSeq) Mknk1, 2410048M24Rik
mmu:17347           K04372 MAP kinase interacting serine/threonine kinase [EC:2.7.11.1] | (RefSeq) Mknk2, 2010016G11Rik
mmu:18033            K02580 nuclear factor NF-kappa-B p105 subunit | (RefSeq) Nfkb1, NF-KB1, NF-kappaB, NF-kappaB1, p105
mmu:18126            K13241 nitric-oxide synthase, inducible [EC:1.14.13.39] | (RefSeq) Nos2, MAC-NOS, NOS-II, Nos-2
mmu:18127            K13242 nitric-oxide synthase, endothelial [EC:1.14.13.39] | (RefSeq) Nos3, 2310065A03Rik, Nos-3
mmu:18597            K00161 pyruvate dehydrogenase E1 component alpha subunit [EC:1.2.4.1] | (RefSeq) Pdha1, Pdha-1
mmu:18598            K00161 pyruvate dehydrogenase E1 component alpha subunit [EC:1.2.4.1] | (RefSeq) Pdha2, Pdhal
mmu:18641            K00850 6-phosphofructokinase 1 [EC:2.7.1.11] | (RefSeq) Pfkl, AA407869, ATP-PFK, PFK-B, PFK-L
mmu:18655            K00927 phosphoglycerate kinase [EC:2.7.2.3] | (RefSeq) Pgk1, Pgk-1; phosphoglycerate kinase 1 
mmu:18706            K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta
mmu:18707            K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta
mmu:18708            K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | (RefSeq) Pik3r1, PI3K
mmu:18709            K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | (RefSeq) Pik3r2, p85beta
mmu:18710            K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | (RefSeq) Pik3r3, AA414954
mmu:18750            K02677 classical protein kinase C alpha type [EC:2.7.11.13] | (RefSeq) Prkca, AI875142, Pkca
mmu:18751            K19662 classical protein kinase C beta type [EC:2.7.11.13] | (RefSeq) Prkcb, PKC-B, PKC-Beta, Pkcb
mmu:18752            K19663 classical protein kinase C gamma type [EC:2.7.11.13] | (RefSeq) Prkcg, PKCgamma, Pkcc, Prkcc
mmu:18787            K03982 plasminogen activator inhibitor 1 | (RefSeq) Serpine1, PAI-1, PAI1, Planh1
mmu:18803            K01116 phosphatidylinositol phospholipase C, gamma-1 [EC:3.1.4.11] | (RefSeq) Plcg1, AI894140, Cded
mmu:19697            K04735 transcription factor p65 | (RefSeq) Rela, p65, p65_NF-kappa_B, p65_NFkB
mmu:20104            K02991 small subunit ribosomal protein S6e | (RefSeq) Rps6, S6R; ribosomal protein S6 
mmu:20525            K07299 MFS transporter, SP family, solute carrier family 2 (facilitated glucose transporter) 
mmu:20848            K04692 signal transducer and activator of transcription 3 | (RefSeq) Stat3, 1110034C02Rik, AW109958
mmu:212032           K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hk3, HK_III, HK-III; hexokinase 3 
mmu:216019           K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hkdc1, BC016235; hexokinase domain containing 1 
mmu:21687            K05121 endothelial-specific receptor tyrosine kinase [EC:2.7.10.1] | (RefSeq) Tek, AA517024, Cd202b
mmu:218268           K03259 translation initiation factor 4E | (RefSeq) Eif4e1b, Eif4eloo, Gm273
mmu:21857            K16451 metallopeptidase inhibitor 1 | (RefSeq) Timp1, Clgi, EPA, TIMP-1, TPA-S1, Timp
mmu:21898            K10160 toll-like receptor 4 | (RefSeq) Tlr4, Lps, Ly87, Ran/M1, Rasl2-8; toll-like receptor 4 
mmu:22041            K14736 transferrin | (RefSeq) Trf, AI266983, Cd176, HP, Tf, Tfn, hpxK14736 transfe rin | (RefSeq) Trf, AI266983, Cd176, HP, Tf, Tfn, hpx
mmu:22042            K06503 transferrin receptor | (RefSeq) Tfrc, 2610028K12Rik, CD71, E430033M20Rik, Mtvr1, TFR, TFR1
mmu:22339            K05448 vascular endothelial growth factor A | (RefSeq) Vegfa, Vegf, Vpf
mmu:22346            K03871 von Hippel-Lindau disease tumor supressor | (RefSeq) Vhl, Vhlh, pVHL; von Hippel-Lindau tumor 
mmu:226265           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno4, 6430537H07Rik; enolase 4 
mmu:228026           K12077 pyruvate dehydrogenase kinase isoform 1 [EC:2.7.11.2] | (RefSeq) Pdk1, B830012B01, D530020C15 
mmu:230899           K12334 natriuretic peptide A | (RefSeq) Nppa, ANP, Anf, Pnd; natriuretic peptide type A 
mmu:234779           K05859 phosphatidylinositol phospholipase C, gamma-2 [EC:3.1.4.11] | (RefSeq) Plcg2, PLC-gamma-2
mmu:23797            K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] | (RefSeq) Akt3, AI851531, D930002M15Rik
mmu:26395            K04368 mitogen-activated protein kinase kinase 1 [EC:2.7.12.2] | (RefSeq) Map2k1, MAPKK1, MEKK1K04368 mitogen-activated protein kinase kinase 1 [EC:2.7.12.2] | (RefSeq) Map2k1, MAPKK1, MEKK1
mmu:26396            K04369 mitogen-activated protein kinase kinase 2 [EC:2.7.12.2] | (RefSeq) Map2k2, AA589381, MEK2
mmu:26413            K04371 mitogen-activated protein kinase 1/3 [EC:2.7.11.24] | (RefSeq) Mapk1, 9030612K14Rik
mmu:26417            K04371 mitogen-activated protein kinase 1/3 [EC:2.7.11.24] | (RefSeq) Mapk3, Erk-1, Erk1, Ert2
mmu:26987            K03259 translation initiation factor 4E | (RefSeq) Eif4e2, 2700069E09Rik, AI036339, AV129531
mmu:328572           K04498 E1A/CREB-binding protein [EC:2.3.1.48] | (RefSeq) Ep300, A430090G16, A730011L11, KAT3B, p300
mmu:433182           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno1b, EG433182, Eno-1, Eno1, Gm5506, NNE; enolase 1B
mmu:56438            K03868 RING-box protein 1 [EC:2.3.2.32] | (RefSeq) Rbx1, 1500002P15Rik, AA517855, ROC1
mmu:56717            K07203 serine/threonine-protein kinase mTOR [EC:2.7.11.1] | (RefSeq) Mtor, 2610315D21Rik, AI327068
mmu:58988            K04688 ribosomal protein S6 kinase beta [EC:2.7.11.1] | (RefSeq) Rps6kb2, S6K-beta-2, S6K2
mmu:67673            K03873 elongin-B | (RefSeq) Elob, 0610040H15Rik, Tceb2
mmu:67923            K03872 elongin-C | (RefSeq) Eloc, 2610043E24Rik, 2610301I15Rik, AA407206, AI987979, AW049146, Tceb1
mmu:68263            K00162 pyruvate dehydrogenase E1 component beta subunit [EC:1.2.4.1] | (RefSeq) Pdhb, 2610103L06Rik
mmu:71745            K03870 cullin 2 | (RefSeq) Cul2, 1300003D18Rik, 4932411N15Rik, AI327301, mKIAA4106
mmu:71775            K14736 transferrin | (RefSeq) 1300017J02Rik, Ica, mICA
mmu:72508            K04688 ribosomal protein S6 kinase beta [EC:2.7.11.1] | (RefSeq) Rps6kb1, 2610318I15Rik, AA959758
mmu:74769            K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta
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mmu:18752            K19663 classical protein kinase C gamma type [EC:2.7.11.13] | (RefSeq) Prkcg, PKCgamma, Pkcc, Prkcc
mmu:18787            K03982 plasminogen activator inhibitor 1 | (RefSeq) Serpine1, PAI-1, PAI1, Planh1
mmu:18803            K01116 phosphatidylinositol phospholipase C, gamma-1 [EC:3.1.4.11] | (RefSeq) Plcg1, AI894140, Cded
mmu:19697            K04735 transcription factor p65 | (RefSeq) Rela, p65, p65_NF-kappa_B, p65_NFkB
mmu:20104            K02991 small subunit ribosomal protein S6e | (RefSeq) Rps6, S6R; ribosomal protein S6 
mmu:20525            K07299 MFS transporter, SP family, solute carrier family 2 (facilitated glucose transporter) 
mmu:20848            K04692 signal transducer and activator of transcription 3 | (RefSeq) Stat3, 1110034C02Rik, AW109958
mmu:212032           K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hk3, HK_III, HK-III; hexokinase 3 
mmu:216019           K00844 hexokinase [EC:2.7.1.1] | (RefSeq) Hkdc1, BC016235; hexokinase domain containing 1 
mmu:21687            K05121 endothelial-specific receptor tyrosine kinase [EC:2.7.10.1] | (RefSeq) Tek, AA517024, Cd202b
mmu:218268           K03259 translation initiation factor 4E | (RefSeq) Eif4e1b, Eif4eloo, Gm273
mmu:21857            K16451 metallopeptidase inhibitor 1 | (RefSeq) Timp1, Clgi, EPA, TIMP-1, TPA-S1, Timp
mmu:21898            K10160 toll-like receptor 4 | (RefSeq) Tlr4, Lps, Ly87, Ran/M1, Rasl2-8; toll-like receptor 4 
mmu:22041            K14736 transferrin | (RefSeq) Trf, AI266983, Cd176, HP, Tf, Tfn, hpxK14736 transfe rin | (RefSeq) Trf, AI266983, Cd176, HP, Tf, Tfn, hpx
mmu:22042            K06503 transferrin receptor | (RefSeq) Tfrc, 2610028K12Rik, CD71, E430033M20Rik, Mtvr1, TFR, TFR1
mmu:22339            K05448 vascular endothelial growth factor A | (RefSeq) Vegfa, Vegf, Vpf
mmu:22346            K03871 von Hippel-Lindau disease tumor supressor | (RefSeq) Vhl, Vhlh, pVHL; von Hippel-Lindau tumor 
mmu:226265           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno4, 6430537H07Rik; enolase 4 
mmu:228026           K12077 pyruvate dehydrogenase kinase isoform 1 [EC:2.7.11.2] | (RefSeq) Pdk1, B830012B01, D530020C15 
mmu:230899           K12334 natriuretic peptide A | (RefSeq) Nppa, ANP, Anf, Pnd; natriuretic peptide type A 
mmu:234779           K05859 phosphatidylinositol phospholipase C, gamma-2 [EC:3.1.4.11] | (RefSeq) Plcg2, PLC-gamma-2
mmu:23797            K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] | (RefSeq) Akt3, AI851531, D930002M15Rik
mmu:26395            K04368 mitogen-activated protein kinase kinase 1 [EC:2.7.12.2] | (RefSeq) Map2k1, MAPKK1, MEKK1K04368 mitogen-activated protein kinase kinase 1 [EC:2.7.12.2] | (RefSeq) Map2k1, MAPKK1, MEKK1
mmu:26396            K04369 mitogen-activated protein kinase kinase 2 [EC:2.7.12.2] | (RefSeq) Map2k2, AA589381, MEK2
mmu:26413            K04371 mitogen-activated protein kinase 1/3 [EC:2.7.11.24] | (RefSeq) Mapk1, 9030612K14Rik
mmu:26417            K04371 mitogen-activated protein kinase 1/3 [EC:2.7.11.24] | (RefSeq) Mapk3, Erk-1, Erk1, Ert2
mmu:26987            K03259 translation initiation fa tor 4E | (RefSeq) Eif4e2, 2700069E09Rik, AI036339, AV129531
mmu:328572           K04498 E1A/CREB-binding protein [EC:2.3.1.48] | (RefSeq) Ep300, A430090G16, A730011L11, KAT3B, p300
mmu:433182           K01689 enolase [EC:4.2.1.11] | (RefSeq) Eno1b, EG433182, Eno-1, Eno1, Gm5506, NNE; enolase 1B
mmu:56438            K03868 RING-box protein 1 [EC:2.3.2.32] | (RefSeq) Rbx1, 1500002P15Rik, AA517855, ROC1
mmu:56717            K07203 serine/threonine-protein kinase mTOR [EC:2.7.11.1] | (RefSeq) Mtor, 2610315D21Rik, AI327068
mmu:58988            K04688 ribosomal protein S6 kinase beta [EC:2.7.11.1] | (RefSeq) Rps6kb2, S6K-beta-2, S6K2
mmu:67673            K03873 elongin-B | (RefSeq) Elob, 0610040H15Rik, Tceb2
mmu:67923            K03872 elongin-C | (RefSeq) Eloc, 2610043E24Rik, 2610301I15Rik, AA407206, AI987979, AW049146, Tceb1
mmu:68263            K00162 pyruvate dehydrogenase E1 component beta subunit [EC:1.2.4.1] | (RefSeq) Pdhb, 2610103L06Rik
mmu:71745            K03870 cullin 2 | (RefSeq) Cul2, 1300003D18Rik, 4932411N15Rik, AI327301, mKIAA4106
mmu:71775            K14736 transferrin | (RefSeq) 1300017J02Rik, Ica, mICA
mmu:72508            K04688 ribosomal protein S6 kinase beta [EC:2.7.11.1] | (RefSeq) Rps6kb1, 2610318I15Rik, AA959758
mmu:74769            K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta  
 
 
Figure 30: RNA-sequencing gene expression clustering 
(A) Sample clustering by Principal Component Analysis shows clear grouping of samples based on genotype. (B) 
Sample distance heat map shows clustering of samples based on genotype. (C) Library sizes are consistent between 
samples with a high percentage of unique reads aligned to known transcripts. N=4. 
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Figure 31: RNA-sequencing gene dispersion 
(A) Minus average plot showing the distribution of expression changes versus total expression. Red dots indicate 
significance while black dots are not significant. (B) Dispersion estimates by DESeq2 to estimate variance of a 
given gene based on expression level. Red line indicates expected variance of a given gene. Black dots indicate 
actual variance of each gene and blue dots indicate DESeq2 correction. N=4.  
 
 
Figure 32: RNA-sequencing gene expression 
(A) Mean read counts showing decreased VHL gene expression in isolate nephron progenitors from VHLNP-/- mice. 
(B) Plot showing the top 10 most dysregulated genes. (C) Annotation-associated gene expression showing cellular 
response to hypoxia (GO term) genes using DAVID analysis. (D) Annotation-associated gene expression showing 
HIF-1α signaling pathway (GO term) genes using DAVID analysis. N=4 
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